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Enterovirus 71 (EV71), a member of the Picornaviridae family, is one of the 
main causative agents of Hand, Foot and Mouth Disease (HFMD) in young children. 
Large scale outbreaks of HFMD were reported in the Asia Pacific region over the last 
few years and have resulted in significant fatalities. Clinically, HFMD caused by EV71 is 
indistinguishable from that caused by Coxsackievirus A16 (CA16), another main 
causative agent of HFMD. Both viruses are closely related genetically and display similar 
clinical symptoms. However, EV71 is associated with serious neurological 
complications, resulting in high mortalities. Currently, there is no rapid diagnostic 
method to detect or effective antivirals to treat EV71 infections. With the increased 
concerns over the neurovirulence caused by EV71, there is a need for a rapid and highly 
specific detection method as well as a potential antiviral strategy against this virus. 
 
In this study, rapid diagnostic methods based on one-step quantitative real-time 
RT-PCR were developed, employing hybridization probe-based and TaqMan probe-
based chemistries to detect EV71 directly from clinical specimens. A multiplex real-time 
Hybridization probe RT-PCR assay to detect and differentiate EV71 from CA16 present 
in the clinical specimens was also investigated. By designing specific primers and probes 
based on conserved VP1 region of EV71 or CA16, all the three real-time RT-PCR assays 
were shown to exhibit high specificity in detecting EV71 or CA16 directly from clinical 
specimens. There was no other enterovirus serotype being detected. The entire real-time 
RT-PCR procedure required only 1 to 2 hours upon receiving the clinical specimens, and 
no post-PCR handling such as agarose gel electrophoresis was required. This approach 
 xviii
for the detection of EV71 or CA16 was more rapid than the tissue culture method which 
requires 2 to 3 weeks, and the conventional semi-nested RT-PCR methods which require 
1 to 2 days. Quantitative analysis showed that all the three real-time RT-PCR assays were 
able to detect as low as 5 viral copies of EV71 or CA16. The real-time RT-PCR assays 
developed in this study were also shown to be highly sensitive in detecting EV71 or 
CA16 directly from clinical specimens, demonstrating that real-time RT-PCR offered a 
more rapid, specific and sensitive approach. This will enable pediatricians to identify and 
manage the patients more effectively. 
 
Over the last few years, RNA interference (RNAi) has emerged as a promising 
approach to be developed as a potential therapeutic strategy against infectious diseases. It 
is a highly efficient and specific post-transcriptional gene silencing phenomenon. Here, 
two different siRNAs systems, namely the psiStrike shRNA expression system and the 
chemically synthesized 29-mer shRNAs were developed in the in vitro system. The 
results showed that both the psiStrike plasmids expressing shRNAs and the chemically 
synthesized 29-mer shRNAs designed to target the viral RNA-dependent RNA 
polymerase, 3Dpol, were most effective in inhibiting EV71 replication as compared to the 
2C and 3Cpro genes. The synthetic 29-mer shRNAs were also shown to be much more 
potent in inhibiting EV71 replication as compared to both the psiStrike plasmid-borne 
shRNAs and the chemically synthesized 19-mer siRNAs. 
 
Upon showing high efficacies in inhibiting EV71 replication in the in vitro 
system, the chemically synthesized 19-mer siRNAs, the psiStrike plasmids expressing 
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shRNAs and the chemically synthesized 29-mer shRNAs were evaluated in murine 
model and their efficacies in inhibiting EV71 infections were also compared. Results 
showed that both synthetic 19-mer siRNAs and plasmid-borne shRNAs targeted at the 
conserved 3Dpol region were able to inhibit EV71 infections in suckling mice when 
delivered with or without lipid carrier via the systemic route, and no interferon response 
was triggered. However, the chemically synthesized 29-mer shRNAs did not protect the 
suckling mice from EV71 infections despite being more potent in the in vitro system. The 
results indicated that RNAi is a potentially promising therapeutic approach against EV71 
infections. 
 
In the last part of this study, the complete VP1 (891bp) and 3Dpol (1386bp) 
sequences of EV71 strains isolated in the Asia Pacific region from 1995 to 2005 were 
obtained from the GenBank and the evolutionary rates of both the VP1 and the 3Dpol 
regions were analysed. The results showed that the evolutionary rate in the VP1 region 
was higher than the 3Dpol region, indicating high conservation in the 3Dpol region. Thus 
the chances of generating escape mutants from RNAi as a result of mutations are 
minimised. The evolutionary rate of the VP1 region of the EV71 strains isolated over the 
last 10 years was also observed to be lower when compared to that of the EV71 strains 
isolated from 1970 to 1998, suggesting that there will be lowered chances of the real-time 
RT-PCR in failing to detect EV71 as a result of mutations. 
 
The results in this study demonstrated an improvement in the diagnosis of EV71 
and development of a potential antiviral strategy against EV71 infections. 
 xx
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Enteroviruses belong to a genera classified under the Picornaviridae family. The 
human enteroviruses are further divided into subgroups, namely Echoviruses, Coxsackie 
A and B viruses, Polioviruses and other Enteroviruses (Melnick, 1996). Based on 
molecular properties, they were reclassified into five species: human enteroviruses A 
through D and polioviruses (King et al., 2000). Enteroviruses are represented by 89 
serotypes and among them, 64 serotypes are known to infect humans (King et al., 2000; 
Lindberg and Johansson, 2002). Traditionally, human enteroviruses were isolated using the 
cell culture method. Cell lines such as the human Rhabdomyosarcoma (RD), HeLa, Vero, 
Primary Monkey Kidney and human diploid lung (WI-38, MRC-5) cell lines were used 
(Schnurr, 1999). The enteroviruses were classified into various serotypes based on 
neutralization by antisera pools such as the LBM pool from the WHO (Melnick et al., 1977) 
or the RIVM (National Institute of Public Health and the Environment) pool from the 
Netherlands which was designed to replace the LBM pool (Schnurr, 1999, Muir et al., 1998). 
 
The stability of enteroviruses in the acidic environment allows them to be 
ingested and inhabit the alimentary tracts of humans and animals (King et al., 2000). 
Enteroviruses have been shown to cause from mild to life threatening diseases such as 
aseptic meningitis, respiratory illness, myocarditis, encephalitis and acute flaccid 
paralysis (Rotbart, 2002). Table 1.1 shows a brief description of the various clinical 
symptoms associated with infections caused by some of the enteroviruses. Currently, 
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there is much concern with the Hand, Foot and Mouth Disease (HFMD) caused by 
Enterovirus 71 due to its neurovirulence and high fatalities in some recent outbreaks in 
the Asia Pacific region.  
 
1.2 Enterovirus 71 
1.2.1 Clinical features of Hand, Foot and Mouth Disease caused by Enterovirus 71  
Enterovirus 71 (EV71) belongs to the human Enterovirus A species. The 
prototype strain, BrCr, was first isolated in 1970 in California from the stools of a 2 
month old infant suffering from encephalitis (Schmidt et al., 1974). EV71 has been 
increasingly recognized as the main etiological agent of HFMD, a mild childhood disease 
usually characterized by 3 to 4 days of fever, development of vesicular exanthem on the 
buccal mucosa, tongue, gums and palate, as well as papulovesicular exanthem on the 
hands, feet and buttocks (Figure 1.1). Other frequently encountered symptoms include 
poor appetite, vomiting and lethargy (Liu et al., 2000). In addition to HFMD, EV71 was 
also identified as a cause of herpangina which is an illness characterized by an abrupt 
onset of fever and sore throat, associated with the development of raised papular lesions 
on the mucosa of the anterior pillars of fauces, soft palate and uvula (Melnick, 1996). 
Children under 5 years of age were found to be highly susceptible to EV71-associated 
neurological diseases (Liu et al., 1998; Chan et al., 2000). Based on clinical findings, it 
was suggested that EV71 enters the host through the alimentary tract and uses the 










Table 1.1. Clinical manifestations of enterovirus serotypes.   
 
 
Clinical Manifestationsa  
 
 




Poliovirus 1-3; Coxsackievirus A7, A9,  
B2-5; Echovirus 4, 6, 9, 11, 30; Enterovirus 
70, 71 
 
Aseptic Meningitis Poliovirus 1-3; Coxsackievirus A2, A4, 
A7, A9, A10, B1-6; Echovirus 1-11, 13-23, 
25, 27, 28, 30, 31; Enterovirus 70, 71 
 
Hand, foot and mouth disease (HFMD) Coxsackievirus A5, A10, A16,  
Enterovirus 71 
 
Herpangina Coxsackievirus A2-6, A8, A10 
 
Acute hemorrhagic conjunctivitis Coxsackievirus A24, Enterovirus 70 
 
Encephalitis Echovirus 2, 6, 9, 19 
 
Meningoencephalitis Coxsackievirus B1-5, Enterovirus 70, 71 
 
Pericarditis, myocarditis Coxsackievirus B1-5 
 
 















Figure 1.1: Vesicles on the palm of a child infected with hand, foot and mouth 
disease (HFMD). Adapted from the Dermatologic Image Database, Department of 











   
Other enterovirus serotypes that are known to cause HFMD include CA16, CA5, CA9 
and Echo 7 (Melnick, 1996). However, EV71 has been increasingly recognized as the 
main causative agent of large scale HFMD outbreaks over the last few years in the Asia 
Pacific region. The HFMD clinical symptoms caused by EV71 are generally 
indistinguishable from CA16. Based on clinical features observed in patients suffering 
from HFMD in Japan (Komatsu et al, 1999), Malaysia (Chan et al., 2000) and Western 
Australia (McMinn et al., 2001), larger vesicles were observed in children suffering from 
CA16 infections when compared to those with EV71 infections, and the rashes were 
more frequently papular and/or petechial with areas of diffuse erythema on the trunk and 
limbs. Another significant clinical observation was that serious neurological diseases like 
brainstem and/or cerebellar encephalitis, acute flaccid paralysis (AFP) and aseptic 
meningitis were recorded for children with acute EV71 infections during the large scale 
HFMD outbreaks in the Asia Pacific region, and these were not presented in children 
with CA16 infections (Alexandra et al., 1994; Lum et al., 1998). It was reported recently 
that clinical symptoms such as fever, vomiting, tachycardia, breathlessness, cold limbs, 
and poor urine output were also found to be associated with severe EV71 infections, 
including neurological complications (Ooi et al., 2007). The neurological manifestations 
were frequently accompanied by complications such as pulmonary edema (Chang et al., 
1999; Chan et al., 2000) and myocarditis (Melnick 1996a), thus resulting in permanent 
paralysis and even death. The neurogenic pulmonary edema due to EV71 infections were 
reported in the major outbreaks in Sarawak in 1997 and in Taiwan in 1998 (Lum et al., 
1998; Cardosa et al., 1999). The infections appeared to be confined to the brainstem and 
there was histological evidence of acute inflammatory encephalitis and the presence of 
 5
LITERATURE REVIEW 
   
EV71 in the neurons (Wang et al., 1999). Leukocytosis and thrombocytosis were found 
to be more frequent in EV71 patients with pulmonary edema and lowered circulating 
CD4+ T cells, CD8+ T cells and natural killer (NK) cells (Lin et al., 2002; Wang et al., 
2003). Patients with both encephalitis and pulmonary oedema were found to have much 
higher levels of interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-alpha), 
interleukin 1 beta (IL-1 beta), white blood cell count and blood glucose (Lin et al., 2002). 
Recently, it was also shown that EV71 patients suffering from brainstem encephalitis and 
pulmonary edema had a significantly lower phytohemagglutinin stimulation index, 
suggesting that lower EV71-specific cellular response may be associated with the 
immunopathogenesis of EV71-related pulmonary edema (Chang et al., 2006). 
 
It was observed that there is a typical clinical course for all fatal EV71-associated 
cases: the symptoms were displayed for less than one week before hospitalization, and 
subsequently the patient’s condition rapidly deteriorated, with death occurring within 
hours to a few days of hospitalization (Chan et al., 2000; Liu et al., 2000). For example, 
the EV71 outbreak in Bulgaria in 1975 was characterized by a rapid onset of central 
nervous system disease described as bulbar polioencephalitis (Shindarov et al., 1979). In 
1998 in Taiwan 1998, 78 fatalities were reported to be due to cardiopulmonary collapse, 
and it was suggested that the collapse was triggered by a combination of CNS and 







   
1.2.2 Genomic structure and analysis of EV71 
EV71 is a positive single-stranded RNA virus of approximately 7.5kb in length, 
consisting of a non-enveloped capsid. The complete sequence of a few EV71 strains have 
been determined, such as the prototype strain BrCr (Accession no. U22521), the 
neurovirulent 7423/MS/87 strain (Accession no. U22522) (Brown and Pallansch, 1995), a 
fatal 5865/sin/000009 strain (Accession no. 316321) and a non-fatal strain 
5666/sin/002209 (Accession no. 352027) isolated from two patients during the outbreak 
in Singapore (Singh et al., 2002). The genome consists of a 5′untranslated region 
(5′UTR), a single open reading frame (ORF) encoding a polyprotein of 2194 amino 
acids, a short 3′ untranslated region (3′UTR) and a poly-A tail of variable length. The 
polyprotein is subdivided into three regions, namely P1, P2 and P3. The P1 region 
encodes four structural proteins (VP1 to VP4), the P2 and P3 regions encode seven 
nonstructural proteins, 2A to 2C and 3A to 3D, respectively (Figure 1.2). The function(s) 
of each of the individual region appeared to be identical to those of other enteroviruses 
(Gromeier et al., 1999).  
 




A previous study carried out on the 5′UTR of poliovirus has shown that this 
region is important in RNA synthesis and translation (Alexander et al., 1994). Basically, 
the 5′UTR region is divided into two main parts; the first 90 base pairs are involved in 












Figure 1.2: Genome structure of EV71. The single ORF is flanked by UTRs at the 5' 
and 3' ends, a variable length poly-A tail is found at the 3' UTR. The ORF is divided into 
three regions: the P1 region encodes four structural proteins VP1– VP4, the P2 and P3 
regions encode seven non-structural proteins 2A–2C and 3A– 3D, respectively. (Adapted 












   
structure will result in defects in RNA synthesis (Andino et al., 1990). The second 
portion contains the determinants for translation of the viral RNA and they are termed as 
the internal ribosomal entry sites (IRES). All Picornaviruses were found to contain this 
portion for replication of the viral RNA (Evans et al., 1985; Hellen at el., 1995). 
Comparison studies have shown that the secondary structures within the 5′UTR could be 
disrupted by point mutations. However, the primary sequences are well conserved 
amongst enteroviruses, in particular the first 650 bases (Rotbart, 1990; Hellen et al., 1995; 
Zheng et al., 1995). In fact, this feature has been exploited for the general detection of 
enteroviruses (Rotbart, 1990; Zoll et al., 1992; Read et al., 2001; Nijhuis et al., 2002; 
Petitjean et al., 2006). The 3′UTR region contains a pseudo-knot like structure and is 
important for the replication of EV71. 
 
1.2.2.2  Virus capsid structural proteins 
The viral capsid is icosahedral (T=1) in symmetry and is composed of 60 identical 
units (protomers) and each protomer is comprised of four structural proteins: VP1 to VP4 
(Hogle et al., 1985). VP1, VP2 and VP3 are the main structural components of the virion, 
whereas VP4 is wholly internal. As an immune response to infection, antibodies are 
usually elicited against the exposed loops that are the major components of the 
neutralizing antigenic sites (Minor, 1990; Rotbart and Romero, 1995). Although the 
antigenic determinants for EV71 have not been characterized yet, surface topography 
analysis and protein structure modeling have shown that VP1 forms peaks separated by 
canyons, and comparisons with other enteroviruses have indicated that the VP1 region 
appears to be the most immunodominant (Oberste et al., 1999).  
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1.2.2.3  Non-structural proteins 
The P2 region of the viral genome encodes the polypeptides 2A, 2B and 2C. 2A 
codes for a trypsin-like proteinase that catalyzes cleavage of its own amino terminus and 
releases the P1 capsid protein precursors from P2 and P3. 2A was also found to be 
involved in the shut-off of the host protein synthesis and initiation of IRES-dependent 
translation (Hellen and Wimmer, 1995). Not much is known about 2B yet. In the case of 
2C, it is found to be the most strongly conserved of all enteroviral proteins. It contains 
three well-characterized sequence motifs, namely, an amino terminal amphipathic helix, a 
binding site and a putative zinc finger in the carboxy-terminal of the polypeptide (Hellen 
and Wimmer, 1995). The 2C protein was found to be closely associated with replication 
complex-associated vesicles, suggesting that they are involved in viral replication (Beinz 
et al., 1990). Recently, a host protein known as reticulon 3 was found to be associated 
with the EV71 viral replication complex through interaction with the N-terminus of the 
2C protein (Tang et al., 2006). This provided further evidence in the involvement of the 
2C protein in EV71 replication. 
 
The P3 region consists of the polypeptides 3A, 3B, 3C and 3D. 3A was found to 
be tightly associated with replication complexes in infected cells and form part of the 
precursor 3AB. The polypeptide complex 3CD is a proteinase that is involved in cleaving 
the P1 precursor to release the structural proteins VP0, VP1, and VP3 (Hellen and 
Wimmer, 1995). The polypeptide 3CD can be proteolytically cleaved to yield 3C and 3D. 
3C forms the catalytic core in the cleavage of the structural proteins while 3D codes for 
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viral RNA-dependent RNA polymerase which forms a replication complex with the viral 
factors to initiate RNA chain elongation (Hellen and Wimmer, 1995). 
 
1.2.3 Epidemiological surveillance of EV71 infections 
Australia was the first country in which EV71 was isolated outside of the USA 
during an epidemic of aseptic meningitis between 1972 and 1973 (Kennett et al., 1974). 
The neurovirulence of EV71 was manifested during a large EV71 outbreak in Bulgaria in 
1975, which resulted in 44 fatalities (Chumakov et al., 1979). Linkage of EV71 with 
HFMD was reported in 1973 during small-scale epidemics in Sweden (Blomberg et al., 
1974) and Japan (Hagiwara et al., 1978). Since then, several major HFMD outbreaks 
with significant fatalities were reported in Malaysia (1997), Taiwan (1998) and Singapore 
(2000). In the outbreak that occurred in Sarawak, Malaysia in 1997, a total of 2,628 
HFMD cases were caused by EV71 and there were 29 fatalities being reported (Chan et 
al., 2000). It was in this outbreak that a new clinical presentation known as pulmonary 
edema was reported, and has led to cardiopulmonary arrest in a large number of pediatric 
patients as a result of EV71 infections (Chan et al., 2000). Other than Sarawak, there 
were 12 fatalities being reported in Peninsular Malaysia around the same time (Lum et al., 
1998). The outbreak in Taiwan in 1998 was the largest HFMD epidemic reported in 
recent time. A severe and widespread outbreak of enterovirus infections involving more 
than 150,000 cases was reported. More than 400 children were hospitalised, with 78 
fatalities arising from central nervous system involvement and cardiopulmonary collapse. 
EV71 was incriminated as the causative agent for the fatal cases (Ho et al., 1999; Wu et 
al., 1999). In Singapore, before the major outbreak in year 2000, HFMD cases were 
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found to be sporadic and rarely complicated by CNS involvement. Small scale outbreaks 
of HFMD were reported in 1993 (310 cases) and in 1997 (358 cases) (Ministry of Health, 
Singapore). EV71 together with CA9, CA16, CB2, CB3 and echoviruses were found to 
be the main etiological agents of HFMD (Ministry of Health, Singapore).  The major 
outbreak in October 2000 was the first of its kind in the country, with a total of 3,790 
HFMD cases and 4 fatalities were reported (Ahmad, 2000). Most of the HFMD patients 
were children below 4 years old and some adults aged 24 to 36 years old were also 
infected. Before the major outbreak in Singapore in 2000, a large-scale outbreak of 
HFMD occurred in Perth, Western Australia in 1999, and 14 cases with severe 
neurological complications were reported. Out of the 14 patients, 9 displayed 
neurological symptoms and 4 sustained long term neurological sequelae (McMinn et al., 
2001). Since the major outbreaks which affected the Asia Pacific region in year 2000, 
small scale HFMD outbreaks were reported in countries such as Malaysia, Taiwan, China, 
Hong Kong, Brunei, India, Singapore, USA and Germany from 2000 to 2006 
(http://www.promedmail.org). EV71 was isolated from some of these cases, and resulted 
in 4 fatalities among the 60 cases reported in Taiwan in 2005 
(http://www.promedmail.org). A larger scale of HFMD outbreak occurred recently in 
Sarawak, Malaysia in 2006. More than 13,000 cases were reported and there were 13 
fatalities. More than half of the patients were infected with EV71 (Ministry of 
Environment, Malaysia; http://www.promedmail.org). About 3,000 cases of non-fatal 
HFMD cases were also reported in Singapore at the same time and 75% of the cases were 




   
The understanding of the molecular epidemiology and evolution of EV71 took a 
major step forward when Brown et al. (1999) reported the phylogenetic analysis of EV71. 
The study compared the complete VP1 gene sequences of 113 EV71 isolates from all 
over the world. To investigate the genetic variability of various EV71 strains and their 
associations with outbreaks, Brown et al. (1999) determined the complete sequences of 
the VP1 region (891bp) of EV71 strains isolated from various countries. Through an 
analysis of the complete VP1 region of EV71 strains over a 30-year period, Brown et al. 
(1999), showed the development of three independent genetic lineages represented by 
genogroups A, B and C. Genogroup A contains only the prototype strain BrCr, whist the 
rest of the EV71 strains were classified under either genogroup B or C and these were 
further subdivided into B1, B2 or C1, C2 sub-lineages (Figure 1.3). Within each of the 
subgenogroups, EV71 strains shared >92% nucleotide sequence identity, whereas the 
nucleotide sequence identity between the three genogroups ranged from 78 to 83%. No 
correlation was established between the EV71 genogroups and severity of the disease 
since EV71 strains from all genogroups were capable of causing severe diseases (Brown 
et al., 1999).  
 
Phylogenetic relationships of EV71 strains isolated from the major outbreaks in 
Asia Pacific were further established based on other regions of the EV71 genome such as 
the 5’UTR (Abubakar et al., 1999; Wang et al., 2000), VP1 (Shih et al., 2000; McMinn 
et al., 2001b; Cardosa et al., 2003), and the VP4 (Shimizu et al., 1999; Chu et al., 2001; 
Cardosa et al., 2003; Lin et al., 2006). Analysis of the partial VP1 region (500bp) of 18 
EV71 strains from the 1998 outbreak in Taiwan showed that majority of the viruses  
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Figure 1.3:  Classification of 113 EV71 strains into genogroups based on the VP1 
gene (position 2442 to 3332). The dendrogram was generated by the neighbor-joining 
method with the DNADIST distance measure program (PHYLIP, version 3.5) (Adapted 







   
belonged to the subgenogroup C2 (Shih et al., 2000). McMinn et al. (2001b) compared 
the complete VP1 gene sequences of 66 EV71 strains isolated from Malaysia, Singapore, 
Taiwan and Western Australia between 1997 and 2001 and established two more 
sublineages within the genogroup B which circulated in Southeast Asia between 1997 
and 2001. EV71 strains in the subgenogroup B3 were the predominant strains isolated 
from the epidemics in Sarawak and Peninsular Malaysia in 1997 and in Western 
Australia in 1999. EV71 strains belonging to the subgenogroup B4 were responsible for 
the outbreak in Singapore in 2000 (Figure 1.4). Based on the phylogenetic analysis of the 
VP1 region of 45 EV71 strains which were isolated over a 6 year period in Yamagata, 
Mizuta et al. (2005) found that the outbreaks in Yamagata were mainly caused by EV71 
strains belonging to the B4, C2 and C4 subgenogroups. However, there were a few EV71 
strains which were isolated that could not be placed into any of the three genogroups and 
these were classified into a new subgenogroup known as B5 (Figure 1.5). More EV71 
strains were classified into the subgenogroup B5 when Ooi et al. (2007) analysed the 
VP1 and VP4 of EV71 isolated from 277 patients in Malaysia from 2000 to 2004. The 
genogroup analysis of infected patients revealed that 168 were infected with EV71 strains 
from the subgenogroup B4, 68 patients with EV71 from the subgenogroup C1, and 41 
patients infected with EV71 from the newly emerged B5 subgenogroup. 
 
Besides the VP1 region, there were a few phylogenetic studies of EV71 focusing 
on the diversity of the VP4 region. Chu et al. (2001) examined a partial VP4 region 
(207bp) of 23 EV71 strains isolated from the 1998 Taiwan epidemic and 21 others 









Figure 1.4: Phylogenetic tree showing classification of 25 EV71 field isolates into 
subgenogroups based on alignment of the complete VP1 sequence (nucleotide 
positions 2442–3332). Branch lengths are proportional to the number of nucleotide 
differences. Strain names indicate a unique number/country or U.S. state of isolation/year 
of isolation: AUS – Australia; CA – California, USA; CT – Connecticut, USA; IA – 
Indiana, USA; MAA – Peninsular Malaysia; OR – Oregon, USA; SAR – Sarawak, 
Malaysia; SIN – Singapore; TW – Taiwan; TX – Texas, USA. The VP1 nucleotide 













Figure 1.5: Phylogenetic classification based on the complete (891-nucleotide) VP1 
sequence. Representative EV71 strains were isolated in Yamagata, Japan, between 1998 




   
7423/MS/87 strain, three strains isolated during the 1986 outbreak in Taiwan, and 16 
strains isolated from Japan. The EV71 prototype BrCr strain was the only strain 
designated as genogroup A. Genogroup B included strains from the United States, Japan 
and Taiwan. Genogroup C consisted of strains from Japan and Taiwan. It was observed 
that strains clustered within genogroup C have a higher evolutionary rate (3.9X10−3) than 
those in genogroup B (1.4X10−3). Cardosa et al. (2003) analysed the partial VP1 and VP4 
regions of 128 EV71 strains isolated from 1970 to 2002 from the United States, Japan, 
Taiwan, Malaysia, Singapore, China, Bulgaria, Hungary and the United Kingdom. 
Analysis of either the VP1 or the VP4 gene sequences provided similar phylogenetic 
classifications of the EV71 strains. However, higher bootstrap values were observed in 
the VP1 dendrograms, thus providing greater confidence when elucidating new 
genogroups (Cardosa et al., 2003). Similar phylogenetic classification between the VP1 
and VP4 regions was further shown in two recent separate studies which carried out 
genetic analysis of a 207bp region within the VP4 sequence and 414 bp within the VP1 
region on the EV71 strains isolated in Taiwan from 1998 to 2005 (Lin et al., 2006; Kung 
et al., 2007). Both studies demonstrated the predominance of the subgenogroup B1 
before 1998 whilst the subgenogroup C2 was the major etiologic group in the 1998 
outbreak. The subgenogroup B4, which was a minor etiologic group during the 1998 
outbreak, was the major subgenogroup isolated from 1999 to 2003. The subgenogroup C4 
emerged in 2004 and became the predominant subgenogroup in Taiwan.  
 
To date, a total of 10 genogroups have been identified amongst EV71 strains. 
Based on the phylogenetic analysis, there is a great diversity of EV71 strains circulating 
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in the Asia Pacific region and other parts of the world. However, no significant 
differences in genome sequences were found between EV71 strains isolated from fatal 
and non-fatal cases. This was evident from a comparative sequence analysis carried out 
by Singh et al. (2002), who showed that the fatal Singapore strain 5865/sin/000009 
belonging to the subgenogroup B4 had 99% nucleotide and 100% amino acid similarity 
with the non-fatal Singapore strain 5666/sin/002209 from the same subgenogroup. Both 
strains showed significant differences when compared to EV71 strains such as the 
prototype BrCr strain (genogroup A) and the neurovirulent strain 7423/MS/87 
(subgenogroup B2). Thus, there is no particular genogroup/subgenogroup which has been 
implicated to be associated with severe neurological complications (Singh et al., 2002; 
Cardosa et al., 2003). Since EV71 can cause severe neurological diseases, further studies 
are required to understand the factors that could contribute to the spread of this virus, and 
the genetic factors that lead to its evolution, neurovirulence and epidemic potential. 
 
1.3 Diagnosis of EV71 infections 
 
1.3.1 Tissue culture isolation and serotyping by neutralization 
Isolation of EV71 in cell cultures, followed by neutralization using pooled 
antisera is regarded as the gold standard and has been the practice for diagnosing EV71 
infections. EV71 has been grown in cell lines such as Vero (African green monkey 
kidney cell line), human Rhabdomyosarcoma (RD) cell line, MRC-5 (human lung 
fibroblast cell line) and MDCK (monkey kidney cell line) (Ho et al., 1999; Wang et al., 
2000). EV71 were isolated from clinical specimens derived from the brainstem, skin, 
myocardium, liver, intestinal mucosa, stools, urine, CSF, serum, throat and rectal swabs 
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(Yan et al., 2000; Singh et al., 2002). Serotypic identification of enteroviruses could be 
determined by neutralization with serotype-specific antisera. The Lim Benyesh-Melnick 
(LBM) pool which was widely used for serotyping of enteroviruses was derived from 
serotype-specific hyper-immune sera (Lim et al., 1960). Alternative intersecting pools of 
antisera developed by the National Institute of Public Health and Environment in the 
Netherlands (RIVM) allowed identification of enteroviruses 68-71 (Kapsenberg, 1988). 
Despite being regarded as the gold standard, the tissue culture method has its limitations 
in detecting EV71. The duration for the isolation and identification of EV71 by 
neutralization requires one to two weeks. In addition, the accuracy of the diagnosis may 
be affected by the nature of the clinical specimens (e.g. CSF). As the viral titre present in 
clinical specimens such as the CSF might be low, there is a need to propagate the virus 
and this contributes to the lengthy period for virus isolation. In some instances, 
neutralization could be hindered due to aggregation of the virus, antigenic drifts, or 
presence of multiple viruses in the clinical specimens (Schmidt et al., 1974; Muir et al., 
1998; Brown et al., 2000), and this was supported by Singh et al., (2002), who has shown   
a sensitivity rate of 20% in isolating EV71 directly from clinical specimens cultivated in 
tissue cultures. Besides being time consuming and of low sensitivity, the micro-
neutralization test is another major factor which renders the tissue culture method 
unsuitable as a diagnostic in outbreak situations. This is due to the fact that the micro-
neutralization test mainly detects the presence of IgG which is elicited at a later stage of 
infection. This renders it unsuitable in outbreak situations where rapid and accurate 
diagnosis at an early stage of EV71 infection is needed so that disease preventive 
measures could be implemented to prevent transmission. 
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1.3.2 Enzyme Linked Immunosorbent Assay (ELISA)  
The detection of IgM in sera from EV71-infected patients by ELISA was shown 
to be effective in diagnosing acute EV71 infections (Tano et al. 2002). A similar 
approach based on the detection of IgM from immune sera to diagnose EV71 showed a 
high sensitivity and specificity of 97.7% and 93.3%, respectively (Wang et al., 2004). 
However, although ELISA is commonly used in diagnostic laboratories, it has its 
limitations. In the IgM-capture ELISA, the whole EV71 virion was used as the antigen 
and the need to prepare large quantities of purified virions and interacting with secondary 
anti-human IgM in the ELISA assay made the method an expensive, laborious and 
lengthy process. Since the whole virus is used as the capture antigen in the ELISA assay, 
cross-reactions with antibodies against other enteroviruses could result in false positives. 
Thus, the specificity of the IgM-based ELISA could be compromised by the presence of 
common epitopes of other enteroviruses. 
 
1.3.3 Immunofluorescence assay (IFA) 
Another approach for EV71 detection is the indirect immunofluorescence assay 
(IFA) which involves the use of a serotype-specific monoclonal antibody to identify the 
virus (Ho et al., 2000). This method allows serotype-specific identification of EV71 
grown in cell cultures without using anti-sera pools. Vero, RD and MRC-5 cell lines are 
commonly used for inoculations of clinical specimens (Ho et al., 1999). To identify 
presence of EV71, immunohistological staining with a monoclonal anti-EV71 antibody 
(Chemicon International, USA) was performed. The monoclonal antibody bound to the 
EV71 isolated from the cell culture and the antigen-antibody complex was detected by a 
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secondary FITC (fluorescent isothiocyanate-labeled) antibody under fluorescent 
microscopy. However, this method involved the isolation and propagation of EV71 in the 
cell culture which generally required one to two weeks. More importantly, the 
monoclonal antibody was also reported to cross-react with CA16 (Yan et al., 2001). In 
addition, the antibody was raised against the prototype BrCr strain and might not detect 
EV71 strains belonging to other genogroups or newly evolved strains. 
 
1.3.4 Molecular Detection Methods 
The polymerase chain reaction (PCR) has been accepted as the “new” standard for 
detection of viruses in diagnostic microbiology laboratories. Most of the PCR primers 
designed for the detection of enteroviruses were targeted at the highly conserved 5′UTR 
region of the genome (Rotbart, 1990; Zoll et al., 1992). The advantage of a detection 
strategy for enteroviruses based on the 5′UTR is that a single pair of primers could be 
used for the identification of enteroviruses in general. However, no information could be 
obtained regarding the identity of the specific enterovirus without sequencing of the 
amplicons. There is little correlation between the enterovirus serotype and the highly 
conserved 5′UTR region. Although there were phylogenetic studies targeting the VP4-
VP2 junction which suggested that this region might be more suitable for developing 
serotype specific diagnostics, it appeared to correlate only partially with serotypes (Arola 
et al., 1998; Oberste et al., 1998). With increasing concerns on fatal HFMD infections 
caused by EV71, specific and rapid identification of EV71 from clinical specimens has 




   
 
 
1.3.4.1  PCR-ELISA 
The PCR-ELISA detection format for enteroviruses was developed by Rotbart et 
al. (1994, 1997) based on their earlier work on identification of enteroviruses using 
conventional RT-PCR. The method was based on the principle of amplification and 
detection of the amplified DNA by ELISA. The Light Diagnostics Pan-Enterovirus 
OligoDetectTM kit (Chemicon International, USA) was able to detect enterovirus specific 
RT-PCR products amplified from clinical specimens. The detection was by ELISA 
analysis of the RT-PCR products through hybridization to an internal biotinylated probe 
conjugated to streptavidin-coated microtitre plates. Colorimetric detection of positive 
specimens is based on the reaction of HRP with the substrate 3, 3′, 5, 5′-
tetramethylbenzidine (TMB) (Figure 1.6). As the primers were designed to target at the 
5′UTR region of the viral genome, the PCR-ELISA method is applicable for the detection 
of enteroviruses in general, but still not able to resolve the specific serotype.  
 




Since analysis of the VP1 region was shown to correlate more closely with 












Figure 1.6: Pan-Enterovirus OligoDetect® Kit Principles.  RT-PCR was first 
performed followed by ELISA analysis using the PCR product.  Colorimetric detection 
was possible upon reaction of HRP with the substrate 3,3′,5,5′– tetramethylbenzidine 
(TMB) and a colour change was observed in positive specimens. (Adapted from 










   
genome (Brown et al., 2000; Singh et al., 2000; Yan et al., 2001; Singh et al., 2002). 
Brown et al. (2000) designed two pairs of primers that targeted sequences within and 
around the VP1 region and were able to amplify EV71 RNA specifically from 125 
different EV71 tissue culture isolates. Singh et al. (2000) designed another pair of 
primers which could detect EV71 isolates from tissue cultures which were inoculated 
with clinical specimens. In a separate study, Yan et al. (2001) developed two sets of 
primers for the specific detection of EV71 and CA16, respectively. Both pairs of primers 
were designed based on the VP1 sequences of the respective viruses and were evaluated 
against 57 isolates of EV71, 16 CA16 isolates and several other enteroviruses. Although 
the EV71-specific primers were shown to be highly specific for amplification of EV71 
RNA, the primers designed against CA16 were found to be nonspecific as they were able 
to amplify EV71 RNA (Yan et al., 2001).  The study by Singh et al. (2002) was the first 
group to detect EV71 directly from clinical specimens using specific primers targeted the 
VP1 region. It was in this study which demonstrated that the three pairs of primers which 
were designed previously by Brown et al. (2000) and Singh et al., (2000) had low 
sensitivities (only 5%) in direct detection of EV71 from clinical specimens. Thus, a semi-
nested RT-PCR strategy was employed and this method achieved a higher sensitivity 
(53%) in detecting EV71 RNA directly from clinical specimens in contrast to only 20% 
detection rate based on the cell culture method. However, conventional PCR analysis 
requires multiple post-PCR handling steps such as agarose gel electrophoresis and DNA 
sequencing which are time consuming and pose higher risks of cross contamination. In 
addition, the sensitivity of conventional PCR may be compromised when applied on 
clinical specimens such as CSF which are often characterized by low viral loads. An 
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improvement of the conventional RT-PCR, known as the miniature RT-PCR system was 
developed by Liao et al. (2005) for rapid diagnosis of RNA viruses, such as Dengue virus 
and EV71. The principle was based on conventional RT-PCR carried out in a miniature 
volume of 12cm by 21 cm by 8.5cm and was operated by 9V batteries. Serum collected 
from a patient was loaded into a valve and the one-step RT-PCR process was carried out 
in the automated system which reduced cross-contamination. Since a microchip was used 
to control the temperature, high efficiencies of PCR with detection limits of as low as 
6pg/ul was achieved. However, the PCR products obtained from this system must still be 
resolved by agarose gel electrophoresis and subsequent DNA sequencing.  
 
1.3.4.3  Combination of RT-PCR and specific probe hybridization  
In a recent study, a combination of multiplex RT-PCR and microarray method 
was developed to differentiate EV71 from CA16 (Chen et al., 2006). Using specific 
primers, RT-PCR was first carried out to amplify EV71 and CA16 viral RNAs. The 
amplicons were then labeled with fluorescent dyes and added to array slides which were 
spotted with 60-mer degenerate oligonucleotide probes which were specific for the 
detection of either EV71 or CA16. A diagnostic accuracy of 92% and 95.8% was 
achieved for specific detection of EV71 and CA16, respectively. In another study, a 
microchip method was developed by Tsao et al. (2006).  By combining conventional RT-
PCR, followed by hybridizing the biotinylated PCR products to specific probes for EV71 
detection, a sensitivity of 82% was achieved (Tsao et al., 2006). However, the detection 
of EV71 from clinical specimens by both approaches is laborious and requires at least 10 
hours which is too long in outbreak situations. 
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1.3.5 Real-time PCR 
Real-time PCR is an improvement of the classical PCR amplification process in 
which monitoring of the accumulating amplicons during the course of the PCR is made in 
real time. It was first described by Higuchi et al. (1993), who proposed a kinetic model 
that the process of denaturation, primer annealing and template extension did not just 
occur at discrete temperatures as is the case for conventional PCR, but may be occurring 
simultaneously during temperature transitions (Figure 1.7).  
 
1.3.5.1  Advantages of real-time PCR over conventional PCR 
In conventional PCR analysis, the detection of the amplified DNA usually relies 
on agarose gel electrophoresis in the presence of ethidium bromide, followed by 
visualization under ultraviolet light. Alternatively, hybridization assays which employ 
labelled oligonucleotide probes that are specific for the respective amplicons are used. 
However, these methods are time consuming, require post-PCR handling and increase the 
chances of cross contamination. In real-time PCR, monitoring of the amplification in 
real-time was made possible by labeling of probes and amplicons with fluorogenic 
molecules (MacKay et al., 2002; Espy et al., 2006). This method has its advantages over 
radiogenic oligoprobes, including avoidance of radioactive emissions, ease of disposal 
and extended shelf life (MacKay et al., 2002). Real-time PCR also offers reduced cycling 










Figure 1.7: Equilibrium versus kinetic thermal cycling theory. A represents the 
denaturation phase, B, the primer annealing phase and C, the template extension phase. 
The kinetic theory postulates that the three processes do not occur at discrete 
temperatures, but rather, during the temperature transitions, the processes may be 










   
In addition, due to the relatively small volumes and the high sensitivity of the real-time 
PCR systems, small changes in fluorescence emission can be monitored readily, thereby 
allowing small initial amounts of templates to be detected (Wittwer et al., 2001). 
Quantitation of the amounts of templates in the specimens can also be achieved based on 
standard curves (Ramussen, 2001). 
 
1.3.5.2  Approaches to real-time PCR 
There are three major chemistries available for amplicon detection based on real-
time PCR, and they are classified into amplicon sequence specific methods or non-
specific methods based on the principles illustrated from Figures 1.8 to 1.11. The 
sequence non-specific detection method is based on the DNA-binding fluorogenic 
molecules. Initially, ethidium bromide was used as a double-stranded DNA (dsDNA) 
binding dye that fluoresces under ultraviolet light. Research led to another similar dye, 
known as SYBR Green I, which is widely used in real-time PCR. When exposed to a 
suitable wavelength of light, the dye will fluoresce when associated with dsDNA and the 
fluorescence will be detected by sensitive fluorimeters in the real-time PCR instruments 
(Figure 1.8). For the SYBR Green I approach, fluorescent melting curve analysis can be 
applied for detection of different amplification products based on differences in melting 
temperatures (Tm) which depend on the %G+C content and length of the amplification 
product. This is similar but not equivalent to agarose gel electrophoresis where the 
separation is based primarily on the size of the PCR amplicons. Since different nucleotide 
substitutions can give rise to changes in Tm, this analysis is very useful for monitoring 
genomic regions that undergo fairly high mutation rates (Wittwer et al., 2001). However,  
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Figure 1.8: Diagram illustrating the concepts for dsDNA binding fluorescent dye 
(SYBR Green I). For SYBR Green I assay, the dye fluoresces only when bound to 









   
formation of primer-dimers can confuse interpretation of results, as the fluorogenic dye 
can bind to any dsDNA product. Thus, the melting curve analysis is useful here; the 
shorter primer-dimer can be discriminated by its reduced Tm compared to the actual 
amplicon (Read et al., 2001; Wittwer et al., 2001).   
 
Another approach involves the use of a pair of adjacent, fluorogenic hybridization 
oligoprobes which have become the method of choice for the LightCycler (Roche Molecular 
Biochemicals, Germany). The upstream oligoprobe is labeled with a 3′ donor fluorophore 
(Fluorescein) and the downstream probe is labeled with either LightCycler Red 640 or Red 
705 acceptor fluorophore at the 5′ terminus, so that when both oligoprobes are hybridized to 
the target template, the two probes are located within 10bp of each other. Their use briefly 
involves the principle of fluorescence resonance energy transfer (FRET), a method in which 
the donor dye transfers a quantum of energy to the acceptor dye upon excitation by 
ultraviolet, and the acceptor dye releases a photon of different wavelength upon return to 
rest (Figure 1.9). If the two probes do not align together because there is no specific DNA 
for them to bind, then FRET does not occur between the two dyes because the distances 
between the probes are too great. Since more fluorescence is emitted with the increasing 
number of amplicons, quantification can be performed (Bernard et al., 2001). In addition, 
since the probes are not significantly hydrolyzed, the LightCycler is able to monitor the 
changes in fluorescence emission when the oligoprobes are denatured from their 
amplicons (Mackay et al., 2003; Espy et al., 2006). When the temperature is slowly 
raised, eventually the probes will no longer be able to anneal to the target PCR product 
and the FRET signal will be lost. The temperature at which half the FRET signal is lost is 
referred to as the Tm of the Hybridization probe system. The Tm depends on the GC 
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content and length of the hybridization probes. The melting curve analysis is able to 
provide significant information about the sequences in which the probes are binding. It is 
especially useful in situations where the genome of the microorganisms such as viruses 
tend to mutate at a high frequency. When a single or limited number (< 3) of known 
polymorphisms occur between two similar targets, hybridization probes can be used for 
discriminating strains of microorganisms. Any mutation(s) in the region where the probes 
bind to can be determined by the decrease in the Tm due to the slight destabilization of 
the probe-sequence duplex (Figure 1.10). This strategy has been successfully used for 
differentiation of Varicella-Zoster virus (Espy et al., 2000a), herpes simplex virus (Espy 
et al., 2000b) and hepatitis C virus (Ratge et al., 2000).  
 
The third chemistry employed in real-time PCR is to use a Taq polymerase that 
has a 5′exonuclease activity. The principle of the process was first described by Holland 
et al. (1991) and it was utilized with fluorescent and quencher dyes by Livak et al. 
(1995). In the TaqMan probe-based approach, the probe contains one fluorophore (6-
carboxy-fluoroscein) at its 5′ terminus and a quencher (6-carboxytetramethyl- rhodamine; 
TAMRA) at its 3′ terminus. When in close proximity, the two dyes formed a quenched 
system and no fluorescence was observed. However, when the probe hybridized to its 
template, the 5′exonuclease activity of the Taq polymerase would hydrolyse the probe 






















Figure 1.9: Diagram illustrating the concept real-time Hybridization probe-based 
PCR. The adjacent hybridization of the probes to the template results in a FRET signal 
due to interaction between the donor (D) and acceptor (A) fluorophores, and fluorescence 














Figure 1.10: Fluorescent melting curve analysis. When one or more mutations are 
present in the template, the Tm is shifted. This can be used diagnostically to discriminate 





   
emissions of the fluorophore were no longer being quenched and fluorescence was 
detected (Figure 1.11). Real-time TaqMan probe assay has been used in the diagnosis of 
viruses such as Epstein-Barr virus and cytomegalovirus (Jebbink et al., 2003). However, 
since the 5′exonuclease activity is irreversible, analysis of the results is completed after 
the PCR amplification. Thus, unlike SYBR Green I and Hybridization probe-based 
assays, no secondary confirmation like the melting curve analysis is available for 
TaqMan probe-based assays. 
 
1.3.5.3  Detection of enteroviruses using real-time PCR 
Several studies which detect enteroviruses using the real-time PCR approach have 
been reported. Read et al. (2001) developed a real-time SYBR Green I assay to detect 
enteroviruses, differentiating them from other viruses like HSV-1, HSV-2 and Varicella-
Zoster virus (VZV) that cause central nervous system infections. In the study, the use of 
the melting curve analysis for differentiation of different viruses were observed based on 
different melting curve peaks (Tm). The Tm values were determined for each enterovirus 
serotype, but the average difference between the Tm of the amplicons between each 
serotype was only 1.37oC.  
 
 The TaqMan probe assay was a popular approach for the detection of 
enteroviruses. Using the ABI Prism 7700 PCR instrument (USA), Verstrepen et al. (2001) 
and Nijhuis et al. (2002) developed TaqMan probe assays for the specific detection of 











Figure 1.11: Diagram illustrating the concepts for the TaqMan probe assay. When in 
close proximity, the reporter dye (R) and the quencher (Q) formed a quenched system 
and no fluorescence is observed. Upon exonuclease digestion during the PCR reaction, 
the fluorigenic dye is released from the close proximity of the quencher dye and is hence 












   
enteroviruses was achieved and the assay was able to detect up to 11.8 genome 
equivalents of enterovirus per ml of CSF. In the study reported by Nijhuis et al. (2002), 
the TaqMan probe assay developed was able to detect 60 different enteroviruses but not 
other viruses from other genera which were also classified under the Picornarviridae 
family. Direct detection of enteroviruses from the cerebrospinal fluid (CSF) clinical 
specimens by real-time TaqMan RT-PCR was developed by Watkins-Riedel et al. (2002) 
and Petitjean et al. (2006) using the LightCycler real-time detection system (Roche 
Molecular Biochemicals, Germany) and the ABI Prism 7700 PCR instrument (USA), 
respectively. Both systems were shown to be highly sensitive and specific in detection of 
enteroviruses from the CSF clinical specimens which were often characterized by very 
low viral titres. 
 
In another study, Kares et al. (2003) developed a hybridization probe-based assay 
which could simultaneously detect and differentiate enteroviruses and rhinovirus based 
on melting curve analysis. In the same study, the poliovirus was found to have a melting 
curve and a specific Tm that could be distinguished from other non-polio enterovirus 
serotypes.   
 
Besides the specificity and rapidity in detection, the real-time PCR assay was also 
shown to be more sensitive than the cell culture method, as the assay was able to detect 
EV71 at far lower concentrations. However, in all the studies, the primers and the probes 
were designed to target at the 5'-untranslated region (5'UTR) of the enterovirus genome 
which is highly conserved among enteroviruses, and molecular epidemiological studies 
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have shown that the diversity in this region did not correlate well with enterovirus 
serotypes (Oberste et al., 1999). Thus, in all these studies, EV71 could not be 
differentiated effectively from other enterovirus serotypes without DNA sequencing. 
 
1.4 Treatment for EV71 infections 
Management of patients with EV71 infections is difficult but important. A 
number of antiviral agents with activities against enteroviruses have been developed but 
none has come close to commercialization. Stages in enterovirus replication such as cell 
susceptibility, attachment to host cell, uncoating, synthesis of viral mRNA and 
maturation of new virus proteins could serve as potential targets for therapeutic 
interventions.  
 
Interferons have been shown to be a potent inhibitor of most enteroviral infections 
and synergistic protection was observed when used in conjunction with capsid-binding 
compounds (Kandolf et al., 1985; Langford at el., 1985). The γ-interferon (γ–IFN) is a 
cytokine secreted by Th1 CD8+ cells and it enhances specific T-cell mediated immune 
responses. By increasing the expression of MHC class-I molecules on the surface of 
infected cells, the γ–IFN increases the possibility that the specific T-cells recognize and 
kill the virus infected cells. Direct antiviral effects of the interferons include degradation 
of the viral mRNA and inhibition of protein synthesis. However, this form of antiviral 




   
Other drugs that showed therapeutic potentials include enviroxime which 
inhibited RNA replication by targeting at the 3A region of the viruses (Heinz and Vance 
et al., 1995). The 3C protease inhibitors were developed by the Agouron Pharmaceuticals 
which resulted in inhibition of specific viral protein processing (Patick et al., 1997). 
However, studies of these antivirals were mainly based on polioviruses and rhinoviruses, 
the two most important members of the Piconarviridae family, and their effects on EV71 
are unknown. Intravenous immunoglobulins (IVIG) was used extensively in the 
management of neurological cases during the earlier outbreaks in Taiwan in 1998 and 
Western Australia in 1999, but there were no reports which showed that IVIG was 
effective in treating EV71 neurological manifestations. However, it was shown recently 
that the administration of IVIG could effectively reduce the levels of cytokines such as 
IL-6 and IL-8 in patients suffering from autonomic nervous system (ANS) dysfunction 
and pulmonary edema, which arise from EV71-associated brainstem encephalitis (Wang 
et al., 2006). 
 
The “WIN” group of compounds is the most promising drugs so far. The antiviral 
activities of these compounds were thought to be mediated by stabilization of the viral 
capsid and the prevention of virus uncoating after receptor binding (Rotbart et al., 1998). 
One of the “WIN” compounds – pleconaril was found to have significant therapeutic 
effects in aseptic meningitis, acute flaccid paralysis and encephalitis as a result of 
enteroviral infections (Rotbart et al., 1998; Pevear et al., 1999). Pleconaril (VP-63843) is 
a novel, broad-spectrum antipicornaviral agent. It also possesses the additional advantage 
of achieving several fold higher concentrations within the nasal and the CNS secretions 
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than in the serum, a characteristic that is highly desirable for an anti-viral which targets a 
virus which causes CNS and respiratory tract infections. Currently, pleconaril is 
undergoing Phase III clinical trials in the US. Clinical studies have shown that there was 
a reduction in the duration and the intensity of symptoms in children and adults with 
enteroviral meningitis (Romero et al., 2001). However, despite having a very good side 
effect profile which was attributed to its metabolic stability, pleconaril was found to show 
limited effectiveness against EV71 (Pevear et al., 1999), especially against EV71-
associated neurological complications.  
 
Recently, there was evidence which showed that milrinone had therapeutic effects 
in EV71-induced pulmonary edema and/or pulmonary hemorrhage (Wang et al., 2005; 
Wang et al., 2006), suggesting that milrinone might be a good therapeutic agent for EV71 
infections. The antiviral activities of Salvia miltiorrhiza (Danshen) were also tested 
against EV71 in an in vitro system, and were found to neutralize EV71-induced CPE in 
Vero, rhabdomyosarcoma and MRC-5 cells, suggesting that the Chinese herb might have 
the potential to be used as a therapeutic agent against EV71 (Wu et al., 2007). 
 
1.5 RNA interference (RNAi) as antiviral therapy 
RNA interference (RNAi) is a defense strategy which was first described in 
Caenorhabditis elegans (Fire et al., 1998). Fire et al. (1998) first stumbled upon RNAi 
when they found that dsRNA introduced into Caenorhabditis elegans silenced expression 
of a homologous target gene approximately 10–100-fold more efficiently than the 
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corresponding antisense RNA. Since then, RNAi has been widely applied and was shown 
to hold promise as potential therapeutic agents against infectious diseases.  
 
By targeting viral transcripts and/or host genes which produce co-factors critical 
for viral replication, RNAi approaches have been shown to be effective against a wide 
range of viruses in vitro, including Human Immunodeficiency virus (Capodici et al., 
2002; Martinez et al., 2002; Surabhi and Gaynor, 2002), Hepatitis C virus (Kapadia et al., 
2003; Randall et al., 2003; Takiwara et al., 2004) and the influenza virus (Ge et al., 2003). 
In the Picornaviridae family, RNAi was widely studied in the Poliovirus (Gitlin et al, 
2002), Rhinovirus (Phipps et al., 2004) as well as Coxsackievirus B3 (Yuan et al., 2005; 
Werk et al., 2005), and was shown to exhibit significant inhibition of the viruses in cell 
culture systems. 
 
1.5.1 RNAi mechanism 
RNAi is a sequence-specific, post-transcriptional gene silencing process of 
initiated by double-stranded RNA (dsRNA) molecules (Fire et al., 1998), and the 
machinery has been best characterized in Drosophila melanogaster. The first step 
involves Dicer which has an N-terminal helicase domain, a Piwi/Argonaute/Zwille (PAZ) 
motif, a dsRNA-specific binding domain and two RNase III motifs at the C-terminus. 
The dsRNA-specific endonuclease activity of the Dicer will cleave the dsRNAs to 
produce functional siRNAs. These siRNAs are subsequently loaded into the RNA-
induced silencing complex (RISC) (Nykanen et al., 2001). The loading of the siRNAs 
into the RISC requires the RISC loading complex (RLC) that contains the DCR2 (one of 
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two Dicer molecules) and a dsRNA-binding domain-containing protein, R2D2 (Liu et al., 
2003). R2D2 is involved in binding to the more thermodynamically stable strand of the 
siRNAs (passenger strand), orienting the DCR2 to bind to the less thermodynamically 
stable strand of the siRNAs (guide strand) (Tomari et al., 2004). Argonaute 2 (Ago2), 
which is a core component of the RISC and is also the endonuclease that cleaves the 
target mRNA, will then bind to the siRNA and displaces it from the RLC components. 
(Hammond et al., 2001; Okamura et al., 2004; Rand et al., 2004). The unwinding of the 
siRNA is facilitated by Armitage which is a DEAD-box helicase in an ATP-dependent 
manner (Tomari et al., 2004). The Ago2 then cleaves the passenger strand, preparing the 
way for the guide strand to pair with the complementary target mRNA sequence 
(Matranga et al., 2005; Rand et al., 2005). The nucleotide positions 2 to 8 of the siRNA 
guide strand are exposed on the surface of the RISC and form the seed sequence that 
directs the target recognition (Ma et al., 2005; Lewis et al., 2005). The paired siRNA-
mRNA is thought to form an A-type helix that aligns the cleavage site (10 nucleotides 
from the 5'-end of the guide siRNA) on the target mRNA with the Ago2 PIWI 
endonuclease domain (Elbashir et al., 2001; Lingel et al., 2005). The Ago2 cleaves the 
phosphodiester bonds in the target mRNA in the central region of the paired siRNA-
mRNA complex in a Mg2+-dependent manner (Martinez et al., 2004; Schwarz et al., 
2004). The mutations of the key nucleotides that disrupt siRNA-mRNA pairing within 
this central region will interfere with the cleavage but have no effect on the binding of the 
siRNA guide strand (Liu et al., 2004). After the target mRNA is cleaved, the activated 
RISC containing the siRNA guide strand will be released to direct subsequent rounds of 
target mRNA cleavage (Hutvagner et al., 2002) (Figure 1.12). 
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Figure 1.12: The RNA interference pathway. RNAi is triggered when a cell encounters 
a long double-stranded RNA (dsRNA). The dsRNA will be processed into 21 nucleotide 
small interfering RNAs (siRNAs) by an RNase III-like enzyme known as Dicer (known 
as Dicing). The siRNAs will then unwind and the sense strand will be degraded. The 
antisense strand will be assembled into endoribonuclease-containing complexes known as 
RNA-induced silencing complexes (RISCs). The antisense strand will subsequently guide 
the RISCs to complementary mRNA molecules, where they will then cleave the mRNAs 





   
1.5.2 Advantages of RNAi 
A variety of approaches have been developed for silencing gene expression. Most 
notable are antisense oligonucleotides (ASOs), ribozymes, and RNAi (Scherer et al., 
2003; Dorsett et al., 2004). All the approaches involve the recognition of a specific 
mRNA target site by complementary oligonucleotides, but the mechanisms in silencing 
the genes differ from one another. Similar to RNAi, ASOs silence gene expression by 
either inhibiting translation or directing mRNA cleavage (Scherer et al., 2003). However, 
unlike RNAi, where the degree of target site homology determines the mode of action, 
the charged characteristics of the ASO backbone largely determine the silencing 
mechanism (Crooke et al., 1999; Dias et al., 2002). Although studies that compare the 
different silencing approaches are limited, they generally have found that siRNAs silence 
gene expression more effectively than ASOs or ribozymes. Direct comparison of an 
optimized phosphorothioate-modified ASO with a siRNA directed against the same target 
mRNA site found that the siRNA was approximately 100 to 1000 folds more efficient. 
The siRNAs have also been found to have longer sustained silencing (Bertrand et al., 
2002). This could be due to the protection of the siRNAs from intracellular degradation 
by its incorporation into the RISC. Virtually, any gene can be specifically and efficiently 
silenced by RNAi. In comparison, ASO approaches have only been found to work 
effectively in a limited number of cases. In fact, some ASOs that showed early promise 
as effective therapeutic agents were found to accomplish their antiviral effects by 
stimulating an innate immune response owing to their high guanine-cytosine (GC) 




   
1.5.3 Design of siRNA  
The optimization of siRNAs for maximum potency is important as it will increase 
the effectiveness and decrease potential nonspecific side effects because nonspecific 
effects are concentration dependent. By studying the functionality of large numbers of 
siRNAs, Reynolds et al. (2004) were able to define characteristics associated with highly 
active siRNAs. These traits include a lack of secondary structure within the siRNAs, low 
internal stability, moderate-to-low GC content, and low stability of binding interactions at 
the 5' terminus of the siRNA strand. The general criteria for designing of effective 
siRNAs are summarized in Table 1.2. The instability of the 5' end of the guide strand 
imposes a functional asymmetry to increase the efficiency of the uptake of the guide 
strand (Reynolds et al., 2004; Boese et al., 2005; Inoue et al., 2006). In fact, an 
inefficient siRNA can be converted into a potent silencer by altering the thermodynamic 
properties of the 5' ends of the guide and passenger strands (Dykxhoorn et al., 2006). 
Biochemical and bioinformatics studies have led to algorithms which are available on the 
Web (For example, http://www.dharmacon.com, http://www.qiagen.com/siRNA, 
http://www.ambion.com) for designing of siRNAs to silence gene expressions. However, 
experimental validations are still required to determine the most effective siRNA for a 
given gene target. For clinical use, comprehensive evaluations of a large array of 
sequences are required not only to optimize silencing, but also to avoid sequence-specific 
off-target silencing of partially homologous genes or the stimulation of inflammatory 
responses by the activation of Toll-like receptors (TLRs) (Sledz et al., 2003). Silencing 




   








between 30% to 
50% 
 
• GC content greater than 50% 
will have difficulty in unwinding 
• GC content lower than 30% may 
not interact well with the mRNA 
target site. 
 
• Reynolds et al., 2004 
• Boese et al., 2005 
No internal 
secondary 
structure within the 
siRNAs 
 
• Secondary structure interfere 
with the formation of a stable 
siRNA duplex  
• Will interfere with the 
interaction of the guide siRNA 
with the RISC. 
 
• Reynolds et al., 2004 





stability at the 5′ 
end 
of the guide siRNA 
strand 
 
• There is a bias toward an A 
residue and against G or C 
nucleotides at position 19 of the 
guide strand  
• Promote the uptake of the guide 
strand into the RISC. 
 
• Khvorova et al., 2003 
• Schwarz et al., 2003 
• Reynolds et al., 2004 






• Several sequence motifs (5′-
UGUGU-3′ or 5′-
GUCCUUCAA-3′) have been 
identified that will activate Toll-
like receptors. 
 
• Judge et al., 2005 









• Bioinformatics searches (such as 
BLAST search) should be used 
to check for potential off-target 
effects.  
 
• Jackson et al., 2003 
• Boese et al., 2005 
 
An A residue at 
position 3 and 
absence of G at 
position 13 of the 
sense strand. 
 
• Shown to be important for 
efficient mRNA cleavage 
 
• Reynolds et al., 2004 







   
which are incorporated into the RISC but still smaller than the 30-nt threshold to avoid 
interferon responses. Kim et al. (2005) suggested that these dsRNAs enter RNAi pathway 
earlier than the shorter siRNAs and could be taken up by Dicer and passed on more 
efficiently to the RISC. In fact, this was demonstrated in recent studies which showed 
that the 27-mer siRNAs and 29-mer short hairpin RNAs (shRNAs) were more efficient 
than the 19-mer siRNAs in silencing genes in in vitro systems without inducing immune 
responses (Kim et al., 2005; Siolas et al., 2005). 
 
1.5.4 Different forms of siRNAs 
 
1.5.4.1  Chemically synthesized siRNAs 
 
 Chemically synthesized siRNAs are the most direct and easiest approach to 
induce RNA interference in mammalian cells. This form of siRNA bypass the cleavage 
step by the Dicer and are immediately incorporated into the RISC to mediate degradation 
of the target mRNA. The chemically synthesizd 19-mer siRNAs can be transfected into 
mammalian cells by generating liposomes with cationic lipids, electroporation, covalent 
binding to hydrophobic carrier molecules or covalent coupling to cell penetrating 
peptides (Tuschl et al., 2001). Suppression of gene expression by siRNAs has been 
shown to be more effective than that mediated by conventional nucleic acid-catalysts 
such as ribozymes and single stranded antisense molecules (DNA/RNA) in mammalian 
cells (Wadhwa et al., 2004). 
 
There are two advantages of using chemically synthesized siRNAs. Firstly, the 
transfection of the chemically synthesized siRNAs was shown to be more efficient than 
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the plasmid mediated siRNAs (McManus et al., 2002). Besides, the amount of siRNAs 
can be controlled more efficiently to knock down genes without inducing interferon 
response. Secondly, the initiation of the silencing effect using chemically synthezised 
siRNAs is immediate, unlike in plasmid-based siRNAs where the transcription process is 
involved. 
 
1.5.4.2  Plasmid vector-mediated siRNA system 
Although the chemically synthesized siRNAs are efficient, the cost of the 
chemically synthesized siRNAs is high and the silencing of genes is transient. An 
alternative strategy involves the use of the endogenous expression of siRNAs by various 
promoter expression cassettes that allow transcription of functional siRNAs. Many 
reports have described successful expression and silencing of genes using the plasmid 
vector-based siRNA system in mammalian cells, providing a low-cost alternative to the 
chemically synthesized siRNAs. Furthermore, the plasmid vector-based strategy is 
capable of mediating stable target gene inhibition, thus allowing gene function analysis 
over an extended period of time (Kawasaki et al., 2001; Miyagishi et al., 2001). 
 
Plasmid vector-based RNAi involves the use of a DNA vector to produce the 
siRNA duplexes. Plasmid-based expression systems using RNA Polymerase III 
(RNAPIII) promoters that can produce short 19-mer siRNAs have been developed 
(Brummelkamp et al., 2002). The two most common types of RNAPIII promoters that 
have been used are the U6 promoter and the H1 promoter. Two methods for expressing 
siRNAs by plasmid constructs that are driven by RNAPIII are currently available. The 
 48
LITERATURE REVIEW 
   
first method involves the sense and the antisense strands of the siRNA being expressed 
from different and tandem promoters. The second involves the generation of short hairpin 
RNAs (shRNAs) that would subsequently be processed by the Dicer into functional 
siRNAs (Brummelkamp et al., 2002). 
 
There are two advantages in using plasmid-based RNAi expression systems. First, 
the recombinant plasmid-borne siRNAs can be readily prepared in larger quantities and is 
cheaper than the chemically synthesized siRNAs. Second, the duration of gene silencing 
can be longer lasting. The plasmid-based RNAi is able to sustain prolonged and stable 
gene silencing. In contrast, transient silencing using the chemically synthesized siRNAs 
might not work for genes that encode proteins with long half lives (Brummelkamp et al., 
2002; Aigner et al., 2006).  
 
1.5.4.3 Viral-vector derived siRNAs 
Viral-vectors including retrovirus, adenovirus and lentivirus are becoming the 
tools of choice for delivering siRNAs to overcome the limitations in using either the 
chemically synthesized or plasmid-based siRNAs (Brummelkamp et al., 2002; Rubinson 
et al., 2003).   Viral-vector derived siRNAs have been evaluated in several studies and 
have shown to posses high therapeutic potentials (Tiscornia et al., 2003; Chang et al., 
2005; Morris et al., 2006). Retroviral vectors are favoured for their ability to integrate 
exogenous genes into the host genome (Barquinero et al., 2004). Replication-defective 
lentiviral vectors can be used to introduce exogenous sequences into non-proliferating 
cells such as the haematopoietic stem cells. Retrovirus-mediated siRNA targeted against 
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the H-ras and the K-ras genes were shown to suppress growth of human ovarian and 
pancreatic carcinoma cells (Brummelkamp et al., 2002). Lentiviral-based siRNA systems 
have been found to be good delivery systems for gene therapy in several studies (Chang 
et al., 2005; Raoul et al., 2005; Morris et al., 2006). Adenoviral vectors that transduced 
exogenous sequences into quiescent cells and sustained their long-term expressions were 
used to reduce the expressions of exogenous and endogenous genes in the in vitro and in 
vivo systems (Xia et al., 2002).  
 
However, there are limitations in the application of viral-vector based siRNA 
systems. There were several reports of severe cytotoxicity in both the in vitro and in vivo 
systems treated with lentiviral vectors bearing siRNAs (Fish et al., 2004; Grimm et al., 
2006). The reasons for the cytotoxicity were unknown, but it was suggested that the 
cytotoxicity was due to the competition with the endogenous miRNAs in the RNAi 
pathway, resulting in oversaturation of the siRNAs in the host and thereby inducing 
interferon response (Grimm et al., 2005). Thus, there is a necessity to carefully control 
the immediate and long term RNAi effects when using viral-vector derived siRNA 
systems (Fish et al., 2004). 
 
1.5.4.4  microRNAs (miRNAs) 
The endogenously generated microRNAs differ from siRNAs in their biogenesis 
but have overlapping functions (Du et al., 2005). The biogenesis of microRNAs involves 
the stepwise action of several RNase III–type endonucleases (Kim, 2005). The 
microRNAs are first expressed as highly structured hairpin transcripts which contain 
 50
LITERATURE REVIEW 
   
numerous bulges and mismatches. The primary microRNA transcripts (pri-miRNA) are 
recognized by a protein complex containing the RNase III–type endoribonuclease known 
as the Drosha, which cleaves the pri-miRNAs into short stem loop pre-miRNAs (Denli et 
al., 2004; Gregory et al., 2004; Han et al., 2004). The pre-miRNAs are then transported 
by Exportin 5 from the nucleus into the cytoplasm (Lee et al., 2003; Yi et al., 2003; Lund 
et al., 2004) where they are recognized and cleaved by Dicer into the mature microRNAs 
(Grishok et al., 2001; Jiang et al., 2005). The subsequent steps in RNAi using 
microRNAs involve the same machinery as that used for silencing using siRNAs. The 
mechanism by which microRNAs inhibit translation remains poorly understood, but it 
has been shown that the microRNAs can direct both cleavage of homologous targets or 
repress the translation of partially complementary targets (Doench et al., 2003).  
 
1.5.5 RNAi as potential antiviral agents against EV71 
Two previous studies have shown that siRNA presented in different forms were 
able to inhibit EV71 replication. In the study reported by Lu et al. (2004), a plasmid-
derived shRNA system producing siRNAs targeting at the VP1 and 3Dpol regions of 
EV71 was shown to inhibit EV71 replication in both HeLa and Vero cell lines. In a 
separate study, chemically synthesized 19-mer siRNAs targeting at the 2C, 3Cpro, 3Dpol 
and 3′UTR regions of EV71 showed significant inhibition of EV71 replication in 
rhabdomyosarcoma (RD) cells without inducing immune response (Sim et al., 2005). In 
both studies, siRNAs targeting at the RNA-dependent RNA polymerase, 3Dpol, was 
shown to be the most effective in inhibiting EV71 replication. In both studies, both RNAi 
strategies involved the use of 21 nucleotides which contain the 19-mer core sequences 
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and 2d-TT at the 3′ ends. Since the 29-mer short hairpin RNAs (shRNAs) have shown to 
have enhanced potency and are more efficient than the 19-mer siRNAs in silencing genes 
without inducing any interferon response (Siolas et al., 2005), the use of 29-mer shRNAs 
might prove to be potentially more efficient as antiviral agents against EV71.  
 
1.5.6          In vivo delivery of siRNAs 
Evidence that RNAi could be used to inhibit viral replication in a murine model 
was shown by McCaffery and co-workers (2003), who demonstrated that mice 
cotransfected with Hepatitis B virus and plasmid vectors expressing siRNAs homologous 
to Hepatitis B mRNAs induced an RNAi response and effectively inhibited viral 
replications in the mouse liver.  
 
The route of siRNA administration is important as it will greatly affect the total 
dose required, the effective tissue distribution, potential side effects and the need for 
carrier agents to facilitate delivery. The intravenous (i.v) route of administration has 
shown to be a very efficient systemic delivery of siRNAs to multiple organs and tissues 
(Lewis et al., 2002; McCaffrey et al., 2002; Song et al., 2003). Besides the i.v. route, 
systemic delivery of siRNAs via the intraperitoneal (i.p.) route have also shown to 
effective in silencing genes in several studies (Verma et al., 2003; Urban-Klein et al., 
2005; Yin et al., 2005). Local deliveries of siRNAs have shown to be effective in 
silencing genes in a localized target site (Takei et al., 2004; Leng et al., 2005; Shen et al., 
2006). The routes of local delivery can be either by direct injection (for example direct 
injection into a tumor or intraocularly) or by topical delivery to tissue surfaces (for 
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example transepithelial absorption through oral, rectal, or vaginal mucosa). A high 
concentration of siRNAs delivery to the intended target sites have been achieved with 
minimized risk of systemic side effects (Takei et al., 2004; Leng et al., 2005; Shen et al., 
2006). Direct administration of siRNAs into the central nervous system (CNS) have been 
successfully demonstrated in several studies and could be carried out either by intrathecal 
or intraventricular injection to bypass the issues of blood–brain barrier penetration 
(Thakker et al., 2004; Thakker et al., 2005). Other routes of siRNA delivery such as 
through inhalation, intranasal or intratracheal administrations were employed for 
pulmonary delivery and were shown to be effective in inhibiting replications of 
respiratory viruses (Chang et al., 2005; Bitko et al., 2005). 
 
Although the life span of unmodified siRNAs in serum may vary from minutes to 
days, it has been shown that chemically modified siRNAs are able to survive longer in 
nuclease-rich environments than the unmodified siRNAs (Braasch et al., 2003; Allerson 
et al., 2005). Soutschek et al. (2004) showed that unmodified siRNAs had an elimination 
half-life of 0.1 hour in murine models, while a cholesterol-conjugated siRNAs had a half-
life of 1.5 hours. It might be reasonable to employ unmodified siRNAs for basic research 
applications in vivo, but more sustained effects and higher potential therapeutic benefits 
could be achieved using chemically modified siRNAs (Braasch et al., 2003; Chiu et al., 
2003; Allerson et al., 2005).  
 
A wide variety of methods have been used to facilitate delivery of siRNAs. Since 
the double stranded siRNAs have a high negative charge density, cationic polymers are 
 53
LITERATURE REVIEW 
   
usually employed to bind and neutralize the negative charges, thus aid in transporting 
siRNAs across the cell membranes. Cationic lipids such as Oligofectamine and 
Lipofectamine are routinely used with great success as transfection agents in vitro 
(Yokota et al., 2003; Lu et al., 2004; Sim et al., 2005). Cationic lipids have also been 
used for siRNA delivery in in vivo studies via the i.p. route (Verma et al., 2003; Flynn et 
al., 2004), direct CNS injection (Hassani et al., 2005; Luo et al., 2005) and applied on 
epithelial surfaces (Palliser et al., 2006). The toxicity pertaining to the use of cationic 
lipids varies with the chemical composition and the dosage of the cationic lipids. 
Variations in chemical compositions have a large impact on the functional properties of 
cationic lipids and new formulations with decreased toxicity that are more compatible for 
in vivo administration have been introduced. Liposomal formulations such as 
Polyethylenimine (PEI) have been approved by FDA for small-molecule drug delivery 
since the late 1990s. Liposomes can be modified with ligands such as folate or small 
peptides which could aid in delivery to specific cell types or tissues. These kinds of lipid 
nanoparticles have been successfully used to deliver antisense oligonucleotides and 
siRNAs in vivo (Chien et al., 2005; Gao et al., 2005) 
 
1.5.7 Potential problems for RNAi as an antiviral therapy 
Initial reports have suggested that siRNAs require complete complementarity with 
its target mRNA over its entire 19 nucleotide sequences for efficient silencing. In fact, a 
single nucleotide change within the siRNA was reported to be capable of completely 




   
Off-target silencing must also be taken into consideration in developing RNAi-
based therapies. Off-target effects can be divided into two types of responses: (a) the 
induction of nonsequence-specific silencing pathways and (b) the silencing of targets that 
have partial complementarity to the siRNA.  
 
While long dsRNAs such as viruses are well-known trigger of type-1 interferon 
(IFN) responses in mammals, it was originally hoped that short dsRNAs like the 19-mer 
siRNAs would be "safe" to use. However, siRNAs are also capable of triggering IFN 
responses (Sledz et al., 2003). Sledz et al. (2003) reported that 19-mer siRNAs could 
cause interferon-mediated activation of the Janus Kinase–Signal Transduction Activating 
Transcription (JAK-STAT) pathway that was attributed to dsRNA-dependent protein 
kinase (PKR) activation. This effect appeared to be sequence independent as two 
different siRNAs that did not share any obvious sequence motifs triggered the same 
effect. Members of the Toll-like receptor (TLR) family that recognize nucleic acids 
reside intracellularly within endosomal or lysosomal compartments (other TLRs reside on 
the cell surface). Of the 11 known TLRs, 3 of them have been identified to interact 
specifically with RNA, including TLRs 3, 7, and 8 (Kapala et al., 2005; Robbins et al., 
2005). Other molecules that recognize dsRNA and can trigger IFN pathway responses 
include PKR and 2',5'-oligoadenylate synthetase (OAS) (Stark et al., 1998) (Figure 1.13).  
Activation of 2',5'-OAS by dsRNA required a minimum RNA length of 30 bp. However, 
the maximal activation was not achieved until the length reached 60–80 bp. Thus, direct 




   
Another potential source of toxicity involved the silencing of mRNA targets that 
were only partially homologous to the siRNA sequence (Jackson et al., 2003). In some 
cases, siRNAs have been shown to be able to inhibit gene expression when the target had 
only 15 complementary nucleotides (Jackson et al., 2003). In general, mRNA microarray 
studies have found that most off-target effects are relatively small, usually resulting in 
less than a two-fold decrease in mRNA levels (Jackson et al., 2003; Saxena et al., 2003). 
However, these studies might underestimate off-target effects because they measured 
changes in mRNA levels and did not account for differences in protein expression   that 
could result from translational inhibition. The rules that govern potential translational 
inhibition are not well understood, making the identification of potential off-target effects 
difficult to predict.  
 
1.6 Animal model for EV71 infection 
One of the major barriers to development of effective antivirals against EV71 is 
the lack of a suitable animal model (McMinn et al., 2001). Pathogenicity of enteroviruses 
was studied in laboratory animals such as the new born mice (Koroleva and Gracheva, 
1980) and cynomolgus monkeys (Hashimoto et al., 1982). Such experimental studies 
could provide information regarding the behaviour of viruses in different hosts and 











Figure 1.13: Interferon (IFN) response in the presence of dsRNA (for example 
viruses). IFN is produced during early phase of viral infection, which in turn induces 
dsRNA-dependent protein kinase (PKR), and 2', 5’-oligoadenylate synthetase (OAS) 
pathways. PKR autophosphorylates itself and subsequently phosphorylates eIF2α, which 
in turn leads to viral protein inhibition. In the case of OAS, it will convert ATP to 2', 5'-
oligoadenylate (2-5A). The 2-5A will in turn activate RNase L which will selectively 





   
A widespread outbreak of a severe neuroparalytic disease which manifested as 
poliomyelitis and meningoencaphalitis occurred in Bulgaria in 1975. Koroleva and 
Gracheva (1980) conducted EV71 infection studies in mice by injecting the virus 
subcutaneously into the newborn cotton (NBC) and new born white (NBW) mice. In 
addition, 3 to 4 weeks old adult cotton mice and white mice were infected intracerebrally, 
intramuscularly or by a combination of both. EV71 which causes poliomyelitis-like 
disease was found to be pathogenic for NBC and NBW suckling mice. The diseases 
displayed in the animals were similar from that observed for the Coxsackie group A 
viruses.  
 
Another study was carried out in Taiwan by Yu et al. (2000). Experimental 
infections with EV71 were found to induce death in the neonatal mice in an age and dose 
dependent manner. The mortality rate was 100% following i.p. inoculation of the one day 
old ICR mice. Mortality rates were found to decrease as the age of the mice increased. 
There was a mortality of 60% in 3 day-old mice and no mortality was observed in mice 
older than six days of age. A lethal dose of 108 plaque forming units (pfu) was necessary 
to cause fatality in the ICR mice. Lethargy, failure to gain weight and limb paralysis were 
the symptoms observed in the infected mice before death.  
 
Nagata et al. (2002) studied the neurovirulence of EV71 by neuropathological 
analysis of Cynomolgus monkeys after experimental infections with five EV71 strains 
isolated from individual patients with fatal encephalitis, meningitis and HFMD. After 
intraspinal inoculations, the monkeys developed neurological manifestations within 1 to 6 
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days post-infection, regardless of the EV71 strains used. These manifestations included 
not only pyramidal tract signs such as flaccid paralysis but also signs of tremors and 
ataxia. Histological examinations confirmed the presence of EV71 in the spinal cord, 
brainstem, cerebral cortex and the cerebrum. The EV71 strains which were neurotropic 
showed no genetic differences (Nagata et al., 2002). Although Cynomolgus monkeys 
were susceptible to EV71 infections and provided a good model for EV71 study, the high 
cost of purchasing and maintaining the animals is a major barrier to their use in large 
scale pathogenesis and treatment studies.  
 
1.7 Evolution of EV71 
 Evolution is the result of changes in the genetic composition of an organism with 
time. It involves sequential steps of complex interplay between the intrinsic modifications 
in the genetic makeup of the organism and the environmental influences (Domingo et al., 
1994). In many positive-stranded RNA viruses, the frequency of RNA recombination is 
relatively high and has a significant influence on virus evolution (King et al., 1982; Nagy 
et al., 1997). Previous studies based on phylogenetic analyses have shown that RNA 
viruses evolve at the rate which ranges from 10-2 to 10-5 substitutions per nucleotide per 
year (Domingo et al., 1994; Drake et al., 1998). For example, in the pol gene of human 
immunodeficiency virus (HIV), the mutation frequency was found to be as high as 1.1 X 
10-2 substitutions per nucleotide (Najera et al., 1995). Generally high mutation rates have 
also been observed in DNA viruses such as hepadnaviruses and hepatitis B virus which 




   
In picornaviruses, studies on the mutation frequencies have been reported based 
on two regions of the viral genome, namely the VP1 which encodes the structural capsid 
protein, and the RNA-dependent RNA polymerase (3Dpol) gene which is responsible for 
synthesis of new viral genomes. Based on the VP1 region, the foot-and-mouth disease 
virus (FMV) was shown to have a mutation frequency ranging from 1.6 X 10-3 to 6.4 X 
10-3 substitutions per nucleotide per year (Villaverde et al., 1988). Relatively high 
evolutionary rates was also observed in the VP1 regions for poliovirus type 1 (3.36 X 10-2 
substitutions per nucleotide per year) and EV70 (2.2 X 10-2 substitutions per nucleotide 
per year) (Takeda et al., 1994; Kew et al., 1998). Analysis of the 3Dpol gene was reported 
in FMV and poliovirus, in which both studies showed a mutation rate of 7.0 X 10-4 and 
4.5 X 10-4 substitutions per nucleotide per year, respectively (Villaverde et al., 1988; 
Ward et al., 1988; Wells et al., 2001).  
 
Brown et al., (1999) analysed the VP1 region of 113 EV71 strains which were 
isolated in the United States and five other countries during the period from 1970 to 1998. 
An evolutionary rate of 1.35 X 10-2 substitutions per nucleotide per year was shown, 
indicating that EV71 is a genetically diverse and rapidly evolved virus (Brown et al., 








   
1.7.1 Distance models for computing evolutionary distances 
Study of spontaneous mutations is critical to understand the genetic structure of 
viral populations over time and subsequently leading to the understanding the course of 
evolution (Drake et al., 1996). The estimation of the pattern of nucleotide substitution 
relates to the analysis of evolutionary distances. The pairwise evolutionary distance 
between the virus and its origin forms the basis of the study of molecular evolution. By 
computing the rate of evolution, the evolutionary relationships and the divergence over 
time among the viruses or genes can be determined (Saitou et al., 1987; Gu et al., 1997). 
Thus, it is essential to obtain reliable estimates of the evolutionary distances. If the 
evolutionary distances are not accurately estimated, all the distance matrix methods in the 
phylogenetic construction may be misleading (Felsenstein, 1988; Nei, 1996). For this 
reason, much effort has been made to develop general methods of nucleotide substitution 
(Saitou et al., 1987).  
 
1.7.1.1  Jukes-Cantor distance model 
In the Jukes and Cantor (1969) model, the rate of nucleotide substitution is 
assumed to be the same for all the four nucleotides. It also assumes an equality of 
substitution rates among sites, equal nucleotide frequencies, but it does not correct for 







   
1.7.1.2 Kimura 2-parameter distance model 
The Kimura 2-parameter distance model (1980) corrects for multiple hits, taking 
into account both the transitional and transversional substitution rates. The model 
assumes that all the four nucleotide frequencies are the same and that the rates of 
substitution do not vary among sites. 
 
1.7.1.3  Tamura 3-parameter distance model 
The Tamura 3-parameter distance model (Tamura, 1992) is an improvement of 
the Kimura 2-parameter distance model. Other than correcting for the factors in the 
Kimura 2-parameter distance model, the Tamura 3-parameter distance model also 
corrects for GC-content bias. 
 
1.7.1.4  Tamura-Nei distance model 
 Similar to the Kimura 2-parameter distance model, the Tamura-Nei distance 
model (Tamura and Nei, 1993) assumes equality in the substitution rates among sites and 
corrects for multiple hits. However, the Tamura-Nei distance model also accounts for 
differences in the substitution rates between nucleotides, any inequality in the nucleotide 
frequencies and also distinguishes between transitional and transversional substitutions. 
 
1.7.2 Molecular Evolutionary Genetics Analysis (MEGA) Software 
The MEGA software was developed by Koichiro Tamura, Joel Dudley, Masatoshi 
Nei and Sudhir Kumar from the Center for Evolutionary Functional Genomics Biodesign 
Institute, Arizona State University in the early 1990s. The MEGA software provides tools 
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for analyzing DNA and protein sequences from an evolutionary perspective. The 
software reduces the time required for data analysis and provides statistical methods of 
molecular evolutionary genetic analysis in an end-user computer. The MEGA software 
contains an array of evolutionary analysis, including sequence alignment, phylogenetic 
analysis under minimum evolution and maximum parsimony, and estimation of 
evolutionary distances using different distance models. MEGA 4 was the latest version 
and was launched in June 2007. Distinct from the previous versions, MEGA 4 also 
includes distance matrix, phylogeny explorers and more advanced graphical features for 
output results. 
 
Scope of study 
The objectives of this study involved: 
1. Development of a rapid diagnostic method of detecting EV71 directly from 
clinical specimens based on real-time PCR approach, 
2. Evaluating the possibility of using RNA interference (RNAi) as antiviral strategy 
against EV71 infections in both in vitro and in vivo models, and 
3. Analysis of the evolution of EV71 and their possible implications on the 
efficacies of the real-time PCR and RNAi. 
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CHAPTER 2 
MATERIALS AND METHODS 
 
2.1 Development of real-time RT-PCR 
2.1.1 Virus strains 
A neurovirulent EV71 strain 7423/MS/87 (Accession No. U22522; genogroup 
B2) and a CA16 strain (CA16-G-10; Accession No. U05876) used in this study were gifts 
from Dr M.A. Pallansch, CDC, USA. Three Japanese strains, namely 1585-Yamagata-01 
(Accession No. AB177812; genogroup C2), 75-Yamagata-03 (Accession No.  
AB177813; genogroup C4) and 2933-Yamagata-03 (Accession No. AB213648; 
genogroup B5) were kind gifts from Prof K. Mizuta, Yamagata Prefectural Institute of 
Public Health, Yamagata, Japan. Two Singapore strains, the fatal 5865/SIN/00009 strain 
(Accession No. AF316321; genogroup B4; designated as Strain 41) and the non-fatal 
5666/SIN/002209 strain (Accession No. AF352027; genogroup B4; designated as Strain 
10) were isolated from patients during the HFMD outbreak in October 2000 and 
cultivated in tissue cultures. Other enterovirus isolates analyzed in this study included 
CA24, Coxsackieviruses B1 (CB1), CB2, CB3, and Echoviruses 6 and 7. The viral 
isolates and the clinical specimens were handled with approval and according to the 
guidelines of the Office of Safety, Health and Environment as well as the Institutional 
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2.1.2 Clinical specimens processing and storage 
A total of 55 clinical specimens obtained from 55 pediatric patients suffering from 
HFMD during the period from 2000 to 2003 in Singapore were evaluated by the real-time 
Hybridization probe RT-PCR assay developed in this study. Another group of 67 clinical 
specimens obtained from 40 pediatric patients admitted to National University Hospital, 
Singapore with suspected HFMD during the period from March 2006 to December 2006 
were evaluated by the real-time TaqMan RT-PCR and real-time multiplex RT-PCR 
assays developed in this study. The clinical specimens included CSF, stools, rectal swabs, 
serum, throat swabs, saliva and urine specimens. The CSF and urine specimens were 
processed immediately upon receiving them. The throat and rectal swabs were first 
suspended in 1X phosphate buffered saline (PBS) before being processed for RNA 
extraction. A 10% stool suspension was made by adding 0.5g of stool (0.5ml of fluid 
stools) to 5ml of 1X PBS. The suspension was then centrifuged at 12,000 x g for 10 min 
and filtered. The filtrate was then subsequently processed for RNA extraction. Blood 
samples were allowed to stand in a vertical position for 15 to 20 min. After centrifuging 
for 10 min at 12,000 x g, the serum was then aspirated and transferred to a 1.5ml sterile 
eppendorf tube. All the clinical specimens were transported in viral transport media to 
maintain the viability of the viruses. 
 
2.1.3 RNA Extraction  
Viral RNA extraction was carried out using QIAamp® Viral RNA Mini Kit 
(Qiagen, Valencia, USA). The extraction was based on the selective binding properties of 
a silica-gel based membrane together with microspin technology to extract viral RNA 
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from the clinical specimens. This kit was used to extract viral RNA from human sera, 
CSF and cell cultures. The samples were first lysed with a buffer which aids in 
denaturing RNases. The RNA will then be bound to the membrane. This is aided by the 
carrier RNA, the buffering conditions and the addition of 100% ethanol. The bound RNA 
was washed with two wash buffers to remove any contaminating proteins and lipids. The 
RNA was then eluted with an elution buffer which is basically RNase-free water 
containing 0.04% sodium azide to prevent microbial growth and subsequent 
contamination with RNases. An aliquot of 140ul taken from the samples were processed 
and the viral RNA was subsequently eluted in 80ul of elution buffer (Qiagen, Valencia, 
USA). 
 
2.1.4 Design of EV71 primers, Hybridization probes and the TaqMan probe 
The VP1 nucleotide sequences of 398 EV71 strains and 2 CA16 strains from the 
GenBank were analyzed. Using the BLAST algorithm 
(http://www.ncbi.nlm.nih.gov/BLAST) together with the DNASTAR program, highly 
conserved sequences of the VP1 region of EV71 strains that differed from CA16 were 
defined. The primers and probes for the respective assays were designed from different 
regions of the VP1 region. For the Hybridization probe-based analysis, two primers 
(designated as EvVP1F and EvVP1R) and two Hybridization probes (designated as 
EvVP1_FL and EvVP1_LC) were designed. For the TaqMan probe analysis, a TaqMan 
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Table 2.1: Nucleotide sequences of the specific primers, Hybridization probes and 












GAG AGT TCT ATA GGG GAC AGT 
 




AGC TGT GCT ATG TGA ATT AGG AA 
 




GAT GAC TGC TCA CCT GTG TGT TTT GAC C-FL 
 




LC640-GCT GGC AGG GCC TGG GTA AGT GCC-Pb
 








2497 to 2521 
 
a EvVP1-FL was labeled with fluorescein at the 3' end and EvVP1-LC was labeled with 
LC Red 640 at the 5' end and phosphorylated at the 3' end. 
b Phosphate 
c 6-carboxy-fluoroscein 
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2.1.5 Design of CA16 primers and Hybridization probes  
Based on the conserved VP1 region of EV71 strains that differ from CA16, a pair 
of degenerate primers (CAFP and CARP) and a pair of Hybridization probes (CA-FL and 
CA-LC) were designed for the specific detection of CA16. The sequences are shown in 
Table 2.2. 
 
2.1.6 Tissue culture and microneutralization for detection of EV71 
 The tissue culture method followed by neutralization with polyclonal antisera is 
regarded as the gold standard for detection of viruses in diagnostic laboratories. In this 
study, the efficacy of the traditional tissue culture method in detecting EV71 was carried 
out as a comparison to the real-time RT-PCR. While a small portion was used for RNA 
extraction, another portion of the each clinical specimen was used for tissue culture. RD 
cells (5 X 104) were first seeded into each well of a 96-well plate and grown at 37oC 
overnight. A volume of 50ul of each clinical specimen was incubated with 50ul of pooled 
EV71-specific polyclonal antisera at 37oC for 2 h. After two hours, the mixture was 
inoculated into the seeded RD cells and incubated at 37oC in 5% CO2. The inoculated RD 
cells were then observed daily for cytopathic effect (CPE) over a period of 8 days. Each 
batch of the experiment was carried out in triplicates with controls which included the 
uninfected RD cells, uninfected RD cells treated with the monoclonal antibodies only and 
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Table 2.2: Nucleotide sequences of the specific primers and Hybridization probes 












ACC AGG CYG TCA CTT CCC RA a
 




GTG GTG GGC ATG GTA ATA ATA CT 
 




CTC ACT AGC ATT GGT GTT GGC GGC GGT-FL 
 








2521 to 2493 
 
a Y – C, T R – A, G 
b CA-FL was labeled with fluorescein at the 3' end and CA-LC was labeled with LC Red 










MATERIALS AND METHODS 
   
2.1.7 Real-time RT-PCR using the LightCycler™ System  
Real-time RT-PCR analysis was carried out using the LightCycler from Roche 
Molecular Biochemicals, Germany. The LightCycler uses air currents and capillary 
reaction vessels which allowed efficient heat transfer to the contents in the capillaries. 
The sensitive fluorimeters allow real time monitoring of the amplification process 
through changes in fluorescence emission. For this project, the LightCycler RNA 
Amplification SYBR Green I kit and the LightCycler RNA Amplification Hybridization 
Probes kit were used. Both test kits allow a one-step RT-PCR in glass capillaries using 
the LightCycler instrument. Each reaction was performed in a reaction capillary by 
mixing the reagents, followed by spinning down the mixture briefly with the help of a 
special LightCycler Centrifuge Adapter.  
 
2.1.7.1 Real-time PCR SYBR Green I assay for specific detection of EV71 
In the LightCycler RNA Amplification SYBR Green I kit, the enzyme mix 
contains a mixture of reverse transcriptase and “Faststart” Taq Polymerase that allowed 
reverse transcription of the RNA template and subsequent cDNA amplification. The 
reaction mix contained reaction buffer, dNTP mix (dUTP instead of dTTP), 30mM 
MgCl2 and SYBR Green I. The specificity of the primers that were designed for the 
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cDNA was first synthesized from the RNA for 10 min at 55oC and followed by 
amplification for 40 cycles at 95oC for 30 sec, 55oC for 15 sec and 72oC for 9 sec. The 
temperature transition rates for all preceding steps were set at 20oC/sec for rapid thermal 
ramping. Melting curve analysis was also carried out after the PCR reaction. A rapid 
thermal ramping to 95oC was achieved for the complete denaturation of the PCR 
amplicons following hybridization at 60oC for 10 sec. A slow steady transition from 60oC 
to 95oC was then performed. Subsequently, a graph was plotted using –dF/dT against 
temperature which would show a melting curve peak, corresponding to the Tm of the 
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2.1.7.2 Real-time Hybridization Probe RT-PCR for specific detection of EV71 
The LightCycler RNA Amplification Hybridization Probe kit can be used for both 
Hybridization Probe-based and TaqMan Probe-based assays. Similar to the RNA 
Amplification SYBR Green kit, the enzyme mix contained a mixture of reverse 
transcriptase and “Faststart” Taq Polymerase that allowed reverse transcription of RNA 
template and subsequent cDNA amplifications. The reaction mix also contained reaction 
buffer, dNTP mix (dUTP instead of dTTP) and 30mM MgCl2 but without the SYBR 
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cDNA was synthesized from the RNA for 10 min at 55oC and amplified for 40 
cycles at 95oC for 30 sec, 55oC for 15 sec and 72oC for 9 sec. The temperature transition 
rates for all preceding steps were set at 20oC/sec for rapid thermal ramping. Melting 
curve analysis was also carried out after the PCR reaction, and the conditions were 
similar as described for the SYBR Green I assay. Agarose gel electrophoresis of the 
204bp amplicon was carried out in a 1.2% agarose gel prepared in 1XTBE buffer at 90V 
for 1 h. 
 
2.1.7.3 Real-time TaqMan RT-PCR for specific detection of EV71 
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cDNA was synthesized from the RNA for 10 min at 55oC and amplified for 40 
cycles at 95oC for 30 sec, 55oC for 15 sec and 72oC for 9 sec. The temperature transition 
rates for all preceding steps were set at 20oC/sec for rapid thermal ramping. Agarose gel 
electrophoresis of the 204bp amplicon was carried out in a 1.2% agarose gel prepared in 
1XTBE buffer at 90V for 1 h. 
 
2.1.7.4 Multiplex real-time Hybridization probe RT-PCR for the detection and 
differentiation of EV71 from CA16 
 
The LightCycler RNA Amplification Hybridization Probe kit was used for 
evaluating the multiplex real-time Hybridization probe RT-PCR. The multiplex real-time 
PCR allowed the detection of EV71 in the F2 channel of the LightCycler which detected 
fluorescence emission at 640nm, whilst the detection of CA16 was observed in the F3 
channel which detected fluorescence emission at 705nm. The LightCycler allowed colour 
compensation to eliminate any possible crosstalk of the fluorescence between both 
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cDNA was first synthesized from the RNA for 10 min at 55oC and followed by 40 
cycles of amplification at 95oC for 30 sec, 58oC for 15 sec and 72oC for 12 sec. The 
temperature transition rates for all preceding steps were set at 20oC/sec for rapid thermal 
ramping. Melting curve analysis was also carried out after the PCR reaction. A rapid 
thermal ramp to 95oC was achieved for the complete denaturation of the PCR amplicons 
following hybridization at 60oC for 10 sec. A slow steady transition from 60oC to 95oC 
was then performed. Subsequently, a graph was plotted using –dF/dT against temperature 
which would show a melting curve peak corresponding to the Tm of the PCR amplicons.  
Agarose gel electrophoresis of the 204bp (EV71) and 287bp (CA16) amplicons were 
carried out in a 1.2% agarose gel prepared in 1XTBE buffer at 90V for 1 h. 
 
2.1.8 RT-PCR amplification of the VP1 region 
 A set of primers, VP1F4 (5′-GAT AGA GTG GCA GAT GTG AT-3′) and 
VP1R1 (5′-AAC TTT CCA AGG GTA GTA ATG-3′) was designed based on the 
conserved sequences of EV71 that differed from CA16. The first-round PCR was first 
carried out using a one step RT-PCR kit from Qiagen (Valencia, USA). This kit was used 
for one-step conventional PCR which allowed reverse transcription of the RNA and 
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The PCR reaction was carried out in a thermal cycler (GeneAmp® PCR System 
2400 PE Applied Biosystems, CA, USA) with the following steps: reverse transcription 
at 50oC for 30 min, followed by 35 cycles of denaturation at 95oC for 1 min, annealing at 
55oC for 30 sec, extension at 72oC for 2 min and final extension at 72oC for 7 min. A 
second-round semi-nested PCR was performed using the primers EvVP1F and VP1R1. 
The second amplification process was carried out under the same conditions as the first. 
Agarose gel electrophoresis of the 867bp amplified product was conducted in a 1.2% 
agarose gel prepared in 1XTBE buffer at 90V for 1 h. 
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2.1.9 Nucleotide sequence analysis 
 The PCR amplicons generated from both the real-time PCR and the conventional 
semi-nested PCR assay were cycle sequenced using the ABI PRISM Big Dye Terminator 
cycle sequencing ready reaction kit version 3.1 (Applied Biosystems, USA). Each 20ul 

































The following amplification profile was used: denaturation at 96oC for 30 sec, 
annealing at 50oC for 30 sec and extension at 60oC for 1 min. The reaction was 
performed in a thermal cycler (GeneAmp® PCR System 2400 PE, Applied Biosystems, 
CA, USA) for 25 cycles. After the cycle sequencing, DNA was precipitated by adding 
50ul of ice-cold absolute ethanol and 2ul of 3M sodium acetate and incubated at -80oC 
for 1 h. The DNA was then precipitated by centrifugation at 12,000 x g for 20 min. After 
removing the supernatant, the DNA pellet was washed by adding 180ul of 70% ethanol 
and centrifuged for 12,000 x g for 20 min. The supernatant was removed and the DNA 
pellets were air-dried. The processed DNA products were sequenced using the ABI  
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PRISM 377 DNA sequencer (Applied Biosystems, CA, USA). Homology searches were 
carried out using the BLAST algorithm available from National Centre for Biotechnology 
Information (http://www.ncbi.nlm.nih.gov/BLAST).  
 
2.1.10 Absolute quantification of EV71 
 For absolute quantification of EV71, conventional PCR was carried out to amplify 
nt2466 to nt2669 within the VP1 region of EV71 (strain 41). The PCR product (204bp) 
was then cloned into the pGEM-T plasmid vector and subsequently transformed into 
E.coli JM109 competent cells. RNA was synthesized in vitro from the recombinant 
plasmids and the concentration was measured spectrophotometrically at 260nm. The 
number of viral copies was then calculated. A series of ten-fold dilutions were then 
prepared, yielding a series of viral copies ranging from 5 X 100 copies to 5 X 109 copies.  
 
2.1.10.1 Reverse transcription of EV71 RNA 
The isolated RNA from strain 41 was first reversed transcribed using the 
Multiscribe reverse transcription kit (Applied Biosystems, CA, USA).  Each 20ul reaction 






MATERIALS AND METHODS 













































 The following reaction conditions were performed in a thermal cycler 
(GeneAmp® PCR System 2400 PE, Applied Biosystems, CA, USA): initial incubation at 
25oC for 10 min, cDNA synthesis at 48oC for 30 min and followed by the deactivation 
step at 95oC for 5 min. The cDNA was then stored at -80 oC before further processing. 
 
2.1.10.2 Conventional PCR 
The primers – EvVP1F and EvVP1R were used for PCR amplification of the 
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 The PCR reaction was carried out in the thermal cycler (GeneAmp® PCR System 
2400 PE Applied Biosystems, CA, USA) using the following steps: denaturation at 95oC 
for 1 min, followed by 35 cycles of amplifications which comprised denaturation at 95oC 
for 30 sec, annealing at 55oC for 30 sec and extension at 72oC for 3 min. 
 
2.1.10.3 Cloning of the PCR amplicon into the pGEM-T easy vector 
DNA ligations were performed using the pGEM-T Easy Vector System II 
commercial kit (Promega, Madison, USA) according to the manufacturer’s instructions. 
For each reaction, 3ul of the PCR products were mixed with 5ul of 2X Rapid ligation 
buffer, 1ul of pGEM-T easy vector and 1ul of T4 DNA ligase. The mixture was then 
incubated overnight at 4oC. 
 81
MATERIALS AND METHODS 
   
 
2.1.10.4 Transformation and selection 
 Transformation was carried out using the highly efficient E.coli JM109 competent 
cells that were provided in the pGEM-T Easy vector System II kit (Promega, USA). The 
plasmid DNA (3ul) was added to the competent cells and incubated on ice for 30 min. 
The cells were then subjected to heat shock at 42oC for 90 sec, and immediately placed 
on ice for 2 min. After which, 800ul of LB were added to the competent cell suspension, 
followed by incubation at 37oC with shaking for 90 min. An aliquot of 200ul of the 
transformed cells was then plated on LB agar supplemented with ampicillin (100ug/ml), 
IPTG (100mM) and X-Gal (40ug/ml) (Appendix I). The vector pGEM-T contains lacZ 
gene encoding β-galactosidase which cleaves X-Gal to yield blue colour products. The 
inducer IPTG induces the expression of galactosidase. The screening of the recombinant 
clones was based on the insertion of the PCR product into the multiple cloning sites in the 
lacZ gene, which in turn disrupts the ability of β-galactosidase to cleave X-Gal. Thus, 
cells carrying the recombinant pGEM-T plasmids will appear as white colonies and were 
selected for further studies (Figure 2.1). 
 
2.1.10.5 Extraction of recombinant pGEM-T plasmids 
 The recombinant pGEM-T plasmids were extracted using the WizardTM SV Mini-
prep kit according to the manufacturer’s instructions (Promega, USA). The plasmid 
extraction method was based on the alkaline lysis method and column purification. This 
involved the use of an anion exchange resin which allows the negatively charged 
plasmids to bind to the resin. After washing twice with ethanol-based washing buffers, 
the plasmids were eluted from the column with nuclease-free water. 
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2.1.10.6 Preparation of EV71 RNA standards 
 The recombinant pGEM-T plasmids were first linearized for production of “run-
off” transcripts. In brief, 6.5ul of plasmid DNA were mixed with 2ul of 1X BSA, 2ul of 
10X RE buffer, 0.5ul of Sal I and the reaction mix was topped up to 20ul with sterile 
ddH2O. The mixture was then incubated at 37oC for 2 h. After restriction digestion, the 
linearized plasmids were extracted with phenol:chloroform:isoamyl alcohol (25:24:1) and 
followed by precipitation with absolute alcohol precipitation. The precipitated plasmid 
was then washed with 70% ethanol before being suspended in sterile water. 
 
In vitro transcription of the linearized plasmids was then carried out using the 
Riboprobe in vitro transcription system commercial kit (Promega, USA) according to the 
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 The reaction mixture was incubated at 37oC for 2 h. Extraction of the RNA was 
then carried out with phenol:chloroform:isoamyl alcohol (25:24:1) and 
chloroform:isoamyl alcohol (24:1), followed by precipitation with absolute ethanol and 
7.5M ammonium acetate. The precipitated RNA was then washed with 70% ethanol and 
resuspended in double distilled sterilized water. The RNA was then stored at -80oC. 
 
2.1.10.7 Quantitation of the in vitro transcribed EV71 RNA 
The concentration of the in vitro transcribed RNA was measured 
spectrophotometrically at 260nm. Based on the OD and the molecular weight of the four 
nucleotides, the number of the EV71 RNA copies was calculated. A series of ten-fold 
dilutions were made, yielding a series of viral copies ranging from 5 X 100 copies to 5 X 
109 copies. The standard plot was calculated by regression analysis of the Ct values 
versus log10 of the standard viral copy number. 
 
2.1.11 Absolute Quantification of CA16 
 For absolute quantification of CA16, a similar approach was applied. Briefly, 
conventional PCR was carried out to amplify nt2467 to nt2734 within the VP1 region of 
CA16. The PCR product (287bp) was then cloned into the pGEM-T plasmid vector and 
subsequently transformed into E.coli JM109 competent cells. RNA was synthesized in 
vitro from the recombinant plasmids and the concentration was measured 
spectrophotometrically. The number of viral copies was then calculated and a series of 
ten-fold dilutions were made, yielding a series of viral copies ranging from 5 X 100 
copies to 5 X 109 copies. 
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2.1.11.1  Reverse Transcription of CA16 RNA 
 The isolated RNA from CA16 was reversed transcribed by the procedure 
described in section 2.1.10.1. 
 
2.1.11.2 Conventional PCR 
The primers, CAFP and CARP, were used for PCR amplification of the cDNA 









































 The PCR reaction was carried out in the thermal cycler (GeneAmp® PCR System 
2400 PE Applied Biosystems, CA, USA) using the following steps: denaturation at 95oC 
for 1 min, followed by 35 cycles of amplifications comprising denaturation at 95oC for 30 
sec, annealing at 58oC for 30 sec and extension at 72oC for 3 min. 
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2.1.11.3 Cloning of the CA16 PCR amplicon 
 The 287bp PCR product was cloned into the pGEM-T easy plasmid vector and 
the recombinant clones were selected as described in sections 2.1.10.3 and 2.1.10.4. 
 
2.1.11.4 Preparation of CA16 RNA standards 




2.2 RNA interference of EV71 in vitro  
2.2.1 Maintenance of RD Cells 
Rhabdomyoscarcoma (RD) cells were maintained in minimal essential medium 
(MEM) (Gibco, USA) supplemented with 5% FCS, 2% HEPES and 1.5% NaHCO3 
(Appendix II). When the growth of the RD cells reached confluence, the cell monolayer 
was rinsed with phosphate buffered saline (PBS) to remove dead cells and debris before 
the addition of 1X trypsin-EDTA. Upon detachment of the RD cells from the bottom of 
the flask, fresh MEM was added to dilute the trypsinisation. The cells were then passaged 
at a ratio of 1:4 in T75 tissue culture flasks and maintained in a 37oC incubator with 5% 
CO2. 
 
2.2.2 Cryo-preservation of RD Cells 
 RD cells were cryo-preserved to maintain cells at a low passage number. A 
confluent monolayer of cells in T75 tissue culture flask was used. The media was first 
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aspirated and the cells were washed with 1X PBS to remove any suspending cells. The 
cell monolayer was then treated with 4ml of 1X trypsin-EDTA to detach the RD cells 
from the flask. Growth media (6ml) were then added to the cells and the contents were 
transferred into a 15ml Falcon tube. After centrifugation for 10mins at 1000 x g at 4oC, 
the supernatant was discarded and the cell pellet was resuspended in 2ml of freezing 
media (Appendix II). The cell suspension was then transferred into a cryo-vial and kept at 
-20oC for a day before transferring to a -80oC freezer to ensure gradual freezing. The 
cryo-vial was then transferred to a liquid nitrogen tank after 2 days.  
  
When required, each cryo-vial of RD cells was retrieved from the liquid nitrogen 
and thawed immediately in a 37oC water bath. When thawed, the cell suspension was 
transferred to a T75 culture flask containing 10ml of reviving media (MEM medium 
supplemented with 10% FCS) to dilute the toxic effects of DMSO in the freezing media. 
The cells were allowed to grow to confluency in approximately one to two days. The 
cells were subjected to at least two passages before being used for further studies. 
 
2.2.3 Chemically synthesized 29-mer short hairpin RNAs (shRNAs) 
2.2.3.1  Design of chemically synthesized 29-mer shRNAs 
The synthetic 29-mer shRNAs were designed to target specific sequences within 
the 2C, 3Cpro, and 3Dpol of the EV71 genome, and were designated as 29mer-2C, 29mer-
3C and 29mer-3D, respectively. The design of the shRNAs was based on the general 
guidelines as described (Elbashir et al., 2001a, 2001b). In general, the 29-mer shRNAs 
were designed with the following criteria: the siRNA duplex should have 30-50% GC 
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content with UU overhangs at the 3' ends. Highly conserved regions within the three 
regions were identified using the siRNA Target Finder software (Ambion Inc, USA). The 
siRNA sequences were then subjected to the BLAST search of the National Center for 
Biotechnology Information database to ensure that they target the desired viral genes 
specifically. To determine the transfection efficiencies, the 29-mer shRNAs designed to 
target at all the three regions were tagged with fluorescein (FITC) at the 5′ end of the 
sense strand. A scrambled sequence (29mer-scr) with the same base composition as the 
29mer-3D was also used as a control. The sequences of the chemically synthesized 
siRNAs were listed in Table 2.3. For comparative purpose, the chemically synthesized 
19-mer siRNAs targeted at the 3Dpol region (designated as 19mer-3D) of EV71 reported 
previously by Sim et al. (2005) was included in this study. All the 29-mer shRNAs were 
synthesized by Dharmacon, USA.  
 
2.2.3.2 Transfection of 29-mer shRNAs and infection with EV71.  
Transfection was carried out under optimal conditions. RD cells (5 X 104) were 
seeded into each well of a 24-well plate and grown at 37oC overnight. The growth 
medium in each well was then replaced with 500ul of pre-warmed reduced-serum 
medium, OPTI-MEM I (Gibco, Boston, MA, USA) for another 24 h. Upon reaching 80% 
confluency, the RD cells were transfected with a transfection mixture containing 1.2μl of 
Lipofectamine™ 2000CD diluted in OPTI-MEM® containing graded concentrations 
(1nmol, 5nmol and 10nmol) of the various 29-mer shRNAs. Mock-transfection was 
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Table 2.3: Sequences of the chemically synthesized 29-mer shRNAs and their 
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was infected with 60 pfu of EV71 for 1 h. The cells were then overlaid with the growth 
medium and incubated at 37oC in 5% CO2. At different time points post-infection, cell 
lysates and cell supernatants were collected and stored at -80oC for further studies. The 
transfection protocol for the chemically synthesized 29mer shRNAs is summarized in 
Figure 2.2. 
 
To evaluate the therapeutic potentials of the 29-mer shRNAs, the RD cells were 
infected with 60 pfu of EV71 and at each hourly interval (up to 5 hours) after infection, 
the RD cells were then transfected with 10nmol of the various 29-mer shRNAs.  
 
2.2.3.3 Determination of transfection efficiencies of 29-mer shRNAs 
RD cells were seeded onto Labteck Permanox® Chamberslide (Nunc, Germany) 
and transfected with 10nM of the fluorescein labelled 29mer-2C, 29mer-3C, and 29mer-
3D. At 48 hours post-transfection, the cells were washed twice with PBS and fixed with 
4% paraformaldehyde for 10 min. The cells were washed again with PBS before the 
addition of Vectashield Mounting Medium with propidium iodide (Vectorlabs, USA). 
The cells were then observed under the Olympus BX60 fluorescent microscope.  
 
In a similar setup, the cells were trypsinized and harvested after being fixed with 
4% paraformaldehyde. The transfection efficiencies of the harvested cells were then 
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2.2.4 The psiStrike plasmid expressing short hairpin RNA (shRNA) system 
The psiStrike U6 hairpin cloning system includes a linearized plasmid vector 
designed for easy and fast cloning of hairpin sequences. Two single stranded DNA 
oligonucleotides were designed, annealed to form an insert that contains the hairpin 
siRNA (shRNA) target sequence, and ligated into the psiStrike vector. The recombinant 
plasmids were transfected into RD cells with the aid of the transfection agent. The 
transfection efficiency was determined by the presence of a green fluorescent protein 
(hMGFP), the expression of which was driven by the CMV promoter (Figure 2.3). 
 
2.2.4.1 Design of psiStrike plasmid expressing shRNA system 
The 19mer shRNAs which were cloned into the psiStrike plasmid vectors were 
designed to target at the 2C, 3Cpro and 3Dpol regions of the EV71 genome and were 
designated as psi-2C, psi-3C and psi-3D, respectively. A scrambled sequence (psi-scr) 
with the same base composition as the psi-3D was also cloned into the psiStrike plasmid 
vector and used as the negative control. The sequences of the 19-mer shRNAs were listed 
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Figure 2.3: Vector map of the psiStrike expression vector system (Adapted from 
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Table 2.4: Sequences of 19mer shRNAs for cloning into the psiStrike expression 
















5'- ACCGaAACCAGATCACGAACTTGG CTTCCTGTCAb 










5'- ACCGa GCTACTTTGCGAGTATGCA CTTCCTGTCAb 










5'- ACCGa GAAATTGGCTCGAATTGTT CTTCCTGTCAb 









5'- ACCGa TTAAACCTTAAGACCTCGG CTTCCTGTCAb 








a – Overhang sequences to allow cloning into the psiStrike expression vector 
 
b – Stem loop sequence 
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2.2.4.2 Annealing of oligonucleotides 
Both the sense and antisense oligonucleotides were first annealed before cloning 
into the psiStrike shRNA expression vector. Each reaction contained 40ng/ul of each 
oligonucleotide in 50ul of oligo annealing buffer (Promega, USA). The annealing process 
was carried out by heating at 90oC for 3 min. This was followed by incubation at 37oC for 
15 min. The annealed oligonucleotides were kept at -20oC until further processing.   
 
2.2.4.3 Cloning of olignucleotides into the psiStrike expression vector 
 
The ligation of the annealed oligonucleotides into the psiStrike expression vector 
was performed according to the manufacturer’s instructions. For each reaction, 2ul of the 
oligonucleotides were mixed with 5ul of 2X Rapid ligation buffer, 1ul of psiStrike 
plasmid vector, 1ul of T4 DNA ligase and made up to 10ul with double distilled water. 
The mixture was then incubated overnight at 4oC. 
 
2.2.4.4 Transformation and selection of psiStrike plasmids expressing 19-mer 
shRNAs 
 
 Transformation was carried out using highly efficient E.coli JM109 competent 
cells. The competent cells (in 200ul aliquot) were first allowed to thaw on ice. The 
recombinant psiStrike shRNA plasmids (4ul) were added to the thawed competent cells 
and incubated on ice for 30 min. The cells were then subjected to heat shock at 42oC for 
90 sec, and placed on ice for 2 min. LB medium (800ul) was then added to the competent 
cell suspension, and the content was incubated in a 37oC orbital shaker for 90 min. An 
aliquot of 200ul of the transformed cells was then plated on LB agar supplemented with 
ampicillin (100ug/ml) which was used as the selection marker. 
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2.2.4.5 Extraction of psiStrike plasmids 
 The recombinant psiStrike plasmids were extracted using the PureYieldTM 
Plasmid Midiprep system according to the manufacturer’s instructions (Promega, USA). 
The system was specifically designed to extract plasmids for use in eukaryotic 
transfection and in vitro expression studies. The bacterial cells were lysed with a lysis 
buffer and the released plasmids were bound to the silica-membrane column. The bound 
plasmids were then treated with an endotoxin removal buffer to remove proteins, RNA 
and endotoxin contaminants which could interfere with subsequent transfection studies. 
After washing with a column washing buffer, the purified plasmids were eluted with 
200ul nuclease-free water. 
 
2.2.4.6 Transfection of psiStrike plasmids expressing 19-mer shRNAs  
The transfection protocol for the psiStrike plasmids expressing 19-mer shRNAs 
was similar to the 29-mer shRNAs as described in section 2.2.3.2. The RD cells (5 X 104) 
were seeded into each well of a 24-well plate and grown at 37oC overnight. The growth 
medium in each well was then replaced with 500ul of pre-warmed reduced-serum 
medium, OPTI-MEM I (Gibco, Boston, MA, USA) for another 24 h. The RD cells were 
then transfected with complexes containing Lipofectamine 2000CD (Invitrogen Life 
Technologies, Carlsbad, CA) and 0.8ug of psi-2C, psi-3C or psi-3D. After 48 h, each well 
was infected with 60 pfu of EV71 for 1 h. The cells were then overlaid with the growth 
medium and incubated at 37oC in 5% CO2. At different time points post-infection, cell 
lysates and cell supernatants were collected and stored at -80oC until further studies. The 
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transfection protocol for psiStrike plasmids expressing 19-mer shRNAs was summarized 
in Figure 2.4. 
 
To evaluate the therapeutic potentials of the psiStrike plasmids expressing 19-mer 
shRNAs, the RD cells were infected with 60 pfu of EV71 and at each hourly interval (up 
to 5 hours) after infection, the RD cells were then transfected with the various psiStrike 
plasmids expressing 19-mer shRNAs.  
 
2.2.4.7 Determination of transfection efficiencies of psiStrike plasmids 
expressing 19-mer shRNAs 
 
The determination of transfection efficiencies of the psiStrike plasmids expressing 
19-mer shRNAs were carried out as described in section 2.2.2.3. 
 
2.2.5 Plaque assay 
To determine the viral infectivity of EV71 after siRNA treatment, plaque assays 
were carried out after the transfection protocol. After 24 h of transfection, 1% w/v 
carboxymethylcellulose (CMC) in 2X growth medium was layered onto the infected cell 
monolayer (Appendix III). The plates were then incubated at 37oC in 5% CO2 for 48 h. 
Plaques of EV71 were observed by fixing with 20% formalin in PBS for 30 min and 
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2.2.6 Real-time RT-PCR  
At 48 h post-infection, total RNA was extracted from each well using TRIzol LS 
reagent, according to the manufacturer’s instructions (Invitrogen Life Technologies, 
Carlsbad, CA). The efficiency of the various shRNAs in inhibiting EV71 replication were 
then analysed using real-time Hybridization Probe RT-PCR developed in this study for 
the detection of EV71 RNA as described in section 2.1.7.2. 
 
2.2.7 SDS-PAGE and Western blot 
RD cells were grown in wells of a 6-well plate and transfection was performed 
according to the experimental set up as described. At 24 h post-infection, the cells were 
harvested for determination of total proteins. The cells were first lysed using 200ul of 
CelLytic M Cell Lysis Reagent (Sigma, USA). An aliquot of 20ul of each lysate was 
electrophoresed in a denaturing 10% polyacrylamide gel (Appendix IV). Western blots 
were then performed following standard procedures. The detection of the proteins was 
based on the chromogenic method using the WesternBreeze® Chromogenic Western Blot 
Immunodetection Kit (Invitrogen, USA) with the use of EV71 VP1 monoclonal antibody 
(1:4000 dilution) (Chemicon International, USA), the anti-PKR antibody (1:2000 
dilution), the anti-phospho PKR antibody (1:1000 dilution) and the ß-actin antibody 
(1:4000 dilution) (Sigma, USA). 
 
2.2.8 Cell viability assay 
To test the toxicity of the 29-mer shRNAs or the psiStrike plasmids expressing 
19-mer shRNAs, cell viability assay was carried out using the CellTiter 96® Aqueous 
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Non-radioactive Cell Proliferative Assay (Promega, USA). The MTS/PMS reagent of the 
assay was composed of a tetrazolium compound that was reduced by dehydrogenases 
within viable RD cells into a formazan product. RD cells were seeded in a 24-well plate 
and the transfection of cells was performed as described above. After 2 days post-
transfection, cells were trypsinized, and 100ul of the resuspended cells were transferred 
to the wells of a 96-well plate in triplicates. A total of 20ul of the MTS/PMS reagent 
(Promega, USA) was then added into each well. After incubation at 37oC for 3 h in the 
dark, the absorbance of formazan was measured at OD 490nm. Hence, the amount of 
formazan formed was directly proportional to the number of viable cells. All assays were 
performed in triplicates and carried out as two independent experiments. 
 
 
2.3 RNA interference of EV71 in the murine model. 
2.3.1 Chemically synthesized 19-mer siRNAs, chemically synthesized 29-mer 
shRNAs and the psiStrike plasmids expressing 19-mer shRNAs 
 
The chemically synthesized 19-mer siRNA, 29-mer shRNAs and the psiStrike 
plasmids expressing 19-mer shRNAs were designed to target at the 3Dpol region of the 
EV71 genome and were designated as 19mer-3D, 29mer-3D and psi-3D, respectively. 
Scrambled sequences of chemically synthesized 19mer-3D and 29mer-3D, as well as the 
psiStrike plasmids expressing 19-mer scrambled shRNAs were included as negative 
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2.3.2 Purification of EV71 
The EV71 virus strain 41 was propagated in the RD cells and was harvested upon 
complete CPE. About 500ml of the cell supernatants containing the EV71 virus were 
obtained and the cell debris was removed by centrifugation at 10,000 x g for 20 min at 
4oC. The supernatant was then transferred to a beaker containing a magnetic stirrer. The 
virions were precipitated from the supernatant by adding 2.3% w/v sodium chloride, 
followed by polyethylene glycol (PEG8000) with constant stirring for about an hour at 
4oC. The virion mixture was then stored at 4oC overnight to allow the virus to precipitate. 
The virion mixture was then centrifuged at 10,000 x g for 20 min at 4oC to collect the 
PEG-virus pellet. The supernatant was gently discarded and the pellet containing the 
PEG-virus complex was resuspended gently with TN buffer (50mM each of Tris-HCL 
and NaCl at pH7.8) to generate a virus pool concentrate. For e.g., the pellet collected 
from 100ml of culture supernatant was reconstituted in 1ml of TN buffer. Any insoluble 
materials were removed by centrifugation at 3,000 x g for 30 min. The purification of the 
virus was performed by loading the supernatant (about 5 to 7ml) gently over a 30% 
sucrose cushion (1ml) in a ultra-speed tube (Optima XL-100K Ultrafuge, Beckman 
Instruments, USA), and spun at a speed of 25,000 x g for 4 h at 4oC. After removing the 
supernatant gently, the pellet (containing the purified virus) was resuspended in 500ul of 
1 X PBS and stored at -80oC. The same procedure was carried out for other strains of 
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2.3.3 TCID50 assay 
 The infective dose (TCID50) of EV71 was determined as described by Hsiung 
(1994), and has been a well accepted assay system for enteroviruses (Yu et al., 2000; 
Shieh et al., 2001). RD cells (100ul) were seeded into each well of the 96-well plate and 
were grown overnight to 90% confluency at 37oC in 5% CO2. To assay the number of 
infectious virions in the EV71 virus stock, a series of 10-fold dilutions of the virus stock 
was prepared in maintenance media, and 25ul of each dilution of the virus stock were 
inoculated into each well in quadruplicates. To the control wells, 25ul of the maintenance 
media was added instead. The inoculated plate was then incubated at 37oC in 5% CO2, 
and was monitored daily for CPE over a period of 2 days. The virus infectivity titre was 
calculated by the Reed and Muench formula as outlined in Appendix V (Lennette, 1969). 
 
2.3.4 siRNA treatment in vivo 
For all the in vivo experiments, 1 day old Balb/c suckling mice were used. The 
suckling mice (n=5) were first infected with 104 TCID50 of EV71 via the intraperitoneal 
(i.p.) route. The first group of infected suckling mice was used as positive control. At 24 
hours post-infection, nine other groups of infected suckling mice were treated with 
1nmol, 5nmol or 10 nmol of 19mer-3D, 1nmol, 5nmol or 10nmol of 29mer-3D, 10ug, 
25ug or 50ug of psi-3D, 10nmol of 19mer-scr, 10nmol of 29mer-scr or 50ug of psi-scr 
via the oral or i.p. route. All the siRNAs were complexed with Oligofectamine 
(Invitrogen, USA) and made up to 100ul with Opti-MEM (Gibco Life Technologies, 
Invitrogen, USA) prior to administration. One group of suckling mice (n=5) was not 
infected by EV71 and used as negative control. When the siRNA was used without 
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Oligofectamine, the Opti-MEM was substituted with 1XPBS. During the course of the 
experiment, the weights of all the suckling mice were monitored every alternate day. On 
day 14 post infection, the intestines were harvested from the suckling mice, and the 
intestinal cells were extracted according to the method described by Zhang et al. (2003).  
The extracted intestinal cells were stored under -20oC until further analysis. All the mice 
experiments were carried out according to the guidelines of the Institutional Animal Care 
and Use Committee in National University of Singapore, and were repeated four times 
independently to ensure good reproducibility. 
 
2.3.5 Real-time RT-PCR  
Total RNA was extracted from the supernatants using the RNeasy extraction kit, 
according to the manufacturer’s instructions (Qiagen, USA). The total RNA extracted 
were then analysed for the presence of EV71 using real-time Hybridization Probe RT-
PCR for detection of EV71 RNA as described in section 2.1.7.2 .  
 
2.3.6 SDS-PAGE and Western blot 
The extracted intestinal cells were then lysed using 200ul of CelLytic M Cell 
Lysis Reagent (Sigma, USA). An aliquot of 20ul of each lysate was electrophoresed in a 
denaturing 10% polyacrylamide gel. Western blots were then performed following 
standard procedures as described in section 2.2.7. The detection procedure was based on 
the chromogenic method as described using EV71 VP1 monoclonal antibody (1:4000 
dilution) (Chemicon International, USA) and the ß-actin antibody (1:4000 dilution) 
(Sigma, USA). 
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2.3.7 Immunohistochemical analysis 
On Day 7 and Day 14 post infection, the intestines of the infected and siRNA - 
treated suckling mice were harvested and stored immediately at -80oC. Cryosections of 
4um from the frozen tissues were made and fixed on poly-L-lysine glass slides. 
Permeabilization of the fixed tissues was carried out by incubation with 0.2% Triton for 
10 mins. Non-specific background was eliminated by incubating the tissue sections with 
commercially available blocking reagents (Zymed Laboratories, USA). EV71 was 
detected by incubating the tissues with the mouse monoclonal antibody against EV71 
(Chemicon International, USA). After washing with 1X PBS, the tissues were incubated 
with horseradish peroxidase (HRP)-conjugated anti-mouse secondary antibodies (Zymed 
Laboratories, USA). After washing with 1X PBS, aminoethyl carbazole substrate was 
added, which in turn was catalysed by the HRP to produce a red coloured deposit which 
demonstrated the location of EV71 within the tissues (Zymed Laboratories, USA).  
 
2.3.8 Interferon assay 
The suckling mice were first injected with 10nmol 19mer-3D or 50ug psi-3D via 
the i.p. route. After 24 hours, homogenates of the intestines were prepared. The levels of 
IFN-α and IFN-β in the homogenates were then measured by ELISA (PBL Biomedical 
Laboratories, USA) according to the manufacturer’s instructions. The homogenates were 
first added to the microtiter plate precoated with antibodies specific to IFN-α or IFN-β. 
After washing with buffers to remove any unbound IFN-α or IFN-β, a secondary 
antibody was added and this was followed by the anti-secondary antibody conjugated to 
HRP. Tetramethyl-benzidine (TMB) was then added. This would produce a blue 
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colouration in the presence of IFN-α after incubation in the dark for 15 mins. After the 
addition of the stop solution (which changed the colour to yellow), the levels of IFN-α or 
IFN-β were determined by measuring the absorbance at 450nm. 
 
2.4 Statistical analysis 
 All the results were expressed as mean ± standard deviation (indicated by error 
bars in graph). Statistical analysis was performed by one-way ANOVA; P values of less 
than 0.05 were considered as statistically significant. 
  
2.5 Estimation of evolution frequency of EV71 
The complete VP1 nucleotide sequences (891bp) of 398 EV71 strains and 3Dpol 
nucleotide sequences (1386bp) of 25 EV71 strains isolated from all over the world during 
the period from 1995 to 2005 were obtained from the GenBank and analysed. 
 
2.5.1 Calculation of genetic distances 
The Tamura-Nei distance model was used to calculate the pairwise genetic 
distance between each individual EV71 strain and the prototype BrCr strain which was 
used as the reference strain. The genetic distance was calculated using the MEGA4 
software, which was able to compute the following quantities for this method: 
Symbols     Description 
d: Transitions & Transversions Number of nucleotide substitutions per site. 
s: Transitions only    Number of transitional substitutions per site. 
v: Transversions only    Number of transversional substitutions per site. 
R = s/v     Transition/transversions ratio. 
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The formulas for computing these quantities are as follows: 
 
Calculation of genetic distance: 
d = -k1 loge (w1) – k2 loge (w2) – k3 loge (w3) 
s = -k1 loge (w1) – k2 loge (w2) – (k3 - 2gRgy) loge (w3)  
v = - 2gRgy loge (w3) 
R = s/v 
where P1 and P2 are the proportions of transitional differences between nucleotides A 
and G, and between T and C, respectively, Q is the proportion of transversional 
differences, gA, gC, gG, gT, are the respective frequencies of A, C, G and T, gR = gA + 




k3 = 2(gRgy – gAgGgy/gR – gTgCgR/gy) 
k4 = 2(gAgG + gTgC + gRgy) 
w1 = 1 – P1/k1 – Q/2gR
w2 = 1 – P2/k2 – A/2gy
w3 = 1 – Q/2gRgy







c4 = k1c1/2gR + k2c2/2gy + k3c3/ (2gRgy) 
c5 = k1c1/2gR + k2c2/2gy + k3c3/2gRgy - c3
c6 = c1/v 
c7 = c2/v 
c8 = (c5 – c3R)/v 
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2.5.2 Z-test of selection 
To determine whether positive selection is acting on the VP1 and the 3Dpol gene 
of EV71, the relative abundance of synonymous and nonsynonymous substitutions within 
the respective gene sequences of all the EV71 strains were determined. This was carried 
out by the MEGA4 software which will determine the number of synonymous 
substitutions (dS), the number of nonsynonymous substitutions (dN), and their respective 
variances: Var(dS) and Var(dN), respectively. 
 
The Z-test was then carried out to test the null hypothesis (H0) using a z-test,  
whereby:                       H0: dN = dS: 
 
Z = (dN - dS) / square root of (Var(dS) + Var(dN)) 
 
The level of significance at which the null hypothesis is rejected depends on the 
alternative hypothesis (H1): 
H0:  dN = dS 
H1: (a) dN ≠ dS (test of neutrality). 
(d) dN > dS (positive selection). 
(c) dN < dS (purifying selection). 
For alternative hypotheses (b) and (c), a one-tailed test was used, and for (a) a two-tailed 
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CHAPTER 3 
 
Development of real-time RT-PCR assays for the specific detection of EV71 directly 
from clinical specimens 
 
 
3.1  Introduction 
The Asia-Pacific region had experienced large epidemics of Hand, Foot and 
Mouth Disease (HFMD) over the last few years, and the two main etiological agents 
commonly isolated were Enterovirus 71 (EV71) and Coxsackievirus A16 (CA16) (Brown 
et al., 1999; Chang et al., 1999; Yan et al., 2001). EV71 and CA16 are closely related 
genetically, sharing 77% nucleotide and 89% amino acid homologies (Brown et al., 
1999). However, infection by EV71 is more often associated with severe neurological 
diseases like aseptic meningitis, brainstem and cerebellar encephalitis which are not 
observed in HFMD infections caused by CA16 (Lum et al., 1998; AbuBakar et al., 
1999). In the major HFMD outbreaks in South-East Asia, EV71 was the main etiological 
agent which caused 41 deaths in Malaysia in 1997 (Lum et al., 1998), 78 deaths in 
Taiwan in 1998 (Ho et al., 1999) and 4 deaths in Singapore in 2000 (Ahmad, 2000).  
 
Since the clinical symptoms of EV71- and CA16- associated HFMD are similar, 
diagnosis depends largely on virus isolation and serotyping by neutralization established 
by Lim et al. (1960). However, this approach requires two to three weeks of growth and 
neutralization of the viral isolates. Besides, the antigenic typing could be hindered by 
non-neutralizable viruses due to aggregation, antigenic drifts, or the presence of multiple 
viruses in the specimen (Melnick et al., 1996a). The development of polymerase chain 
reaction (PCR) techniques has contributed significantly to laboratory diagnosis of viral  
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infections in terms of sensitivity, specificity and the rate of detection in comparison to the 
cell culture method. Using conventional reverse-transcription PCR (RT-PCR) strategy, 
specific detection of EV71 or CA16 had been reported (Brown et al., 2000; Bendig et al., 
2001; Singh et al., 2002; Tsao et al., 2002; Nix et al., 2006). However, the two-step RT-
PCR process was time-consuming and the risk of cross-contamination could be increased 
by this approach. In addition, detection of the viruses based on conventional RT-PCR 
required at least 6 to 8 hours and required further DNA sequencing for confirmation. This 
could be a limiting factor during outbreak situations. In a recent study, a conventional 
multiplex RT-PCR in combination with the microarray method was developed to 
differentiate EV71 from CA16 using specific primers targeting at a specific region of 
each viral RNA (Chen et al., 2006). RT-PCR was first carried out to amplify EV71 and 
CA16 viral RNA, respectively. In the microarray analysis, the amplicons were then 
labeled with fluorescent dyes and added to array slides which were spotted with 60-mer 
degenerate oligonucleotide probes specific for either EV71 or CA16. A diagnostic 
accuracy of 92% and 95.8% was achieved for specific detection of EV71 and CA16, 
respectively (Chen et al., 2006). In another study, Tsao et al. (2006) evaluated a 
microchip method developed by DR. Chip Biotechnology (Taiwan). The detection was 
based on the biotinylated PCR products hybridising to specific probes, and this approach 
achieved a sensitivity accuracy of 82% (Tsao et al., 2006). However, the detection of 
EV71 from clinical specimens using both approaches was laborious. Besides, the entire 
diagnostic process using both methods required at least 10 hours which was too long in 
outbreak situations. 
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In recent years, real-time PCR has gained wider acceptance for viral diagnosis in 
laboratories due to higher sensitivity and specificity, faster rate of detection and the 
approach provided real time monitoring of the amplification process through fluorescence 
emission (Mackay et al., Espy et al., 2006). Previous studies have shown that 
enteroviruses which caused HFMD could be differentiated from other viruses such as 
Varicella-Zoster virus (VZV), poliovirus and Herpes Simplex virus (HSV) using real-
time PCR SYBR Green I based (Read et al., 2001) and TaqMan probe-based assays 
(Verstrepen et al. 2001; Nijhuis et al., 2002; Watkins-Riedel et al. 2002; Petitjean et al., 
2006). In all the studies, the primers and probes were designed to target at the 5'-
untranslated region (5'UTR) of the enterovirus genome which is highly conserved among 
enteroviruses. However, with increased concerns over HFMD infections caused by 
EV71, there is a need for a rapid and highly specific method to distinguish this virus from 
enteroviruses such as CA16, CB2, Echo 4, 6 and 7 which were commonly isolated from 
large HFMD outbreak situations. 
 
In this study, a one-step quantitative real-time RT-PCR based on both 
Hybridization probe and TaqMan probe chemistries were developed to detect EV71 
directly from clinical specimens. A multiplex real-time Hybridization probe RT-PCR 
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3.2.1 Specificity of the primers designed for the detection of EV71  
The primers, EvVP1F and EvVP1R designed in section 2.1.4 for developing the 
real-time Hybridization probe RT-PCR, real-time TaqMan RT-PCR and multiplex real-
time Hybridization probe RT-PCR were first evaluated using the SYBR Green I assay. 
The specificity of the primers was investigated by testing 3 EV71 viral isolates (strains 
41, 10 and 7423/MS/87) and enteroviruses such as CA16, CA24, CB1, CB2, CB3, CB4, 
CB5, Echo 4, Echo 6 and Echo 7. Results showed that the primers were found to be 
specific for the direct detection of EV71 as amplifications were observed for all three 
EV71 viral isolates (strains 41, 10 and 7423/MS/87), whilst no amplification was 
observed for the other enteroviruses tested. Agarose gel electrophoretic analysis of the 
PCR products showed that the real-time SYBR Green I assay yielded the predicted 204bp 
amplicons from the three EV71 strains but not from the other enteroviruses (Figure 3.1).  
 
Based on the melting curve analysis, distinct high fluorescence emission spectra 
were obtained for the DNA amplicons derived from the three EV71 strains when 
compared to the absence of fluorescence for the other enteroviruses. The melting curve 
analysis of the amplicons generated showed that the Tm values for the different EV71 
strains ranged from 84.4oC (strain 7423/MS/87) to 85.0oC (strains 41 and 10) (Figure 
3.2). The differences in the Tm reflected small changes in nucleotides between the 204bp 
amplicons derived from different EV71 strains. 
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Figure 3.1: Agarose gel showing amplicons generated from the real-time PCR 
Hybridization probe assay. M – 100bp 100bp DNA molecular weight markers; Lane 1 
– Strain 41; Lane 2 – Strain 10; Lane 3 – 7423/MS/87; Lane 4 – CA16; Lane 5 – CA24; 
Lane 6 – CB1; Lane 7 – CB2; Lane 8 – CB3; Lane 9 – CB4; Lane 10 – CB5; Lane 11 – 
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Figure 3.2: SYBR Green melting curve analysis of the amplicons generated from 
different EV71 viral isolates using the primers, EvVP1F and EvVP1R. The Tm value 
for strain 7423/MS/87 was 84.4oC and 85.0oC for EV71 strain 41 and strain 10. No 
fluorescence was observed for the other enteroviruses such as CA16, CA24, CB1 to CB5, 
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3.2.2 Development of real-time Hybridization probe RT-PCR 
3.2.2.1  Specificity of real-time Hybridization probe RT-PCR  
The specificity of the primers, EvVP1F and EvVP1R, and the Hybridization 
probes, EvVP1_FL and EvVP1_LC, designed for the real-time Hybridization probe RT-
PCR assay to detect EV71 was investigated by testing different EV71 strains (strains 41, 
10 and 7423/MS/87) against other enteroviruses which are also known to cause HFMD. 
Amplicons were generated from EV71 strains 41, 10 and 7423/MS/87 in an one-step real 
time RT-PCR with Ct values of 18, 20 and 24, respectively, whilst all other enteroviruses 
such as CA16, CA24, CB1 to CB5, Echo 4, Echo 6 and Echo 7 were not amplified 
(Figure 3.3). The amplicons were sequenced and shown to correlate with the VP1 region 
of EV71 (98% to 100% homology), thus indicating the high specificity of the primers and 
probes for EV71.  
 
The amplicons generated from the real-time Hybridization probe RT-PCR were 
also analyzed by melting curve analysis. The Tm (melting temperature) of strain 
7423/MS/87 was established to be 72.0oC and the Tm of the other two EV71 strains 
(strains 41 and 10) were 71.5oC, indicating slight differences in the nucleotide sequence 
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Figure 3.3: Detection of EV71 based on amplification of the VP1 region by the real-
time Hybridization probe RT-PCR. Different EV71 strains (Strains 41, 10 and 
7423/MS/87) were evaluated against enteroviruses such as CA16, CA24, CB1 to CB5, 
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Figure 3.4: Hybridization probe-based melting curve analysis of the amplicons 
generated from three different EV71 viral isolates. The Tm value of isolate 
7423/MS/87 was established to be 72.0oC whilst the Tm values of both isolate 41 and 
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3.2.2.2  Quantitative analysis of real-time Hybridization probe RT-PCR  
The sensitivity and reproducibility of the real-time Hybridization probe RT-PCR 
assay were assessed by serially-diluted EV71 RNA in 2 independent experiments. The 
standard curve was calculated by regression analysis of the Ct values versus log10 of the 
standard viral copy number (Figure 3.5). The real-time Hybridization probe RT-PCR was 
able to detect EV71 RNA over a linear range from 5 to 5 X 109 copies. Statistical analysis 
of the standard curve showed that there was a good correlation coefficient (R2=1.000) 
between the Ct value and the copy number, and the linearity was consistent in both sets 
of experiments. 
 
3.2.2.3 Detection of EV71 directly from clinical specimens by real-time 
Hybridization probe RT-PCR 
 
A total of 55 clinical specimens obtained from pediatric patients suffering from 
HFMD during the period from 2000 to 2003 were evaluated for the presence of EV71. 
The clinical specimens analysed include CSF, stool, rectal swabs, blood, throat swabs and 
urine and the results are shown in Tables 3.1 and 3.2. The real-time Hybridization probe 
RT-PCR assay was able to detect the presence of EV71 in 46 out of the 55 clinical 
specimens. To verify that the positive clinical specimens did contain EV71, the 
traditional cell culture method and a conventional semi-nested RT-PCR amplification of 
the VP1 region of EV71 (using the primer pairs, VP1F4 and VP1R1 for the first round of 
PCR, and EvVP1F and VP1R1 for the second round of PCR) were carried out. None of 
the clinical specimens were tested positive for EV71 by the cell culture method. 
However, amplification of the VP1 region was observed for all the positive clinical 
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specimens by the semi-nested conventional RT-PCR, and DNA sequencing showed that 
the 867bp PCR amplicons generated correlated highly with the VP1 region of EV71 
(98% to 100% sequence homology). No EV71 RNA was detected in 9 clinical specimens 
by the real-time Hybridization probe RT-PCR assay. To determine whether these 
specimens contained EV71, conventional semi-nested RT-PCR was conducted with these 
9 clinical specimens. In concordance with the data from the real-time Hybridization 
probe RT-PCR, no amplification of the VP1 region of EV71 was observed for each of the 
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y = -3.365x + 43.10 
Error = 0.247 
R2 = -1.00 
 
Figure 3.5: Quantification of real-time Hybridization probe RT-PCR for the 
detection of EV71. The standard curve was obtained by plotting the Ct values against the 
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Table 3.1: Detection of EV71 directly from clinical specimens by the real time 






























002 Serum + - + 
 
003 Serum + - + 
 
004 CSF + - + 
 
005 Urine + - + 
 
006 Urine + - + 
 
007 Serum + - + 
 
008 RD-CSF + - + 
 
009 RD-CSF + - + 
 
010 Stool + - + 
 
011 RD-CSF + - + 
 
012 Stool + - + 
 
013 RD-CSF + - + 
 
014 RD-CSF + - + 
 
015 Stool + - + 
 
016 CSF + - + 
 
017 RD-CSF - - - 
 
018 RD-CSF + - + 
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019 RD-CSF + - + 
 
020 RD-CSF - - - 
 
021 RD-CSF + - + 
 
022 RD-CSF + - + 
 
023 Stool + - + 
 
024 Stool + - + 
 
025 Stool + - + 
 
026 Stool + - + 
 
027 Stool + - + 
 
028 Stool - - - 
 
029 Urine + - + 
 
030 Throat swab + - + 
 
031 Stool + - + 
 
032 RD-CSF + - + 
 
033 Rectal swab + - + 
 
034 RD-CSF + - + 
 
035 Serum + - + 
 
036 Urine + - + 
 
037 RD-CSF + - + 
 
038 CSF + - + 
 
039 Stool + - + 
 
040 RD-CSF + - + 
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041 Stool + - + 
 
042 Throat swab + - + 
 
043 Stool + - + 
 
044 Stool + - + 
 
045 Ulcer swab + - + 
 
046 Stool + - + 
 
047 RD-CSF + - + 
 
048 Stool - - - 
 
049 Ulcer swab + - + 
 
050 RD-CSF - - - 
 
051 RD-CSF - - - 
 
052 RD-CSF - - - 
 
053 RD-CSF - - - 
 








+ - Specimens tested positive for the presence of EV71  
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Table 3.2: Detection of EV71 from tissue cultures and clinical specimens by real 
time Hybridization probe RT-PCR 
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3.2.3 Development of real-time TaqMan RT-PCR 
3.2.3.1  Specificity of real-time TaqMan RT-PCR 
The specificity of the real-time TaqMan RT-PCR developed in this study to detect 
EV71 was determined by testing the three EV71 strains and several other enteroviruses. 
The results showed that the RNA templates of strains 41 (genogoup B4), 10 (genogroup 
B4) and 7423/MS/87 (genogroup B2) were amplified by the real-time TaqMan RT-PCR 
with Ct values of 20, 22 and 18, respectively. No amplification was observed for the 
other enteroviruses (Figure 3.6). The 204bp amplicons from the three EV71 strains 
generated by real-time RT-PCR assays were sequenced and correlates well with the VP1 
region of EV71 (98% to 100% homology).  
 
The specificity of the real-time TaqMan RT-PCR assay was also evaluated 
against three EV71 Japansese strains classified under other genogroups, including strains 
1585-Yamagata-01 (genogroup C2), 75-Yamagata-03 (genogroup C4) and 2933-
Yamagata-03 (genogroup B5). The results showed that the real-time TaqMan RT-PCR 
developed in this study was able to detect all the three EV71 strains classified under 
different genogroups (Figure 3.7). 
 
3.2.3.2  Quantitative analysis of real-time TaqMan RT-PCR  
The analytical sensitivity of the developed real-time TaqMan RT-PCR was 
assessed in 2 independent experiments using the serially-diluted EV71 RNA which were  
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Figure 3.6: Detection of EV71 based on amplification of the VP1 region by real-time 
TaqMan RT-PCR. Different EV71 strains (strains 41, 10 and 7423/MS/87) were 
evaluated against other enterovirus serotypes including CA16, CA24, CB1 to CB5, Echo 
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Figure 3.7: Detection of EV71 strains belonging to other genogroups. The real-time 
TaqMan RT-PCR was evaluated against other EV71 strains from other genogroups, 
namely strains 1585- Yamagata-01 (genogroup C2), 75-Yamagata-03 (genogroup C4) 
and 2933-Yamagata-03 (genogroup B5). Strain 41 was used as a positive control. The 
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in vitro transcribed from the recombinant pGEM-T plasmid containing the 204bp VP1 
sequence. The standard plot was calculated by regression analysis of the Ct values versus 
log10 of the standard viral copy number. The detection limit of the real-time TaqMan RT-
PCR assay was 5 EV71 viral copies. Statistical analysis of the standard curves showed 
that there was a good correlation coefficient (R2=1.000) between the Ct value and copy 
number, and the linearity was consistent for both experiments (P < 0.001) (Figure 3.8). 
 
3.2.3.3  Detection of EV71 directly from clinical specimens by real-time 
TaqMan RT-PCR 
 
The efficacy of the real-time TaqMan RT-PCR assay in detecting EV71 directly 
from clinical specimens was evaluated and compared with the tissue culture method. A 
total of 67 clinical specimens were collected from 40 pediatric patients admitted to 
National University Hospital with suspected HFMD during the period from March 2006 
to December 2006 and were analyzed for the presence of EV71. The results are presented 
in Tables 3.3 and 3.4. The real-time TaqMan RT-PCR was able to detect the presence of 
EV71 directly in 49 out of the 67 clinical specimens. In comparison, the tissue culture 
method failed to detect EV71 in any of the 67 clinical specimens. 
 
To verify that the positive clinical specimens did contain EV71, a conventional 
semi-nested RT-PCR amplification of the VP1 region of EV71 was carried out with the 
RNA extracted from all the 49 clinical specimens that were tested positive based on the 
real-time TaqMan RT- PCR. Amplification of the VP1 region was observed for all the 49 
clinical specimens by the semi-nested conventional RT-PCR, and DNA sequencing 
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showed that the 867bp PCR amplicon generated from each of the 49 clinical specimens 
correlated highly with the VP1 region of EV71 (96% to 98% sequence homology).  
 
No EV71 RNA was detected in 18 clinical specimens, and these were verified as 
true EV71-negative specimens by the conventional semi-nested RT-PCR designed to 
amplify the VP1 region of the EV71 genome. Another conventional RT-PCR was thus 
carried out on these 18 clinical specimens using specific primers targeting at the 5'UTR 
region as reported previously (Nijhuis et al., 2002). DNA sequence analysis showed that 
CA16 was present in 11 clinical specimens, 4 clinical specimens contained Echo 7 and 2 
clinical specimens were found to contain CB2. No amplification was observed for one of 
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y = -4.229x + 32.83 
Error = 0.266 
R2 = -1.00 
 
Figure 3.8: Quantitative analysis of real-time TaqMan RT-PCR for the detection of 
EV71. The standard curve was obtained by plotting the Ct values against the viral copy 
number. The coefficients (R2) and linear equations are as shown. The linearity was 
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Table 3.3: Comparative detection of EV71 in clinical specimens by real-time 



















targeted at the VP1 
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23 Throat Swab 
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27 Rectal swab 
 
- - - 
28 Rectal swab 
 





















+ - + 
32 Serum 
 
- - - 
33 Stools 
 
- - - 
34 Stools 
 
- - - 
35 Throat swab 
 
- - - 
36 Stools 
 
- - - 
37 Stools 
 
- - - 
38 Throat swab 
 
- - - 
39 Rectal swab 
 
- - - 
40 Urine 
 
- - - 
 
a Conventional semi-nested RT-PCR was carried out as described in section 2.1.7 
b Tested positive for the presence of EV71 
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Table 3.4: Direct detection of EV71 from clinical specimens by the real-time 
TaqMan RT-PCR in comparison with the cell culture method.  
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3.2.4 Development of multiplex real-time Hybridization probe RT-PCR to detect 
and differentiate EV71 from CA16 
 
3.2.4.1  Specificity of multiplex real-time Hybridization probe RT-PCR  
  The detection and differentiation of EV71 from CA16 using the multiplex real-
time Hybridization probe RT-PCR assay was analysed by evaluating EV71 strain 41, the 
prototype CA16-G-10 strain and other enterovirus serotypes such as CA24, CB1, CB2, 
CB3, Echo 6 and Echo 7. Specific amplification of EV71 strain 41 was observed at 
640nm (Figure 3.9a). Melting curve analysis of the EV71 PCR amplicon showed a Tm of 
71.5oC (Figure 3.9b). Specific detection of CA16 was at 705nm (Figure 3.9c), and the 
amplicon had a melting temperature (Tm) of 72.8oC (Figure 3.9d). Sequence analysis of 
the PCR amplicons generated from the multiplex real-time Hybridization probe RT-PCR 
assay showed high homologies to the respective EV71 or CA16 VP1 region (99% 
sequence homology). No amplification was observed for the other enteroviruses. Agarose 
gel electrophoretic analysis of the PCR products showed that the multiplex real-time 
Hybridization probe RT-PCR yielded the predicted 204bp and 287bp amplicons from 
EV71 and CA16, respectively (Figure 3.10). 
 
The specificity of the multiplex real-time Hybridization probe RT-PCR assay was 
then evaluated against three EV71 Japansese strains classified under other genogroups, 
including 1585-Yamagata-01 (genogroup C2), 75-Yamagata-03 (genogroup C4) and 




















Figure 3.9: Multiplex detection of EV71 and CA16 using different detection channels of the LightCycler. (a) Specific detection 
of EV71 was observed in the F2 channel which detects fluorescence emission at 640nm. (b) A Tm value of 71.5oC was observed for 
EV71 by the melting curve analysis. (c) Specific detection of CA16 was observed in the F3 channel which detects fluorescence 
emission at 705nm. (d) A Tm value of 72.8oC was observed for CA16 by the melting curve analysis. 
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Figure 3.10: Electrophoretic analysis of amplicons generated from the multiplex 
real-time PCR Hybridization probe assay. M – 100bp DNA molecular weight markers; 
Lane 1 – EV71 strain 41; Lane 2 – CA16; Lane 3 – CA24; Lane 4 – CB1; Lane 5 – CB2; 
Lane 6 – CB3; Lane 7 – CB4; Lane 8 – CB5; Lane 9 – Echo 4; Lane 10 – Echo 6; Lane 
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Hybridization probe RT-PCR developed in this study was able to detect all the three 
EV71 strains (Figure 3.11). 
 
The amplicons of the three EV71 strains generated from the multiplex real-time 
Hybridization probe RT-PCR were also analyzed by melting curve analysis. The Tm of 
strain 1585-Yamagata-01 was established to be 72.0oC and the Tm of the other two EV71 
strains (strains 2933-Yamagata-03 and 75-Yamagata-03) were 72.5oC (Figure 3.12). 
 
3.2.4.2 Quantitative analysis of the multiplex real-time Hybridization probe 
RT-PCR 
 
The analytical sensitivity of the real-time Hybridization probe-based RT-PCR 
developed was assessed using serially-diluted EV71 or CA16 in vitro transcribed RNA in 
2 independent experiments. The standard plot was calculated by regression analysis of 
the Ct values versus log10 of the standard viral copy number. Consistent with the data 
obtained in section 3.2.2.2, the detection limit for EV71 was 5 viral copies (Figure 3.13a). 
The same detection limit (5 viral copies) was also observed for quantitative analysis of 
CA16. Statistical analysis of the standard curve for CA16 showed that there was a good 
correlation coefficient (R2=0.98) between the Ct value and copy number, and the linearity 
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Figure 3.11: Detection of EV71 strains belonging to other genogroups. The multiplex 
real-time Hybridization probe RT-PCR was evaluated against EV71 strains from other 
genogroups, namely 1585- Yamagata-01 (genogroup C2), 75-Yamagata-03 (genogroup 
C4) and 2933-Yamagata-03 (genogroup B5). Strain 41 was used as a positive control. 
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Figure 3.12: Hybridization probe-based melting curve analysis of the amplicons 
generated from three different EV71 viral isolates. Strain 41 was used as a positive 
control and had a Tm value of 71.5oC. The Tm value of 1585-Yamagata-01 was 
established to be 72.0oC whilst the Tm values of both strains 2933-Yamagata-03 and 75-
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y = -3.483x + 44.79 
Error = 0.249 





y = -3.449x + 43.83 
Error = 0.276 
R2 = -0.98 
y = -3.449x + 43.83 
Er or = 0.276 
















Figure 3.13: Quantitative analysis of multiplex real-time Hybridization probe RT-
PCR. The standard curve was obtained by plotting the Ct values against the copy 
number. The coefficients (R2) and linear equations are as shown. (a) Standard curve for 
the detection of EV71 in channel F2 of the LightCycler. (b) Standard curve for the 
detection of CA16 in channel F3 of the LightCycler. The linearity was consistent in two 
independent experiments (P < 0.001) 
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3.2.4.3 Detection of EV71 or CA16 directly from clinical specimens by the 
multiplex real-time Hybridization probe RT-PCR 
   
The efficacy of the developed multiplex real-time RT-PCR in detecting EV71 or 
CA16 directly from clinical specimens was evaluated using the 67 clinical specimens 
which were analyzed in section 3.2.3.3. The multiplex real-time Hybridization probe-
based RT-PCR detected the presence of EV71 in 48 clinical specimens and CA16 in 11 
clinical specimens. One clinical specimen was found to contain both EV71 and CA16. 
No amplicon specific for either EV71 or CA16 was observed in the remaining 7 clinical 
specimens (Tables 3.5 and 3.6). To verify that the positive clinical specimens did contain 
EV71 or CA16, a conventional RT-PCR was carried out with all the 60 clinical 
specimens using specific primers targeting at the 5'UTR region (Nijhuis et al., 2002). 
Amplification of the 5'UTR region was observed for all the 60 clinical specimens which 
were tested positive for EV71 or CA16 by the multiplex real-time RT-PCR. The DNA 
sequence analysis showed that the PCR amplicons correlated highly with the 5'UTR 
region of EV71 or CA16 (96% to 99% sequence homology). The conventional RT-PCR 
was also carried out with the 7 clinical specimens which were tested negative for EV71 
or CA16. DNA sequence analysis of the 5'UTR region showed that 4 clinical specimens 
contained Echo 7 and 2 clinical specimens were found to contain Coxsackievirus B2 
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Table 3.5: Detection of EV71 or CA16 directly from clinical specimens by the 
multiplex real-time Hybridization probe RT-PCR and the cell culture method.  
 
 














































+ - EV71 
5 Urine 
 












+ - EV71 
8 Serum 
 
+ - EV71 









10 Throat Swab 
 










12 Rectal swab 
 
+ - EV71 
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23 Throat Swab 
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27 Rectal swab 
 
- + CA16 
28 Rectal swab 
 

























- + CA16 
33 Stools 
 
- + CA16 
34 Stools 
 
- + CA16 
35 Throat swab 
 
- + CA16 
36 Stools 
 




- + CA16 
38 Throat swab 
 
- + CA16 
39 Rectal swab 
 




- + CA16 
 
a – Conventional RT-PCR was carried out using primers targeted at the 5′UTR region as 
described by Nijhuis et al. (2002). 
b – Conventional semi-nested RT-PCR targeted at the VP1 region of EV71 was carried 
out. The 867bp amplicons were sequenced and analysed to confirm the presence of 
EV71. Conventional RT-PCR was carried out using primers targeted at the 5′UTR 
region as described by Nijhuis et al. (2002). The amplicons were sequenced and 
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Table 3.6: Direct detection of EV71 or CA16 from clinical specimens by the 
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3.3  Discussion 
In February 2006, EV71 re-emerged as the main causative agent in two HFMD 
outbreaks in Sarawak, Malaysia as well as in Singapore. In Sarawak, more than 8000 
cases were reported. There were 13 fatalities and EV71 was isolated from more than half 
of the infected patients (Ministry of Health, Malaysia). In Singapore, more than 3000 
HFMD cases were reported and 75% of the pediatric patients were infected with EV71 
(Ministry of Health, Singapore). At present, there is no antiviral for treatment or vaccine 
for prevention of EV71 infections, and most cases of HFMD are managed with 
symptomatic treatment (personal communication). It has been reported by clinicians that 
most deaths from HFMD caused by EV71 occurred within 24 hours when the children 
were admitted with complications associated with HFMD (Ho et al., 1999; Wang et al., 
2006). Thus, rapid and specific diagnosis of EV71 from clinical specimens will enable 
clinicians to identify those who require closer monitoring, or even hospitalisation before 
deterioration of clinical conditions.  
 
An earlier study showed that enteroviruses could be differentiated from other 
viruses like HSV-1, HSV-2 and Varicella-Zoster virus based on real-time PCR SYBR 
Green-based melting curve analysis (Read et al., 2001).  The differentiation of poliovirus 
from non-poliovirus was possible through the melting curve analysis, since they produced 
markedly different Tm values. However, the SYBR Green I-based analysis could be 
rather non-specific as fluorescence could be emitted from the fluorophore when it was in 
association with any double-stranded DNA, including primer-dimers. In addition, the 
approach employed a conventional nested PCR which was coupled to a real-time PCR. 
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By using a nested multiplex PCR reaction of RNA extracted from using tissue culture 
isolates of different enterovirus serotypes, Read et al. (2001) found that a specific Tm 
value was observed for each serotype. The Tm values were found to vary by only a very 
small range (between 0.12oC to 1.37oC). This approach was time consuming, requiring at 
least 8 to 9 hours and was also labour-intensive. In addition, the use of a nested PCR 
reaction also increases the chances of false positives as a result of possible cross-
contaminations between specimens due to the additional processing steps. 
 
In another study, a TaqMan probe real-time PCR assay was developed using the 
ABI Prism 7700 Sequence Detection System (Applied Biosystems, California, USA) to 
differentiate 60 different enteroviruses from viruses belonging to other genera under the 
Picornaviridae family (Nijhuis et al., 2002). However, the ABI Prism 7700 Sequence 
Detection System required at least 2½ hours to generate results, and the whole procedure 
of processing and detection required about 4 to 5 hours. This is not rapid enough for 
outbreak situations. Direct detection of enteroviruses from cerebrospinal fluid (CSF) 
specimens by real-time TaqMan RT-PCR assay was developed by Watkins-Riedel et al. 
(2002) and Petitjean et al. (2006) using the LightCycler real-time detection system 
(Roche Molecular Biochemicals, Germany) and the ABI Prism 7700 PCR instrument 
(USA) and both studies showed high sensitivies in detecting enteroviruses from CSF 
specimens which were often characterized by low viral titres. 
 
However, in all the above studies, the primers and probes were designed based on 
the 5'-untranslated region (5'UTR) of the enteroviral genome which is highly conserved 
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among the enteroviruses. Molecular epidemiological studies have shown that the 
diversity in this region did not correlate well with enterovirus serotypes (Oberste et al., 
1999). Thus, in these studies, different enterovirus serotypes could not be differentiated 
effectively from one another without DNA sequencing.  
 
In this study, real-time RT-PCR based on the Hybridization probe and TaqMan 
probe chemistries were developed to detect EV71 specifically from clinical specimens. 
High efficacies of a multiplex real-time Hybridization probe-based RT-PCR to detect 
EV71 or CA16 directly from clinical specimens were also demonstrated. The primers and 
probes were designed based on the VP1 region of either the EV71 or the CA16 genome 
as VP1 possesses a high degree of antigenic and genetic diversity that can be used to 
distinguish enterovirus serotypes (Oberste et al., 1999). Several studies have indicated 
that this region correlated more accurately with enterovirus serotypes when compared to 
the 5′UTR (Oberste et al., 1999; Brown et al., 2000). No amplification was observed for 
the other enterovirus serotypes, and both the EV71 and CA16 amplicons generated were 
verified by DNA sequence analysis. Thus, all the three real-time RT-PCR assays were 
shown to exhibit high specificity in detecting EV71 or CA16. The entire procedure for 
the real-time RT-PCR required only 1 to 2 hours upon receiving the clinical specimens, 
and no post-PCR handling such as agarose gel electrophoresis was required. This 
approach for the detection of EV71 or CA16 was more rapid than the tissue culture 
method which requires 2 to 3 weeks and the conventional semi-nested RT-PCR method 
which requires 1 to 2 days (Singh et al., 2002). The real-time RT-PCR assays developed 
in this study were shown to be highly sensitive in detecting EV71 or CA16 as  
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quantitative analysis showed that all the three real-time RT-PCR assays were able to 
detect as low as 5 EV71 or CA16 viral copies.  
 
EV71 strains are classified into three major genogroups based on phylogenetic 
analysis of the VP1 and VP4 regions (Brown et al., 1999; McMinn et al., 2001; Cardosa 
et al., 2003; Mizuta et al., 2005). The prototype strain, BrCr strain, is the sole member of 
genogroup A, while the rest of the EV71 strains are classified under either genogroup B 
or genogroup C. The annual rate of evolution with genogroup B and C was found to be 
1.35 X 10-2 substitutions per nucleotide, indicating the high genetic diversity and the 
rapidly evolving nature of EV71 (Brown et al., 1999). Thus, it is important to design 
primers and probes for real-time RT-PCR assays from highly conserved regions so as to 
detect heterologous EV71 strains which can be genetically diverse from one another. In 
this study, the primers and probes were designed to target the VP1 region which encodes 
the structural proteins. Our results demonstrated the versatility of the primers designed 
for the developed real-time RT-PCR assays to detect EV71 strains belonging to other 
genogroups. This was evident from the results which showed that other than strains 41, 
10 (both classified under genogroup B4) and 7423/MS/87 (genogroup B2),  the real-time 
RT-PCR assays developed in this study were also able to detect EV71 strains belonging 
to genogroups C2, C4 and B5 isolated from other regions in the Asia Pacific.  
 
3.2.1 Detection of EV71 or CA16 directly from clinical specimens 
In the present study, clinical specimens such as rectal swabs, throat swabs, urine 
and saliva were collected by non-invasive means. Only those patients whose blood was 
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taken for other clinical investigations had their blood or CSF collected for EV71 
detection. This is important as it will not cause discomfort to the pediatric patients as 
clinical specimens (other than blood and CSF) could be collected easily, especially in 
large outbreak situations. It was also shown that the tissue culture method failed to detect 
EV71 in all the clinical specimens examined. This supported previous observations by 
Singh et al. (2002) of the lack of sensitivity in detecting EV71 directly from clinical 
specimens using the cell culture method. This is due to the fact that clinical specimens 
such as CSF and saliva are often characterized by low viral load and might be diagnosed 
as false negatives for EV71 by the tissue culture method (Singh et al., 2002).  
 
In this study, all the three real-time RT-PCR assays achieved high sensitivities in 
detecting EV71 or CA16 directly from clinical specimens. This supported the recent 
findings by Ooi et al. (2007), who also demonstrated the high success rate of isolating 
EV71 from clinical specimens collected by non-invasive means. No EV71 or CA16 was 
detected in one clinical specimen by the real-time TaqMan RT-PCR and the multiplex 
real-time Hybridization probe RT-PCR assays. Possible reasons could be either due to 
very low initial virus titre or it could contain other enterovirus serotypes. However, no 
amplification was observed for this clinical specimen when conventional RT-PCR was 
carried out with specific primers targeting the 5′UTR region. Therefore, it is very likely 
that the viral titre of this clinical specimen was either too low to be detected by the 
multiplex real-time Hybridization probe RT-PCR and the conventional RT-PCR, or there 
was no virus present and it is truly a negative specimen.  
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3.2.2 Comparison between the Hybridization probe and the TaqMan probe-based 
chemistries 
 
In this study, equal specificity and sensitivity were shown by both Hybridization 
probe and TaqMan probed-based chemistries in detecting EV71 directly from clinical 
specimens. In comparison between the two chemistries, the availability of the melting 
curve analysis for the Hybridization probe-based assay provided an additional advantage 
over the TaqMan probe-based assay. Since the two hybridization probes were not 
hydrolysed during amplification, the LightCycler was able to monitor the fluorescence 
changes during the denaturation of the two probes from their templates. Thus, this 
allowed fluorescent melting curves to be generated. The differences in the Tm were due 
to slight changes in their nucleotide sequences, as any mutation(s) in the viral templates 
could result in a decrease in Tm due to the destabilization of the probe/target duplex 
(Wittwer et al., 2001; MacKay et al., 2003; Espy et al., 2006). This is important 
especially in outbreak situations as a rapid Tm determination can provide significant 
information about the EV71 strain(s) involved. If there are several EV71 strains involved 
in an outbreak, the differences in the sequences between the different EV71 strains can be 
reflected by their respective Tm values. In cases where the outbreak is caused by both 
EV71 and/or CA16, the Tm values will enable the pediatricians to rapidly identify the 
virus involved. 
 
However, although the Hybridization probe-based chemistry provided an 
advantage of melting curve analysis, the assay could only be applied using the 
LightCycler real-time PCR machine. On the other hand, since 6-FAM is a widely used 
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reporter for the TaqMan probe chemistry, the real-time TaqMan RT-PCR developed in 
this study is more versatile and can be adapted for use in other real-time PCR systems.  
 
In conclusion, the three real-time RT-PCR developed in this study provided a vast 
improvement to current diagnostic methods for the direct detection of EV71 from clinical 
specimens. The real-time RT-PCR assays offered a more rapid, specific and sensitive 
approach of detecting EV71 or CA16 directly from clinical specimens within 1 to 2 hours 
upon receiving them. Since the clinical symptoms of HFMD caused by EV71 and CA16 
are indistinguishable from each other, rapid diagnosis to differentiate EV71 from CA16 
in outbreak situations will enable pediatricians to identify and manage the patients more 
effectively. 
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CHAPTER 4 
RNA interference (RNAi) against EV71 in the in vitro system 
 
4.1 Introduction 
The significant mortalities in recent HFMD outbreaks in the Asia Pacific region 
have raised public concerns about the virulence of EV71 (Ho et al., 1999). Although a 
number of antiviral agents with activities against enteroviruses have been developed, 
none has come close to commercialization. One of the “WIN” compounds, pleconaril was 
found to have significant therapeutic effects against enteroviral infections, but was shown 
to have limited effectiveness against EV71 (Robart et al., 1998; Pevear et al., 1999; 
McMinn, 2002). Thus, there is a need to develop a specific antiviral therapy against 
EV71. 
 
Since its first discovery in Caenorhabditis elegans (Fire et al., 1998), RNA 
interference (RNAi) has emerged as a promising approach to be developed as potential 
therapeutic strategy against infectious diseases. It is an evolutionarily conserved, 
sequence-specific, post-transcriptional gene silencing phenomenon. It is a multi-step 
intracellular pathway triggered by the processing of double stranded RNAs by the RNase 
III-like enzyme (known as Dicer) into short (19 to 21 nucleotides) RNA duplexes known 
as small interfering RNAs (siRNAs) (Fire et al., 1998; Elbashir et al., 2001). These 
effector siRNAs contain a symmetric 2 nt overhang at the 3′end. The effector siRNAs are 
incorporated into a nuclease-containing multiprotein complex, the RNA-induced 
silencing complexs (RISC) (Hammond et al., 2000). Through unwinding of the siRNA 
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duplex by an ATP-dependent RNA helicase activity, one of the RNA strands (the 
antisense or template strand) remains bound to the RISC complex. The template strand 
then acts as a guiding sequence and directs the RISC complex to its target RNA. Upon 
the complementary binding of the siRNA to the target mRNA, the RISC complex 
catalyses the endonucleolytical cleavage of the target mRNA strand within the target site, 
resulting in the rapid degradation of the mRNA molecule and preventing its translation 
into functional proteins (Liu et al., 2004; Martinez and Tuschl, 2004; Song et al., 2004). 
 
The advantages of RNAi over other therapeutic modalities include its high 
specificity, high versatility in targeting virtually any gene, and high efficiency (over 90% 
silencing effects) (Charles et al., 2006). The high efficiency and specificity makes RNAi 
highly attractive to be developed as potential anti-viral therapies. RNAi has been shown 
to be effective against EV71 in two previous in vitro studies. Lu et al. (2004) reported a 
plasmid-derived shRNA which targeted the VP1 and 3Dpol regions of the EV71 genome, 
and were able to inhibit EV71 replication in both HeLa and Vero cell lines. In a separate 
study, chemically synthesized 19-mer siRNAs targeted at the 2C, 3C, 3Dpol and 3′UTR 
regions of the EV71 genome have also shown significant inhibition of EV71 replication 
in the RD cell line. Both studies showed that siRNAs targeting the RNA-dependent RNA 
polymerase, 3Dpol, were the most effective in inhibiting EV71 replication (Lu et al., 
2004; Sim et al., 2005).  
 
Majority of the studies which use RNAi strategies involve the use of 21 
nucleotides which contain the 19-mer core sequences and 2d-TT at the 3′ ends. However, 
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it has been shown that 29-mer short hairpin RNA (shRNAs) have enhanced potency and 
are more efficient than 19-mer siRNAs in silencing genes without inducing any interferon 
response (Siolas et al., 2005). Therefore, the use of 29-mer shRNAs may prove to be 
even more efficient as potential therapeutic agents against EV71 in comparison to the two 
different forms of 19-mer siRNAs reported previously (Lu et al., 2004; Sim et al., 2005). 
 
In this study, two different siRNAs systems, namely the psiStrike shRNA 
expression system and the chemically synthesized 29-mer shRNAs were developed. Both 
the siRNA systems were designed to target specifically at the 2C, 3Cpro, and 3Dpol genes 
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4.2 Results 
 
4.2.1 Efficacy of the psiStrike plasmids expressing shRNAs in inhibiting EV71 
4.2.1.1 Transfection efficiencies of the psiStrike plasmids expressing shRNAs 
 
Oligonucleotides which contained short hairpin RNAs (shRNAs) targeting the 2C, 
3Cpro, and 3Dpol genes of the EV71 genome (designated as psi-2C, psi-3C and psi-3D, 
respectively) and an oligonucleotide bearing scrambled shRNA sequence (psi-scr) were 
successfully cloned into the psiStrike plasmid vectors and were verified by DNA 
sequencing. Lipofectamine 2000CD (Invitrogen, Carlsbad, CA) was used as the 
transfection agent to deliver the recombinant plasmids into the RD cells. The transfection 
efficiencies of the psiStrike recombinant plasmids into the RD cells were evaluated based 
on the GFP expression from the psiStrike recombinant plasmids. Relatively high 
transfection efficiencies were observed in the RD cells transfected with each of the four 
psiStrike recombinant plasmids (Figure 4.1). Further quantitative analysis of the uptake 
of the recombinant plasmids by flow cytometry showed an average of 71% transfection 
efficiency when the RD cells were transfected with 0.8ug of either psi-2C, psi-3C, psi-3D 
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Figure 4.1: Transfection efficiency of the psiStrike plasmids expressing shRNAs 
targeted at the 3Dpol gene of the EV71 genome (psi-3D) under 40X magnification. 
Successful transfections of the psiStrike plasmids expressing shRNAs were shown by the 
expression of GFP which fluoresce under the fluorescent microscope. Similar results 
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Figure 4.2: Flow cytometric analysis of GFP expression by the psiStrike plasmids 
expressing shRNAs targeting the 2C (psi-2C), 3Cpro (psi-3C), 3Dpol (psi-3D) genes of 
EV71 genome. The transfection efficiencies (%) of (a) psi-2C, (b) psi-3C and (c) psi-3D 
were compared to the untreated RD cells (coloured region). (d) The psiStrike plasmid 
expressing scrambled shRNAs (psi-scr) was used as control. The results represent the 
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4.2.1.2 Protection of RD cells from EV71-induced CPE by the psiStrike 
plasmids expressing shRNAs 
 
The efficacies of the psiStrike plasmids expressing shRNAs in inhibiting EV71 
replication were first evaluated by transfecting the RD cells with 0.8ug of either psi-2C, 
psi-3C or psi-3D. At 48h post-transfection, the RD cells were infected with 60 pfu of 
EV71. There was significant inhibition of EV71-induced CPE when the RD cells were 
treated with 0.8ug of psi-2C, psi-3C or psi-3D, and the inhibitory effects was observed to 
last up to 48h post infection (hpi) (Figure 4.3). This showed that the psiStrike plasmids 
expressing shRNAs targeted at the 2C, 3Cpro and 3Dpol genes of the EV71 genome were 
able to inhibit EV71-induced CPE in RD cells. 
 
To ascertain that there is no cytotoxicity induced by the psiStrike plasmids 
expressing shRNAs, the MTS assay which measured the viability of cells was carried out. 
The assay was performed at 48 h post-transfection and it was observed that all the four 
psiStrike plasmids (psi-2C, psi-3C, psi-3D and psi-scr) did not cause any cytotoxic 
effects on the growth and viability of the RD cells (Figure 4.4). 
 
4.2.1.3 Inhibition of EV71 replication by the psiStrike plasmids expressing 
shRNAs 
 
The inhibitory effects of the psiStrike plasmids expressing shRNAs on EV71 
replication were determined by transfecting the RD cells with 0.8ug of either psi-2C, psi-
3C or psi-3D for 48 hours, followed by infection with 60 pfu of EV71. The inhibitory 
efficacies of each of the three psiStrike plasmids on EV71 replication were analyzed 
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(a)           (b) 
 
(c) 
Figure 4.3: Inhibition of EV71-induced CPE by the psiStrike plasmids expressing 
shRNAs. The morphological changes of the RD cells were observed at 48hpi under the 
light microscope at 40X magnification. (a) Uninfected RD cells. (b) Untreated infected 
RD cells. (c) EV71-infected RD cells treated with 0.8ug of the psiStrike plasmids 
expressing shRNAs targeted at the 3Dpol region of EV71 genome (psi-3D). Similar 
observations were obtained when the RD cells were treated with 0.8ug of psi-2C or psi-
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Figure 4.4: Viability of RD cells was determined by the MTS assay after transfection 
with 0.8ug of psiStrike plasmids expressing shRNAs targeted at the 2C (psi-2C), 
3Cpro (psi-3C) and 3Dpol (psi-3D) genes of the EV71 genome. Absorbance values were 
obtained by measuring at 490nM. The data represent the mean ±SD from two 
independent experiments, as indicated by error bars. The psiStrike plasmids expressing 
shRNAs with scrambled sequence (psi-scr) and untransfected (-) RD cells were used as 
controls. The ANOVA analysis for comparison between the psiStrike plasmids and the 
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by real-time Hybridization probe RT-PCR, plaque assay and Western blots, respectively. 
Compared to untreated RD cells which were infected with EV71, a 1.8 log unit reduction 
in viral RNA transcripts was observed when the RD cells were treated with 0.8ug of psi-
3D. The RD cells treated with 0.8ug of psi-2C or psi-3C showed a 1.3 log unit decrease 
in viral RNA transcripts (Figures 4.5).  
 
To corroborate with the significant decrease in the EV71 viral RNA transcripts, 
the infectious titre of EV71 in the RD cells transfected with psi-2C, psi-3C or psi-3D was 
determined by plaque assay. Our results indicated that a reduction of 86% in EV71 viral 
titre was observed when the RD cells were transfected with 0.8ug of psi-2C or psi-3C. 
When the RD cells were transfected with 0.8ug of psi-3D, there was a reduction of 87% 
in the EV71 viral titre (Figure 4.6).  
 
Western blots were carried out to analyse the VP1 viral protein levels in the RD 
cells treated with 0.8ug of psi-2C, psi-3C or psi-3D. A significant decrease in the VP1 
viral proteins was observed when the infected RD cells were treated with 0.8ug of psi-2C, 
psi-3C or psi-3D (Figure 4.7). There was no decrease in the viral RNA transcripts, viral 
titre or VP1 protein levels in the RD cells treated with the psiStrike plasmids producing 
shRNAs with scrambled sequence (psi-scr). 
 
Based on the results, the psiStrike plasmids expressing shRNAs targeted at the 
specific sequences of the 2C, 3Cpro and 3Dpol of EV71 were effective in inhibiting 
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 EV71 Standard 10.86  5 X 109 - 
 
Figure 4.5: Decrease in EV71 viral RNA transcripts after treatment with the 
psiStrike plasmids expressing shRNAs targeted at the 2C (psi-2C), 3Cpro (psi-3C) 
and 3Dpol (psi-3D) genes of the EV71 genome as shown by real-time RT-PCR. The 
infected-RD cells treated with 0.8ug of psiStrike plasmids expressing scrambled shRNAs 
(scr) RD cells were used as controls. The negative control contains all the reagents 
without any RNA template. The Ct values and the viral copies represented the mean Ct 
and mean viral copies from two independent experiments, respectively. 
 
 
 Scrambled (psi-scr) 10.96 4.86 X 109 - 
 psi-2C 14.81  2.18  X 108 1.35 
 psi-3C 14.85  2.18  X 108 1.35 
 psi-3D 15.74  6.54  X 107 1.88 
 Negative - - - 
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Figure 4.6: Inhibition of EV71 replication with the psiStrike plasmids expressing 
shRNAs targeted at the 2C (psi-2C), 3Cpro (psi-3C) and 3Dpol (psi-3D) genes of the 
EV71 genome. The RD cells were transfected with 0.8ug of psi-2C, psi-3C or psi-3D, 
followed by infections with 60pfu of EV71. The RD cells treated with 0.8ug of psiStrike 
plasmid expressing scrambled shRNAs (psi-scr) and untransfected (-) RD cells were used 
as controls. The viral titres were determined by plaque assay. The data shown represent 
the mean ±SD from two independent experiments, as indicated by error bars.  The 
ANOVA analysis for comparison of the viral titres between the untransfected RD cells 
and the RD cells treated with each of the three psiStrike plasmids expressing shRNAs 
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Figure 4.7: Western blot analysis of the VP1 protein expression in infected-RD cells 
treated with the psiStrike plasmids expressing shRNAs targeted at the 2C (psi-2C), 
3Cpro (psi-3C) and 3Dpol (psi-3D) genes of the EV71 genome. Western blot analysis 
was performed using monoclonal antibodies against the VP1 structural proteins of EV71 
after the RD cells were transfected with 0.8ug of psi-2C, psi-3C or psi-3D. The RD cells 
treated with 0.8ug of psiStrike plasmids expressing scrambled shRNAs (psi-scr) and 
untransfected (-) RD cells were used as controls. ß-actin was included as an internal 
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EV71 replication in RD cells, and the psiStrike plasmids expressing shRNAs targeting 
the 3Dpol gene (psi-3D) of EV71 was found to exhibit the most potent effects in inhibiting 
EV71 replication in RD cells. 
 
 The efficacy of the psiStrike plasmids expressing shRNAs in inhibiting an on-
going EV71 infection was tested by infecting the RD cells with 60pfu of EV71 over a 
period of five hours. At every hourly interval, the RD cells were transfected with 0.8ug of 
psi-2C, psi-3C or psi-3D and CPE was monitored 48hpi. Significant CPE was observed 
in the untreated EV71-infected cells. In contrast, survival of the RD cells treated with psi-
2C, psi-3C or psi-3D was still evident 3 hours post-infection. Thus, administration of the 
psiStrike plasmids expressing shRNAs to RD cells after EV71 infection could still 
effectively inhibit viral replication. 
 
4.2.1.4 No activation of interferon pathway when RD cells were treated with 
the psiStrike recombinant plasmids expressing shRNAs 
 
There is a possibility that inhibition of viral replication is due to activation of 
protein kinase R (PKR) and induction of the interferon response. To rule out such 
possibility, Western blots using a specific monoclonal antibody directed against the 
endogenous PKR was performed. As a positive control for the induction of PKR, the RD 
cells were treated with human alpha interferon (Sigma, USA) as described previously 
(Kanda et al., 2004). The results showed that there was no increase in PKR expressions in 
the RD cells after they were transfected with psi-2C, psi-3C or psi-3D for 48 h. In 
contrast, α-IFN specifically stimulated the PKR expressions (Figure 4.8). It is well-
established that activation of the interferon response is characterized by the transient 
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autophosphorylation of PKR in the early stages of the initiation process (Khabar et al., 
2003).The expression of phopho-PKR in the transfected RD cells was then analysed by 
western blot using specific monoclonal antibody directed against phospho-PKR (Sigma, 
USA). Other than the positive control, no phospho-PKR expression was detected in the 
RD cells treated with psi-2C, psi-3C or psi-3D (Figure 4.8). These observations indicated 
that the psiStrike plasmids expressing shRNAs did not elicit interferon response and the 
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Figure 4.8: Western blot analysis of the levels of PKR or phospho-PKR protein 
levels in the RD cells. The RD cells treated with alpha-interferon (IFN) were used as a 
positive control. The RD cells treated with the psiStrike plasmids expressing scrambled 
shRNAs (psi-scr) and untransfected (-) RD cells were used as controls. Western blot 
analysis was performed using monoclonal antibodies against the PKR or phosphor-PKR. 
ß-actin was included as an internal control, using anti-ß-actin monoclonal antibodies. The 
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4.2.2 Efficacy of chemically synthesized 29-mer shRNAs in inhibiting EV71 in the 
in vitro system 
 
4.2.2.1  Transfection efficiencies of chemically synthesized 29-mer shRNAs 
The transfection efficiencies of the 29-mer shRNAs were first analysed by 
transfecting the RD cells with 10nM of the FITC-labelled 29-mer shRNAs targeting at 
2C (29mer-2C), 3Cpro (29mer-3C), 3Dpol (29mer-3D) genes of EV71 genome for 48 
hours. For comparison purpose, the chemically synthesized 19-mer siRNA targeted at the 
3Dpol gene (designated as 19mer-3D) of EV71 reported previously (Sim et al., 2005) was 
included as part of this study. Lipofectamine 2000CD (Invitrogen, Carlsbad, CA) was 
used as the transfection agent to deliver the chemically synthesized 19-mer siRNA and 
the 29-mer shRNAs into the RD cells and the transfection efficiencies were evaluated 
based on the green fluorescence emitted by FITC. Relatively high transfection 
efficiencies were observed in the RD cells transfected with each of the three chemically 
synthesized 29-mer shRNAs or the 19-mer siRNA (19mer-3D) (Figure 4.9). Further 
quantitative analysis of the uptake by flow cytometry showed an average of 72.5% 
transfection efficiency when the RD cells were transfected with 10nM of either 19mer-
3D, 29mer-2C, 29mer-3C, 29mer-3D or 29mer-scr (Figure 4.10). 
 
4.2.2.2  Protection of RD cells from EV71-induced CPE by 29-mer shRNAs 
The efficacies of the chemically synthesized 29-mer shRNAs in inhibiting EV71 
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Figure 4.9: High transfection efficiency of chemically synthesized 29-mer shRNAs 
targeted the 3Dpol gene (29mer-3D) of EV71 genome. The 29-mer shRNAs were 
labelled with FITC at the 3′ end which emits green fluorescence under fluorescent 
microscopy. The figure showed two identical fields under bright field and fluorescent 
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Figure 4.10: Flow cytometric analysis of FITC fluorescence by the chemically 
synthesized 29-mer shRNAs targeting the 2C (29mer-2C), 3Cpro (29mer-3C), 3Dpol 
(29mer-3D) genes of EV71 genome. The transfection efficiencies (%) of (a) 29mer-2C, 
(b) 29mer-3C and (c) 29mer-3D and (d) 19-mer siRNA (19mer-3D) were compared to 
the untreated RD cells (coloured region). (e) The chemically synthesized 29-mer 
scrambled shRNA (29mer-scr) was used as a control. The results represent the mean 
percentages from two independent experiments. 
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29mer-3C, 29mer-3D or 29mer-scr at a final concentration of 1nM and 10nM. At 48 h 
post-transfection, the RD cells were infected with 60pfu of EV71. Significant inhibition 
of EV71-induced CPE was observed with as low as 1nM of 29mer-2C, 29mer-3C or 
29mer-3D (Figure 4.11). This is in sharp contrast to the RD cells treated with the 
scrambled shRNA (29mer-scr) which showed 100% CPE. No significant CPE was 
observed in RD cells transfected with 10nM of 29mer-2C, 29mer-3C or 29mer-3D 
(Figure 4.11). The inhibition of EV71-induced CPE was observed to last by up to 72 hpi, 
indicating that the chemically synthesized 29-mer shRNAs targeted the 2C, 3Cpro and 
3Dpol genes of EV71 genome were able to inhibit EV71-induced CPE in RD cells. 
 
To ascertain that there is no cytotoxicity induced by the various chemically 
synthesized 29-mer shRNAs, the MTS assay which measured the viability of cells was 
carried out. The assay was performed at 48 h post-transfection and it was observed that 
all the synthetic 29-mer shRNAs and 19-mer siRNA did not cause any cytotoxic effects 
on the growth and viability of the RD cells (Figure 4.12). 
 
4.2.2.3  Inhibition of EV71 replication by 29-mer shRNAs 
The inhibitory effects of the chemically synthesized 29-mer shRNAs on EV71 
replication were determined by transfecting the RD cells with graded concentrations of 
each of the three 29-mer shRNAs (1nM, 5nM and 10nM), followed by infections with 60 
pfu of EV71. The inhibitory effects of each of the 29-mer shRNAs on EV71 replication 
were analyzed by real-time Hybridization probe RT-PCR, plaque assay and Western 
blots, respectively.  
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Figure 4.11: Inhibition of EV71-induced CPE by 29-mer shRNAs. The morphological 
changes of the RD cells were observed at 72hpi under the light microscope at 40X 
magnification. (a) Uninfected RD cells. (b) Uninfected RD cells transfected with 10nM 
of 29mer-3D. (c) Infected RD cells in the absence of 29mer-3D. (d) EV71-infected RD 
cells treated with 1nM of 29mer-3D. (e) EV71-infected RD cells treated with 10nM of 
29mer-3D. (f) RD cells treated with 10nM of scrambled 29-mer shRNA (29mer-scr). 
Similar results were observed when the RD cells were treated with 29mer-2C and 29mer-
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Figure 4.12: Viability of RD cells was determined by MTS assay after transfection 
with 10nM of 29-mer shRNAs targeted at the 2C (29mer-2C), 3Cpro (29mer-3C) and 
3Dpol (29mer-3D) genes of the EV71 genome. Absorbance values were obtained by 
measuring at 490nM. The data shown represent the mean ±SD from two independent 
experiments, as indicated by error bars. The 29-mer scrambled shRNAs (29mer-scr) and 
the untransfected (-) RD cells were used as controls. The ANOVA analysis for 
comparison between the chemically synthesized 29-mer shRNAs and the untransfected 
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Compared to untreated RD cells which were infected with EV71, a 2.5 log unit 
reduction in viral RNA transcripts was observed when the RD cells were treated with 
10nM of 29mer-3D (Figure 4.13a). This is in contrast to only 0.8 log unit decrease in the 
EV71 viral transcripts when the infected RD cells were treated with the 19-mer siRNAs 
(19mer-3D) (Figure 4.13b). The RD cells treated with 10nM of 29mer-2C and 29mer-3C 
showed a 1.5 log unit decrease in viral RNA transcripts (Figures 4.13c and 4.13d). 
 
To corroborate with the significant decrease in the EV71 viral RNA transcripts, 
the infectious titre of EV71 in the RD cells transfected with 29-mer shRNAs was 
determined by plaque assay. Transfection of RD cells with 29mer-2C resulted in 
inhibition of EV71 viral titre by 52%, 73% and 87% when the concentrations of 29mer-
2C were increased from 1nM to 10nM. Similar dosage dependency effects were observed 
when the RD cells were treated with 1nM, 5nM and 10nM of 29mer-3C (60%, 77% and 
89%) and 29mer-3D (64%, 81% and 91%). In contrast, when the RD cells were treated 
with the 1nM, 5nM and 10nM of 19mer-3D, the efficiency of EV71 inhibition was found 
to be only 60%, 66% and 71%, respectively (Figure 4.14). 
 
Western blots were carried out to analyse the VP1 viral protein levels in the RD 
cells treated with graded concentrations of 29mer-2C, 29mer-3C, 29mer-3D or 19mer-
3D. The results showed that when the concentration of each of the 29-mer shRNAs was 
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Figure 4.13: Dose dependent reduction of EV71 viral RNA as shown by real-time Hybridization probe RT-PCR. (a) The RD 
cells treated with 1nM, 5nM and 10nM of 29-mer shRNAs targeted at the 3Dpol (29mer-3D) gene of the EV71 genome. (b) RD cells 
treated with 1nM, 5nM and 10nM of 19-mer siRNAs (19mer-3D). The RD cells treated with 10nM of scrambled shRNAs (29mer-scr) 
were used as controls. The negative control contains all the reagents without any RNA template.  The Ct values and the viral copies 














     
 
     
 EV71 Standard 10.87  5 X 109 - 
 29mer-scr (10nM) 10.88  
 EV71 Standard 10.87  5 X 109 - 
4.98 X 109 - 
 19mer-3D (1nM) 11.42  
 29mer-scr (10nM) 10.88  4.98 X 109 - 
2.99 X 109 0.20 
 19mer-3D (5nM) 11.89  
 29mer-3D (1nM) 14.51  1.56 X 108 1.50 
2.02 X 109 0.40 
 19mer-3D (10nM) 12.78  
 29mer-3D (5nM) 15.89  5.66 X 107 1.94 
7.61 X 108 29mer-3D (10nM) 17.87  1.45 X 107 2.50 
 Negative - - - 
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Figure 4.13 (cont): Dose dependent reduction of EV71 viral RNA as shown by real-time Hybridization probe RT-PCR. (c) The 
RD cells treated with 1nM, 5nM and 10nM of 29-mer shRNAs targeted at the 2C (29mer-2C) gene of the EV71 genome. (d) RD cells 
treated with 1nM, 5nM and 10nM of 29-mer shRNAs targeted at the 3Cpro (29mer-3C) gene of the EV71 genome. The RD cells 
treated with 10nM of scrambled shRNAs (29mer-scr) were used as controls. The negative control contains all the reagents without any 
RNA template.  The Ct values and the viral copies represented the mean Ct and mean viral copies from two independent experiments, 
respectively. 





     
 EV71 Standard 10.87  5 X 109 - 
 29mer-scr (10nM) 10.88  4.98 X 109 - 
 29mer-3C (1nM) 12.22  9.65 X 108 0.71 
 29mer-3C (5nM) 12.23  9.65 X 108 0.71 
 29mer-3C (10nM) 14.12  1.49 X 108 1.52 
 Negative - - - 













     
 EV71 Standard 10.87  5 X 109 - 
 29mer-scr (10nM) 10.88  4.98 X 109 - 
 29mer-2C (1nM) 12.52  8.36 X 108 0.78 
 29mer-2C (5nM) 13.68  4.72 X 108 1.02 
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Figure 4.14: Dose dependent inhibition of EV71 replication with 29-mer shRNAs 
targeted at the 2C (29mer-2C), 3Cpro (29mer-3C) and 3Dpol (29mer-3D) genes of the 
EV71 genome. The RD cells treated with 1nM, 5nM and 10nM of 19-mer siRNAs 
(19mer-3D), 10nM of scrambled shRNAs (29mer-scr) and untransfected (-) RD cells 
were used as controls. The viral titres were determined by plaque assay.  The data shown 
represent the mean ±SD from two independent experiments, as indicated by error bars. 
The ANOVA analysis for comparison of the viral titres between different concentrations 
of each of the 29-mer shRNAs was found to be P < 0.05.  The ANOVA analysis for 
comparison of the viral titres between the untransfected RD cells and the treated RD cells 
was P < 0.01. The ANOVA analysis for comparison of the viral titres between the sh-3D 
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Similar dosage dependency effects in inhibiting EV71 replication were obtained when the 
RD cells were treated with 1nM, 5nM and 10nM of 19-mer siRNA (19mer-3D). 
However, the decrease in the VP1 protein levels were not as significant as what was 
observed in the RD cells transfected with the 29-mer shRNAs. There was no decrease in 
the VP1 protein levels in the RD cells treated with the scrambled 29-mer shRNAs 
(29mer-scr) (Figure 4.15). 
 
Based on all the results, the chemically synthesized 29-mer shRNAs targeted at 
the specific sequences of the 2C, 3Cpro and 3Dpol genes of EV71 were effective in 
inhibiting EV71 replication in RD cells in a dosage dependent manner. The 29-mer 
shRNAs targeting at the 3Dpol gene (29mer-3D) of EV71 was found to exhibit the most 
potent anti-EV71 effects in RD cells. It was also established in this study that a much 
lower concentration of the 29-mer shRNAs was able to inhibit EV71 replication more 
effectively as compared to the chemically synthesized 19-mer siRNAs. 
 
The efficacy of 29-mer shRNAs in inhibiting an on-going EV71 infection was 
tested by first infecting the RD cells over a period of 5 hours. At every hourly interval, 
the RD cells were transfected with 10nM of the 29mer-2C, 29mer-3C or 29mer-3D and 
CPE was monitored 48hpi. Significant CPE was observed in the untreated EV71-infected 
cells. In contrast, survival of the RD cells treated with 10nM of each of the 29-mer 
shRNAs was still observed 3 h post-infection. Thus, administration of 29-mer shRNAs to 
RD cells after EV71 infection can still effectively inhibit viral replication. 
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Figure 4.15: Western blot analysis of the VP1 protein expression in infected-RD 
cells treated with chemically synthesized 29-mer shRNAs targeted at the 2C (29mer- 
2C), 3Cpro (29mer-3C) and 3Dpol (29mer-3D) genes of the EV71 genome. Western blot 
analysis was performed using monoclonal antibodies against the VP1 structural proteins 
of EV71 after the RD cells were transfected with 1nM, 5nM and 10nM of 29mer-2C, 
29mer-3C or 29mer-3D. The RD cells treated with 1nM, 5nM and 10nM of 19-mer 
siRNAs (19mer-3D), 10nM of scrambled shRNAs (29mer-scr) and untransfected (-) RD 
cells were used as controls.  ß-actin was included as an internal control, using anti ß-actin 
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4.2.2.4 No enhanced inhibitory effects on EV71 replication by combinations 
of two 29-mer shRNAs 
 
 It has been reported that an enhanced antiviral effects of combinations of siRNAs  
was observed in HIV infection (Ji et al., 2003). To test whether cotransfection with two 
specific siRNAs targeted at different genes of the EV71 genome will improve the 
antiviral effect in this study, two 29-mer shRNAs were cotransfected into the RD cells, 
followed by infection with 60 pfu of EV71. A combination of 29mer-3D and each of the 
remaining two 29-mer shRNAs (29mer-2C and 29mer-3C) were evaluated at a combined 
final concentration of 10nM. The efficacy in inhibiting EV71 replication was measured 
by real-time Hybridization probe RT-PCR. Results by the real-time RT-PCR showed that 
similar inhibitory efficacy on EV71 replication was observed as compared to the 29-mer 
shRNAs when used individually (Figure 4.16), showing that there is no enhanced 
antiviral effect when a combination of 29-mer shRNAs was used. 
 
4.2.2.5 No activation of interferon pathway when RD cells were treated with 
29-mer shRNAs 
 
In order to rule out the possibility that the inhibition of viral replication is due to 
activation of PKR and induction of the interferon response, western blot was carried out 
using specific monoclonal antibodies against endogenous PKR. α-IFN was used as a 
positive control for the induction of PKR. Results showed that other than α-IFN, there 
was no increase in PKR expressions in the RD cells after they were transfected with each 
of the three 29-mer shRNAs for 48 h (Figure 4.17). The expression of phopho-PKR was 
also analysed in the transfected RD cells by western blot using specific monoclonal 
antibodies against phospho-PKR (Sigma, USA). Other than α-IFN, no phospho-PKR 
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expression was observed in the RD cells treated with each of the chemically synthesized 
29-mer shRNAs. These observations indicated that each of the three 29-mer shRNAs did 
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Mean Ct values 
 





     
 EV71 Standard 10.79  5 X 109 - 
 29mer-scr 11.07  4.89  X 109 - 
 29mer-2C + 29mer-3D 14.74 1.06  X 108 1.77 
 29mer-3C + 29mer-3D 14.75  1.06  X 108 1.77 
 29mer-2C + 29mer-3C 13.98  1.77  X 108 1.45 
 Negative - 
 
- - 
     
Figure 4.16: No enhanced inhibitory effects on EV71 replication by combinations of 
two 29-mer shRNAs as shown by real-time Hybridization probe RT-PCR. The RD 
cells were transfected with a combination of two 29-mer shRNAs for 48 hours, followed 
by infection with 60 pfu of EV71. The negative control contains all the reagents without 
any RNA template. The Ct values and the viral copies represented the mean Ct and mean 
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Figure 4.17: Western blot analysis of the levels of PKR or phospho-PKR protein 
levels in the RD cells. The RD cells treated with alpha-interferon (IFN) were used as a 
positive control. The RD cells treated with scrambled shRNAs (29mer-scr) and 
untransfected (-) RD cells were used as controls. Western blot analysis was performed 
using monoclonal antibodies against the PKR or phosphor-PKR. ß-actin was included as 
an internal control, using anti-ß-actin monoclonal antibodies. The tests were carried out 
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4.2.3 Efficacies of psiStrike plasmids expressing shRNAs and chemically 
synthesized 29-mer shRNAs in inhibiting heterologous EV71 strains  
 
It was shown that the psiStrike plasmids expressing shRNAs (psi-3D) and 
chemically synthesized 29-mer shRNA (29mer-3D) targeted the 3Dpol gene of EV71 
genome were most effective in inhibiting EV71 Strain 41. The efficacies of both the psi-
3D and 29mer-3D on heterologous EV71 strains were then evaluated by testing against 
other EV71 strains which were classified under different subgenogroups, namely the 
strain 10 (genogroup B4), strain 7423/MS/87 (genogroup B2) and three EV71 Japanese 
strains including 1585-Yamagata-01 (genogroup C2), 75-Yamagata-03 (genogroup C4) 
and 2933-Yamagata-03 (genogroup B5). The inhibitory effects of the different forms of 
siRNAs on the various heterologous EV71 strains were analyzed by real-time 
Hybridization probe RT-PCR, plaque assays and Western blots, respectively.  
 
The amount of the EV71 viral transcripts in the RD cells treated with 0.8ug of psi-
3D or 10nM of 29mer-3D was determined by real-time Hybridization probe RT-PCR. 
Compared to untreated RD cells which were infected with EV71, a significant decrease in 
viral RNA transcripts was observed when the RD cells were treated with psi-3D or 
29mer-3D and infected with each of the heterologous EV71 strains (Figures 4.18a and b). 
To corroborate with the significant decrease in the viral RNA transcripts, the infectious 
titres of the heterologous EV71 strains in the RD cells transfected with psi-3D or 29mer-
3D were determined by plaque assay. As high as 87% and 91% reduction in the viral 
titres were obtained when the RD cells were treated with 0.8ug of psi-3D or 10nM of 
29mer-3D, respectively (Figures 4.19a and b). Western blots were carried out to analyse 
the VP1 viral protein levels in the RD cells treated with 0.8ug of psi-3D or 10nM 29mer-
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3D and infected with each of the heterologous EV71 strains. The results indicated that the 
VP1 viral protein levels decrease significantly when the infected-RD cells were pre-
transfected with either psi-3D or 29mer-3D (Figures 4.20a and b).  
 
Gathering all the results, the psiStrike plasmids expressing shRNAs (psi-3D) and 
chemically synthesized 29-mer shRNA (29mer-3D) targeted the 3Dpol gene of EV71 
genome were effective in inhibiting EV71 heterologous strains belonging to other 
genogroups including strains 10 (genogroup B4), 7423/MS/87 (genogroup B2), 1585-
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EV71 Standard 10.79  5 X 109 -  
psi-scr 10.88  4.97 X 109 -  
1585-Yamagata-01 13.08  5.98 X 108 0.92  
7423/MS/87 13.24  5.33 X 108 0.97  
2933-Yamagata-03 13.30  5.32 X 108 0.97  
Strain 10 13.68  4.62 X 108 1.02  
75-Yamagata-03 14.05  1.95 X 108 1.41  
Strain 41 15.34  8.02 X 107 1.79  
Negative - - -  
     
Figure 4.18a: Decrease in the viral RNA transcripts of the heterologous EV71 
strains after treatment with 0.8ug of the psiStrike plasmids expressing shRNAs (psi-
3D) targeted 3Dpol gene of the EV71 genome as shown by real-time RT-PCR. The 
RD cells treated with 0.8ug of psiStrike plasmids expressing scrambled shRNAs (psi-scr) 
were used as controls. The negative control contains all the reagents without any RNA 
template. The Ct values and the viral copies represented the mean Ct and mean viral 
copies from two independent experiments, respectively. 
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 EV71 Standard 10.82  5 X 109 - 
 29mer-scr 11.00  4.88  X 109 - 
 1585-Yamagata-01 14.50  1.50  X 108 1.52 
 75-Yamagata-03 16.05  5.22  X 107 1.98 
 2933-Yamagata-03 16.03  5.22  X 107 1.98 
 Strain 10 16.14  4.80  X 107 2.01 
 7423/MS/87 16.04  5.22  X 107 1.98 
 Strain 41 17.38  1.55 X 107 2.50 
 Negative - - - 
     
Figure 4.18b: Decrease in the viral RNA transcripts of the heterologous EV71 
strains after treatment with 10nM chemically synthesized 29-mer shRNAs (29mer-
3D) targeted 3Dpol gene of the EV71 genome as shown by real-time RT-PCR. The 
RD cells treated with 10nM of scrambled shRNAs (29mer-scr) were used as controls. 
The negative control contains all the reagents without any RNA template. The Ct values 
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Figure 4.19: Inhibition of heterologous EV71 with psiStrike plasmids expressing 
shRNAs (psi-3D) and chemically synthesized 29-mer shRNAs (29mer-3D) targeted 
3Dpol gene of the EV71 genome. (a) The RD cells transfected with 0.8ug of psi-3D. (b) 
The RD cells transfected with 10nM of 29mer-3D. The RD cells treated with 0.8ug of 
scrambled shRNAs (psi-scr) or 10nM of 29mer-scr and untransfected (-) RD cells were 
used as controls. The viral titres were determined by plaque assay. The data shown 
represent the mean ±SD from two independent experiments, as indicated by error bars.  
The ANOVA analysis for comparison of the viral titres between the untransfected RD 
cells and the treated RD cells was P<0.01. 
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Strain      Strain          7423          1585          75             2933         psi-scr        (-)                









Strain      Strain          7423          1585           75            2933     29mer-scr        (-)               




 VP1 (37kDa) 
 
Figure 4.20: Decrease in VP1 protein expression in RD cells infected with 
heterologous EV71 strains and treated with either psiStrike plasmids expressing 
shRNAs (psi-3D) or chemically synthesized 29-mer shRNAs (29mer-3D) targeted the 
3Dpol gene of EV71 genome. Western blot analysis was performed using monoclonal 
antibodies against the VP1 structural proteins of EV71. (a) The RD cells were transfected 
with 0.8ug of psi-3D (b) The RD cells transfected with 10nM of 29mer-3D. The RD cells 
treated with 0.8ug of psiStrike plasmids expressing scrambled shRNAs (psi-scr) or 10nM 
of 29mer-scr and untransfected (-) RD cells were used as controls.  ß-actin was included 
as an internal control, using anti ß-actin monoclonal antibodies. The tests were carried 
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4.3 Discussion 
RNAi has been extensively exploited as a potential therapeutic approach to treat 
infectious diseases such as polioviruses (Gitlin et al., 2002), HIV (Capodici et al., 2002), 
Hepatitis C virus (Yokota et al., 2003) and Hepatitis B virus (Li et al., 2004). Currently, 
antivirals have been developed against some members of the enteroviruses, but none of 
them was found to be effective against EV71. The ‘WIN’ group of compounds was found 
to be the most promising among these antiviral agents (Robart et al., 1998). One of the 
“WIN” compounds, pleconaril, was found to be effective in treating aseptic meningitis 
and encephalitis caused by some enteroviruses but showed limited therapeutic benefit 
against EV71 (Robart et al., 1998; Pevear et al., 1999). Thus, it is of great interest to 
develop therapeutic strategies against EV71 infections. 
 
In this study, two siRNA systems – the psiStrike plasmid-derived shRNA system 
and the chemically synthesized 29-mer shRNAs were evaluated in their efficacies in 
inhibiting EV71 replication. The psiStrike plasmid borne shRNA system developed in 
this study was different from the pSilencer 3.1-H1 neo shRNA system developed by Lu 
et al. (2004). In the pSilencer 3.1-H1 neo shRNA system by Lu et al. (2004), the 
selection of the recombinant clones (which contained the shRNAs inserts) was based on 
neomycin and ampicillin as the selection markers. However, the transfection efficiencies 
of the pSilencer 3.1-H1 neo shRNA expression systems into the HeLa cell lines were 
unable to be determined. In contrast, the transfection efficiencies of the psiStrike 
plasmid-derived shRNA expression systems into the RD cell lines were able to be 
determined by flow cytometry based on the presence of a green fluorescent protein 
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(hMGFP), the expression of which was driven by the CMV promoter (page 93). In this 
study, the inhibitory effects exerted by the psiStrike plasmid-derived shRNAs on EV71 
replication were higher than the pSilencer plasmid-derived shRNAs (Lu et al., 2004), 
even though both the plasmid-borne shRNA expression systems were designed to target 
the 3Dpol gene and were used at the same concentrations. In the study by Lu et al., (2004), 
the pSilencer plasmid-borne shRNAs were designed to target at nucleotide position 6052 
to 6072 of the EV71 genome. In this study, the pStrike plasmid-borne shRNAs (psi-3D) 
were designed to target at nucleotide position 7304 to 7322 of the EV71 genome. Since 
both the plasmid borne shRNA systems were targeting at different regions of the 3Dpol 
gene, the difference in their efficacies in inhibiting EV71 replication could be due to the 
secondary structure of the viral RNA which could possibly interfere with the accessibility 
of the siRNAs to the complementary target sequence. 
 
Another significant observation in this study was that the synthetic 29-mer 
shRNAs were much more potent in inhibiting EV71 replication as compared to both the 
psiStrike plasmid-borne shRNAs and the chemically synthesized 19-mer siRNAs. The 
flow cytometric analysis showed that the 29-mer shRNAs, the 19-mer siRNAs and the 
plasmid borne shRNAs have relatively high and similar transfection efficiencies, thus the 
higher efficacies exerted by the synthetic 29-mer shRNAs was not due to the higher 
delivery of the 29-mer shRNAs into the RD cells. The mechanism for the higher 
efficiencies of the longer shRNAs is unknown, but it was suggested that the enhanced 
potency could be due to higher affinity of the 29-mer shRNAs for the Dicer enzyme 
(Rusk, 2005; Siolas et al., 2005). An alternative explanation is that the hairpin RNAs may 
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interact with specific cellular proteins which facilitate the delivery of these 29-mer 
shRNA substrates to the Dicer (Siolas et al., 2005).  
 
In this study, specific sequences within the 2C, 3Cpro and 3Dpol genes of EV71 
were chosen as the target sites as they are highly conserved and are less likely to mutate 
to generate mutants. This is an important feature for the design of siRNAs and is more 
significant when targeting viruses that mutate frequently such as poliovirus (Gitlin et al., 
2005). Both the psiStrike plasmids expressing shRNAs and the chemically synthesized 
29-mer shRNAs targeting the viral RNA-dependent RNA polymerase, 3Dpol, were most 
effective in inhibiting EV71 replication. This supported the findings by Lu et al. (2004) 
and Sim et al. (2005). The specific function of 2C has yet to be identified. The 3C gene 
encodes a protease which performs majority of the secondary processing of the 
polyprotein. The 3Dpol gene encodes the viral RNA-dependent RNA polymerase which 
oligomerizes into a complex and subsequently binds to the viral RNA. Since the 3Dpol 
gene and the other cellular factors form an important component in facilitating viral 
replication, its down-regulation could produce the most potent inhibitory effect on EV71 
replication. In addition, since the 3Dpol gene encodes the non-structural proteins, it is 
generally conserved among different EV71 strains, thus minimising the chances of escape 
mutants due to mutations. This was evident when both the psiStrike plasmids expressing 
shRNAs and the chemically synthesized 29-mer shRNAs were able to inhibit other EV71 
strains which belong to other subgenogroups such as C2, C4, B2 or B5. 
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It has been shown that cotransfection of cells with two or more siRNAs targeted 
at different sites resulted in enhanced gene silencing when compared to single siRNA is 
used (Ji et al., 2003). The underlying mechanism of enhanced gene silencing with 
multiple siRNAs has yet to be elucidated. But it was postulated that the binding of one 
siRNA may change the secondary structure of the target RNA, thus result in more 
accessible sites for another siRNA (Ji et al., 2003). However, no enhancement effect was 
observed when the RD cells were cotransfected with different combinations of the three 
29-mer shRNAs. The possible reason for the discrepancy may be because the 29-mer 
shRNAs developed in this study did not affect the secondary structure of the EV71 
mRNA, and thus do not increase accessibility to other 29-mer shRNAs. Nevertheless, 
gene silencing with multiple siRNAs may be a good approach for treatment of viral 
infections, especially for viruses which mutate and escape from RNA interference (Ji et 
al., 2003; Khabar et al., 2003).  
 
Longer dsRNAs (~30 nts) can elicit non-specific interferon response, leading to 
subsequent inactivation of the cellular transcriptional machinery and resulting in death of 
the mammalian cells (Persengiev et al., 2004; Sledz et al., 2004). The interferon response 
is also responsible for protection against viral infections (Khabar et al., 2003). The main 
mechanism in the interferon pathway is the induction of dsRNA dependent PKR. PKR is 
a serine-threonine kinase which is normally inactive. Upon activation by interferon or 
dsRNA, PKR are phosphorylated and the levels are upregulated. The activated PKR will 
then phosphorylate the cellular proteins, notably eIF2α, which are downstream of the 
interferon pathway, and subsequently leading to translational arrest (Khabar et al., 2003; 
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Persengiev et al., 2004; Sledz et al., 2004). Thus, during the design of RNAi strategy, the 
siRNAs must be long enough for effective gene silencing, but short enough to prevent the 
induction of the interferon response. In this study, since no increase in the endogenous 
PKR and phospho-PKR levels was detected, it was concluded that there was no 
engagement of the interferon pathway in the RD cells when they were transfected with 
the psiStrike plasmids expressing shRNAs or 29-mer shRNAs. 
  
In conclusion, an improvement in triggering RNAi in mammalian cells using 
psiStrike plasmids expressing shRNAs and the more potent 29-mer shRNAs was shown 
in the in vitro system. This indicated the potentials of both plasmid-borne shRNAs and 
29-mer shRNAs to be developed as an antiviral therapeutic agent against EV71. 
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CHAPTER 5 
Inhibition of Enterovirus 71 replication in virus-infected mice by RNA Interference 
 
5.1 Introduction 
Although there are other enteroviruses such as CA16, CA5, CA9 and Echo 7 
which have been reported to cause HFMD, serious neurological manifestations like 
brainstem and/or cerebellar encephalitis, acute flaccid paralysis (AFP) and aseptic 
meningitis were observed mainly in children with acute EV71 infections during the large 
scale HFMD outbreaks in the Asia Pacific region (Lum et al., 1998). These neurological 
manifestations were frequently accompanied by complications such as pulmonary edema 
and myocarditis and could lead to death (Chang et al., 1999; Chan et al., 2000). At 
present, there is no effective antiviral or vaccine available against EV71, and most deaths 
from HFMD caused by EV71 occurred within 24 hours when children were admitted 
with complications associated with HFMD (Lum et al., 1998; Chan et al., 2000; personal 
communication). With the rising concerns about the virulence of EV71, there is a need to 
develop a specific antiviral therapy against EV71.  
 
RNA interference (RNAi) is a defense strategy which was first described in C. 
elegans (Fire et al., 1998). Since then, RNAi has been widely applied as cellular defence 
against viruses, and has shown promise as a potential therapeutic strategy against 
infectious diseases. It is a multi-step process of sequence-specific, post-transcriptional 
gene silencing initiated by double-stranded RNA (dsRNA) molecules (Fire et al., 1998). 
The dsRNA is processed by the RNase III-like enzyme, Dicer, into small interfering 
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RNAs (siRNA) of 21–23 nucleotides. The siRNA will induce the formation of the RNA-
induced silencing complexes (RISCs) which subsequently recognize and degrade 
homologous target mRNAs.  
 
By targeting viral transcripts and/or host genes which produce co-factors critical 
for viral replication, the RNAi approach has been shown to be effective against a wide 
range of viruses such as human immunodeficiency virus (Capodici et al., 2002; Martinez 
et al., 2002; Surabhi et al., 2002), Hepatitis C virus (Kapadia et al., 2003; Randall et al., 
2003; Takigawa et al., 2004) and the influenza virus A (Ge et al., 2003) in the in vitro 
systems. This approach has also been used successfully against viruses of the 
Picornaviridae family, including the Poliovirus (Gitlin et al., 2002), Rhinovirus (Phipps 
et al., 2004) as well as the Coxsackievirus B3 (Werk et al., 2005; Yuan et al., 2005). 
Several studies have shown that siRNAs was effective in inhibiting replication of viruses 
such as Hepatitis B (Giladi et al., 2003), influenza virus A (Ge et al., 2004) and the 
respiratory syncytial virus (Bitko et al., 2005) in murine model. Thus, RNAi possess 
great potentials to be developed into antiviral therapeutics against EV71.  
 
Previous investigations have shown that both chemically synthesized 19-mer 
siRNAs and DNA plasmid-based expressing shRNAs system targeted at specific regions 
of EV71 were able to significantly inhibit replication of EV71 in the in vitro systems 
without inducing the interferon response (Lu et al., 2004; Sim et al., 2005).  It was also 
shown in Chapter 4 that the chemically synthesized 29-mer shRNAs were more potent 
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than the chemically synthesized 19-mer siRNAs and the plasmid-based shRNAs in 
inhibiting EV71 replication in RD cells. 
   
In this study, the chemically synthesized 19-mer siRNAs, the psiStrike plasmids 
expressing shRNAs and the chemically synthesized 29-mer shRNAs were evaluated and 
compared in their efficacies to inhibit EV71 infections in a murine model. The siRNAs 
were designed to target at the RNA dependent RNA polymerase, 3Dpol region of the 
EV71 genome. It was shown that both the chemically synthesized 19-mer siRNAs and 
psiStrike plasmids expressing shRNAs were equally effective in inhibiting EV71 
infections in mice. However, despite showing enhanced potency in inhibiting EV71 
infections in the in vitro system, the chemically synthesized 29-mer shRNAs failed to 
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5.2 Results 
 
5.2.1 Designing siRNAs against EV71 infections 
A previous study has shown that the chemically synthesized 19-mer siRNAs were 
effective in inhibiting EV71 replication in RD cell line (Sim et al., 2005). In Chapter 4, 
the oligonucleotide bearing the same sequence as the chemically synthesized 19-mer 
siRNAs was cloned into the psiStrike shRNA expression vector and a recombinant 
plasmid expressing 19-mer shRNAs (psi-3D) was constructed. The results showed that 
the 19-mer shRNAs expressed from the recombinant psiStrike plasmids (psi-3D) were 
highly effective in inhibiting EV71 replication in the in vitro system.  It was also shown 
in Chapter 4 that an enhanced potency in inhibiting EV71 replication was observed when 
the chemically synthesized 29-mer shRNAs were evaluated on the infected RD cells. All 
the three studies showed that the siRNAs designed to target the RNA dependent RNA 
polymerase, 3Dpol was most effective in inhibiting EV71 replication. In this study, the 
efficacies of the chemically synthesized 19-mer siRNAs (19mer-3D), 29-mer shRNAs 
(29mer-3D) and psiStrike plasmids expressing shRNAs (psi-3D) which targeted the 3Dpol 
region in protecting the suckling mice from EV71 infections were evaluated. 
 
5.2.2 siRNA-mediated inhibition of EV71 in vivo 
 To test the prophylactic activity of the various siRNAs, the suckling mice were 
first injected with 10nmol of chemically synthesized 19-mer siRNAs (19mer-3D), 
10nmol of 29-mer shRNAs (29mer-3D) or 50ug of psiStrike plasmids expressing 19mer-
shRNAs (psi-3D) coupled with Oligofectamine via the intraperitoneal route (i.p.). After 
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twenty four hours, the suckling mice were infected with 104 TCID50 of EV71.  As 
controls, the suckling mice were either not treated with any siRNAs or treated with 
siRNAs with scrambled sequences (19mer-scr, psi-scr or 29mer-scr) prior to infection. 
Results showed that the suckling mice treated with 10nmol of 19mer-3D or 50ug of psi-
3D showed significant protection against EV71 infection as the treated suckling mice 
showed no signs of significant weight loss (Figures 5.1a and b) and acute flaccid 
paralysis at the hind limbs after 14 days of EV71 infection (Figure 5.2a). In contrast, the 
suckling mice without any siRNA treatment or treated with the scrambled siRNAs 
showed significant weight loss and hind limb paralysis at day 6 post infection and all the 
infected mice died between day 12 and day 14 post infection (Figure 5.2b). Surprisingly, 
the suckling mice which were treated with 29mer-3D did not recover from EV71 
infection (Figures 5.1c and 5.2a). Thus, the administration of both synthetic 19-mer 
siRNAs and the psiStrike plasmids expressing shRNAs were able to inhibit EV71 
replication in murine model.  
 
 To examine the therapeutic potentials of 19mer-3D, psi-3D or 29mer-3D, the 
mice were first infected with 104 TCID50 of EV71. After 24 hours, the infected suckling 
mice were administered with 10nmol of 19mer-3D, 10nmol of 29mer-3D or 50ug of psi-
































































































Figure 5.1: Prophylactic effect of different forms of siRNAs in protecting mice (n=5) from EV71 infection as shown by changes 
in weight. (a) The EV71 infected suckling mice treated with 10nmol of chemically synthesized 19-mer siRNAs (19mer-3D). (b) The 
EV71 infected suckling mice treated with 50ug of psiStrike plasmids expressing shRNAs (psi-3D). (c) EV71 infected mice treated 
with chemically synthesized 29-mer shRNAs (29mer-3D). The untreated mice and mice treated with scrambled siRNAs (19mer-scr, 
psi-scr or 29mer-scr) were used as negative controls. All the data represent the mean weights ± SD of four independent experiments, 



























Figure 5.2: Prophylactic effects of different forms of siRNAs in protecting mice (n=5) from EV71 infections as shown by 
absence of hind limb paralysis. (a) A representative picture of a suckling mouse treated with 10nmol of chemically synthesized 19-
mer siRNAs (19mer-3D) or 50ug of psiStrike plasmids expressing shRNAs (psi-3D) compared to a suckling mouse was treated with 
chemically synthesized 29-mer shRNAs (29mer-3D) or scrambled siRNAs (on the left). (b) A representative picture of an untreated 
mouse showing hind limb paralysis (indicated by the arrow) and significant weight loss caused by EV71 infection at day 6 post 
infection. (c) A representative picture of an age-matched healthy uninfected suckling mouse. All the observations represented the 
results from four independent experiments.  
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It was observed that the infected mice without any siRNA treatment or treated with the 
scrambled siRNAs showed significant weight loss at day 6 post infection  and all died 
between day 12 and day 14 post infection (Figure 5.3). When the infected suckling mice 
were administered with 10nmol of 19mer-3D or 50ug of psi-3D via the i.p. route, 
significant protection against EV71 infection was observed as the treated suckling mice 
showed no signs of weight loss or hind limb paralysis after 14 days of EV71 infections 
(Figures 5.3a and b). In contrast, the infected suckling mice did not recover from EV71 
infections when they were treated with 29mer-3D (Figure 5.3c). All the treated suckling 
mice were further monitored for another 2 weeks for any delayed EV71 infections. Since 
all the treated mice did not show any signs of hind limb paralysis and weight loss, this is 
indicative of full recovery from EV71 infections. Notably, similar protective effects of 
the suckling mice from EV71 infections were observed when 19mer-3D and psi-3D was 
administered without Oligofectamine as the lipid carrier (Figure 5.4). This indicated that 
the siRNAs were also capable of providing significant protection against EV71 infections 
when they were administered without coupling to lipid carrier. However, the suckling 
mice were not protected from EV71 infections when they were treated with 19mer-3D, 
psi-3D or 29mer-3D via the oral route (Figure 5.5). 
 
5.2.3 Efficiency of siRNA delivery to mice tissues 
 The uptake efficiences of the three different forms of siRNAs by the intestinal 
cells and the brainstem neuronal cells were determined by injecting the suckling mice 

















































































Figure 5.3: Changes in weight in EV71 infected mice (n=5) treated with different forms of siRNAs coupled with 
Oligofectamine and administered via the i.p. route. (a) The EV71 infected suckling mice treated with 10nmol of chemically 
synthesized 19-mer siRNAs (19mer-3D). (b) The EV71 infected suckling mice treated with 50ug of psiStrike plasmids expressing 
shRNAs (psi-3D). (c) EV71 infected mice treated with chemically synthesized 29-mer shRNAs (29mer-3D). The untreated mice and 
mice treated with scrambled siRNAs (19mer-scr, psi-scr or sh-scr) were used as negative controls. All the data represent the mean 


















































































Figure 5.4: Changes in weight in EV71 infected mice (n=5) treated with different forms of siRNAs without coupling to 
Oligofectamine and administered via the i.p. route. (a) The EV71 infected suckling mice treated with 10nmol of chemically 
synthesized 19-mer siRNAs (19mer-3D). (b) The EV71 infected suckling mice treated with 50ug of psiStrike plasmids expressing 
shRNAs (psi-3D). (c) EV71 infected mice treated with chemically synthesized 29-mer shRNAs (29mer-3D). The untreated mice and 
mice treated with scrambled siRNAs (19mer-scr, psi-scr or sh-scr) were used as negative controls. All the data represent the mean 



















































































Figure 5.5: Changes in weight in EV71 infected mice (n=5) treated with different forms of siRNAs coupled with 
Oligofectamine and administered via the oral route. (a) The EV71 infected suckling mice treated with 10nmol of chemically 
synthesized 19-mer siRNAs (19mer-3D). (b) The EV71 infected suckling mice treated with 50ug of psiStrike plasmids expressing 
shRNAs (psi-3D). (c) EV71 infected mice treated with chemically synthesized 29-mer shRNAs (29mer-3D). The untreated mice and 
mice treated with scrambled siRNAs (19mer-scr, psi-scr or sh-scr) were used as negative controls. All the data represent the mean 
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Oligofectamine as the lipid carrier. Flow cytometry analysis was carried out on the 
intestinal cells and the brainstem neuronal cells which were harvested 24 hours after 
siRNAs injection and the uptake efficiencies were determined based on the emission 
from FITC fluorescent which was tagged to the 3′ end of the chemically synthesized 
19mer-3D and 29mer-3D. In the case of psi-3D, the uptake efficiency was determined 
based on the GFP expression from the recombinant plasmids bearing the 19-mer 
shRNAs. Results by the flow cytometry showed an average of 70.0% siRNA delivery 
efficiencies in the intestinal cells when the suckling mice were treated with 10nM of 
19mer-3D or 29mer-3D or 50ug of psi-3D coupled with or without Oligofectamine 
(Figure 5.6). However, very poor delivery efficiencies were observed in the brainstem 
neuronal cells harvested from the suckling mice treated with 19mer-3D, 29mer-3D or psi-
3D, indicative of poor penetrance of the siRNAs into the central nervous system (Figure 
5.7). 
 
5.2.4 Dosage dependency of siRNAs in inhibiting EV71 replication in vivo 
 To determine the dose-response kinetics and the optimal concentrations of 19mer-
3D, 29mer-3D and psi-3D in inhibiting EV71 replication, the suckling mice were treated 
with different concentrations of 19mer-3D, 29mer-3D or psi-3D. On day 14 post-
infection, the intestinal cells were harvested from the suckling mice and the inhibitory 
effects of each of the three different forms of siRNAs on EV71 replication were analyzed 
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(a)    (b)    (c) 
 
 





Figure 5.6: Delivery efficiencies of siRNAs into the mice intestinal cells shown by 
flow cytometric analysis. The uptake efficiencies (%) of (a) 19mer-3D, (b) psi-3D and 
(c) 29mer-3D by the intestinal cells were compared to untreated intestinal cells  (coloured 
region). The scrambled siRNAs, namely (d) 19mer-scr, (e) psi-scr and (f) 29mer-scr were 
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(a)    (b)    (c) 
 
 
 (d)    (e)    (f) 
 
Figure 5.7: Delivery efficiencies of siRNAs into the mice brainstem neuronal cells 
shown by flow cytometric analysis. The uptake efficiencies (%) of (a) 19mer-3D, (b) 
psi-3D and (c) 29mer-3D by the brainstem neuronal cells were compared to untreated 
brainstem neuronal cells (coloured region). The scrambled siRNAs, namely (d) 19mer-
scr, (e) psi-scr and (f) 29mer-scr were used as controls. The results represent the mean 
percentages from two independent experiments. 
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 It was observed that treatment with 1nmol of 19mer-3D led to about 40% 
decrease in EV71 viral transcripts while treatment with 10mol of 19mer-3D led to 100% 
reduction in the intestines (Figure 5.8).  Similar dosage dependency effects were 
observed when the concentration of psi-3D was increased from 10ug to 50ug (Figure 
5.9). However, there was no significant decrease in the EV71 viral RNA transcripts in the 
suckling mice when they were treated with 29mer-3D (Figure 5.10).  
 
 To correlate the results obtained from real-time RT-PCR, western blot was carried 
out to analyse the EV71 viral proteins in the intestinal cells harvested from the suckling 
mice treated with 19mer-3D, psi-3D or 29mer-3D. When the concentration of 19mer-3D 
was increased from 1nmol to 10nmol, the VP1 viral protein levels decreased 
correspondingly (Figure 5.11). Similar dosage dependency effects were observed when 
the mice were treated with 10ug, 25ug or 50ug of psi-3D (Figure 5.11). There was no 
significant decrease in the VP1 protein levels observed in the intestinal cells harvested 
from the suckling mice treated with 29mer-3D (Figure 5.11). No significant decrease in 
the VP1 protein levels or EV71 RNA transcripts was observed when the suckling mice 
were treated with 10nmol of the chemically synthesized scrambled siRNAs (19mer-scr 
and 29mer-scr) or 50ug of psiStrike plasmids expressing scrambled shRNAs (psi-scr).  
  
 Gathering all the results, both the chemically synthesized 19-mer siRNAs (19mer-
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 EV71 positive control 11.15  5 X 109 - 
 
Figure 5.8: Decrease in EV71 viral RNA transcripts after treatment with chemically 
synthesized 19-mer siRNAs targeted at the 3Dpol (19mer-3D) gene of EV71 as shown 
by real-time RT-PCR. The percentage of the reduction in the EV71 RNA transcripts 
was calculated based on the EV71 RNA transcripts harvested from the treated mice 
relative to the EV71 RNA transcripts harvested from the untreated mice. The infected 
suckling mice which were treated with 10nmol of scrambled shRNAs (19mer-scr) were 
used as controls. The negative control contains all the reagents without any RNA 
template. The Ct values and the viral copies represented the mean Ct and mean viral 




 Scrambled (19mer-scr) 30.75  1.32 X 103 - 
 Untreated 30.75  1.32 X 103 - 
 19mer-3D (1nmol) 33.88  8.23 X 102 38% 
 19mer-3D (5nmol) 35.09 4.63 X 102 65% 
 19mer-3D (10nmol) - - 100% 
 Negative - - - 
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 EV71 positive control 11.15  5 X 109 - 
 Scrambled (psi-scr) 30.80  1.32 X 103 - 
 Untreated 30.75  1.32 X 103 - 
 psi-3D (10ug) 32.98  9.44 X 102 28% 
 psi-3D (25ug) 34.57 4.95 X 102 62.5% 
 psi-3D (50ug) - - 100% 
 Negative - - - 
     
 
Figure 5.9: Decrease in EV71 viral RNA transcripts after treatment with psiStrike 
plasmids expressing shRNAs targeted at the 3Dpol (psi-3D) gene of EV71 as shown 
by real-time RT-PCR. The percentage of the reduction in the EV71 RNA transcripts 
was calculated based on the EV71 RNA transcripts harvested from the treated mice 
relative to the EV71 RNA transcripts harvested from the untreated mice. The suckling 
mice which were treated with 0.8ug of scrambled shRNAs (psi-scr) were used as 
controls. The negative control contains all the reagents without any RNA template. The 
Ct values and the viral copies represented the mean Ct and mean viral copies from two 
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EV71 positive control 11.15  5 X 109 -  
Scrambled (29mer-scr) 31.05  1.32 X 103 -  
Untreated 30.75  1.32 X 103 -  
29mer-3D (1nmol) 31.05 1.32 X 103 -  
29mer-3D (5nmol) 31.05 1.32 X 103 -  
29mer-3D (10nmol) 31.05 1.32 X 103 -  
 
Figure 5.10: Decrease in EV71 viral RNA transcripts after treatment with 
chemically synthesized 29-mer shRNAs targeted at the 3Dpol (29mer-3D) gene of 
EV71 as shown by real-time RT-PCR. The percentage of the reduction in the EV71 
RNA transcripts was calculated based on the EV71 RNA transcripts harvested from the 
treated mice relative to the EV71 RNA transcripts harvested from the untreated mice. The 
suckling mice which were treated with 10nmol of scrambled shRNAs (29mer-scr) were 
used as controls. The negative control contains all the reagents without any RNA 
template. The Ct values and the viral copies represented the mean Ct and mean viral 




 Negative - - - 










ig e 5.11: Dose dependent inhibition of siRNAs on EV71 replication shown by Western blot. The infected suckling mice (n=5) 
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were treated with graded concentrations of 19mer-3D, 29mer-3D and psi-3D. The untreated infected suckling mice and the infected 
suckling mice treated with 10nmol of 19mer-scr, 10nmol of 29mer-scr or 50ug of psi-scr were used as controls. Western blot analysis 
was performed using specific monoclonal antibodies against the VP1 structural proteins of EV71. ß-actin was used as an internal 
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inhibiting EV71 replication in suckling mice in a dosage dependent manner, and the most 
effective inhibitory concentrations of 19mer-3D and psi-3D were 10nmol and 50ug, 
respectively. On the other hand, the chemically synthesized 29-mer shRNAs (29mer-3D) 
failed to protect the suckling mice from EV71 infections despite showing enhanced 
potency in inhibiting EV71 replication in the in vitro system. 
  
 A kinetic study was conducted to determine the inhibitory effects of 19mer-3D 
and psi-3D in protecting the suckling mice from EV71 infection by treating the infected 
suckling mice with 19mer-3D or psi-3D from day 1 to day 4 post EV71 infections.  It was 
observed showed that the protective effects of 19mer-3D and psi-3D were the strongest 
when they were administered into the infected suckling mice on day 1 post infection, as 
the suckling mice did not show acute flaccid paralysis and significant weight loss. The 
inhibitory effects were observed to diminish thereafter, and 19mer-3D failed to protect 
the suckling mice from EV71 infections when they were administered after 3 days of 
EV71 infection. In the case of psi-3D, protection of the suckling mice was still evident 
when they were administered after 4 days of EV71 infection. 
 
5.2.5 Immunohistochemistry staining for presence of EV71 in the organs of the 
treated suckling mice 
 
 The effects of 19mer-3D, 29mer-3D and psi-3D on EV71 replication was 
determined histologically by immunohistochemical staining the intestines harvested from 
the mice on day 7 and day 14 post EV71 infection. It was observed that on day 7 post 
infection, presence of EV71 was observed in the intestines harvested from untreated 
suckling mice, and there were extensive damage to the intestinal epithelia and intestinal 
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cells after 14 days of infection with EV71 (Figure 5.12). Similar extensive intestinal 
damage was also observed in the intestines harvested from the suckling mice treated with 
29mer-3D (Figure 5.12). In contrast, no presence of EV71 was observed in the intestines 
when the suckling mice were treated with either 10nmol of 19mer-3D or 50ug of psi-3D 
(Figure 5.12). These results further enhanced the significance of both 19mer-3D and psi-
3D in their ability to inhibit EV71 replication in vivo. 
 
5.2.6 siRNAs do not activate interferons 
 To provide further evidence that the EV71 inhibition was due to the specific 
antiviral effects exerted by both 19mer-3D and psi-3D and not due to activation of 
interferons, the levels of IFN-α and IFN-β in the homogenates of the intestines harvested 
from the treated suckling mice were measured. The results showed no activation of IFN-α 
or IFN-β, indicating that the EV71 inhibition in the suckling mice was mediated 
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staining was carried out with specific anti-EV71 antibody. (a) Presence of EV71 was detected (indicated by arrow) at the epithelia of 
the intestines at day 7 post infection. (b) Extensive damage to the epithelia and the intestinal cells caused by EV71 at day 14 post 
infection. (c) Presence of EV71 and extensive damage in the intestines harvested from mice treated with chemically synthesized 29-
mer shRNAs (29mer-3D) (d). No presence of EV71 was detected when the suckling mice were treated with either 19mer-3D or psi-
3D. (e) Normal morphology of the intestines in healthy suckling mice which served as negative control. The results represented the 
observations from two independent experiments. 
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Figure 5.13: Absence of interferon induction following treatment with siRNAs. The 
levels of (a) IFN-α and (b) IFN-β were determined by measuring the absorbance values at 
490nm. The data shown represent the mean ±SD from two independent experiments, as 
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5.2.6 Efficacies of psiStrike plasmids expressing shRNAs and chemically 
synthesized 19-mer siRNAs in inhibiting heterologous EV71 strains in 
murine model  
 
The results obtained so far showed that the chemically synthesized 19-mer 
siRNAs (19mer-3D) and the psiStrike plasmids expressing shRNAs (psi-3D) targeted the 
3Dpol region of EV71 genome were effective in inhibiting EV71 Strain 41. The efficacies 
of the psi-3D and 19mer-3D in inhibiting other hetrologous EV71 strains in murine 
model was next evaluated by testing against other EV71 strains such as strain 10 
(genogroup B4), strain 7423/MS/87 (genogroup B2) and three EV71 Japanese strains, 
namely 1585-Yamagata-01 (genogroup C2), 75-Yamagata-03 (genogroup C4) and 2933-
Yamagata-03 (genogroup B5). The inhibitory effects of both 19mer-3D and psi-3D on 
the heterologous EV71 strains were analyzed by observations for significant weight loss, 
real-time RT-PCR and Western blots. 
 
All the suckling mice (n=20) which were infected with either of the six EV71 
heterologous strains recovered when they were treated with either 10nmol of 19mer-3D 
or 50ug of psi-3D. No sign of significant weight loss or hind limb paralysis was 
observed, and the treated mice essentially grew at the same rate as the untreated mice 
(Figures 5.14). Real-time Hybridization probe RT-PCR assay was carried out to 
determine the EV71 RNA transcripts harvested from the intestines of the suckling mice 
which were treated with either 10nmol of 19mer-3D or 50ug of psi-3D. Compared to 
untreated mice which were infected with EV71, no EV71 RNA transcript was detected, 
indicative of protections from infections with the various EV71 heterologous strains 
(Figures 5.15a and b). 
 220
RNAi against EV71 in vivo 


















































Figure 5.14: Changes in weight in the suckling mice infected with EV71 
heterologous strains and treated with chemically synthesized 19-mer siRNAs 
(19mer-3D) or the psiStrike plasmids expressing shRNAs (psi-3D) coupled with 
Oligofectamine. (a) The EV71 infected suckling mice were treated with 10nmol of 
19mer-3D. (b) The EV71 infected suckling mice were treated with 50ug of psi-3D. The 
untreated mice were used as controls. The infected suckling mice represent the suckling 
mice infected with Strain 41. Similar weight loss were also observed in the suckling mice 
which were infected either Strain 10, strain 7423/MS/87, 1585-Yamagata-01, 75-
Yamagata-03 or 2933-Yamagata-03. All the data represent the mean weights ± SD of 
four independent experiments, as indicated by error bars. 
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 EV71 Standard 10.09  5 X 109 - 
Figure 5.15a: Decrease in the viral RNA transcripts in the intestinal cells harvested 
from the suckling mice infected with the heterologous EV71 strains and treated with 
chemically synthesized 19-mer siRNAs (19mer-3D) targeted at 3Dpol gene of the 
EV71 genome as shown by real-time RT-PCR. The negative control contains all the 
reagents without any RNA template. The Ct values and the viral copies represented the 
mean Ct and mean viral copies from two independent experiments, respectively. 
 
 Untreated 32.68 9.45 X 102 - 
 1585-Yamagata-01 - - - 
 75-Yamagata-03 - - - 
 2933-Yamagata-03 - - - 
 Strain 10 - - - 
 7423/MS/87 - - - 
 Strain 41 - - - 
 Negative - - - 
     
 222
RNAi against EV71 in vivo 





Mean Ct values 
 






     
EV71 Standard 10.30  5 X 109 -  
Untreated 31.66 1.33 X 103 -  
 
Figure 5.15b: Decrease in the viral RNA transcripts in the intestinal cells harvested 
from the suckling mice infected with the heterologous EV71 strains and treated with 
the psiStrike plasmids expressing shRNAs (psi-3D) targeted at 3Dpol gene of the 
EV71 genome as shown by real-time RT-PCR. The negative control contains all the 
reagents without any RNA template. The Ct values and the viral copies represented the 




 1585-Yamagata-01 - - - 
 75-Yamagata-03 - - - 
 2933-Yamagata-03 - - - 
 Strain 10 - - - 
 7423/MS/87 - - - 
 Strain 41 - - - 
 Negative - - - 
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To correlate the significant decrease in the EV71 viral RNA transcripts as shown 
by real-time RT-PCR, Western blot was carried out to analyse the EV71 viral proteins in 
the intestinal cells harvested from the treated suckling mice. No significant EV71 VP1 
protein was detected in the intestinal cells harvested from the suckling mice treated with 
either 19mer-3D or psi-3D (Figures 5.16a and b). 
 
Based on all the results, both the chemically synthesized 19-mer siRNAs (19mer-
3D) and the psiStrike plasmids expressing shRNAs (psi-3D) targeted the 3Dpol region of 
EV71 genome were effective in inhibiting EV71 heterologous strains belonging to other 
genogroups including strains 10 (genogroup B4), 7423/MS/87 (genogroup B2), 1585-
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Figure 5.16: Decrease in VP1 protein expression in the intestinal cells harvested 
from the suckling mice infected with the heterologous EV71 strains and treated with 
siRNAs. (a) Infected mice treated with 10nmol of chemically synthesized 19-mer 
siRNAs (19mer-3D). (b) Infected mice treated with 0.8ug of psiStrike plasmids 
expressing shRNAs (psi-3D). Western blot analysis was performed using monoclonal 
antibodies against the VP1 structural proteins of EV71. The uninfected mice and the 
infected mice without any siRNA treatment (-) were included as controls. The infected 
suckling mice (-) also represent the suckling mice infected with Strain 41. Similar results 
were also obtained in the suckling mice which were infected either Strain 10, strain 
7423/MS/87, 1585-Yamagata-01, 75-Yamagata-03 or 2933-Yamagata-03.  ß-actin was 
included as an internal control, using anti ß-actin monoclonal antibodies. The tests were 
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5.3 Discussion 
 Currently, most cases of HFMD are managed with symptomatic treatment. There 
are a number of antiviral agents with activities against enteroviruses being developed, but 
these are still under going clinical trials, and are not commercially available. Currently, 
the “WIN” group of compounds is the most promising drug so far. One of the “WIN” 
compounds – pleconaril was found to have significant therapeutic effects in aseptic 
meningitis, acute flaccid paralysis and encephalitis as a result of enteroviral infections 
(Rotbart et al., 1998; Pevear et al., 1999). However, despite having very little side effects 
profile which was attributed to its metabolic stability, pleconaril was found to show 
limited effectiveness against EV71 (Pevear et al., 1999), especially EV71-associated 
neurological complications. Thus, it is of great interest to develop therapeutic strategies 
against EV71 infections.  
  
 The success of RNAi has been widely reported for in vitro culture systems, and 
this has gradually led to growing interest in in vivo applications. These applications could 
eventually lead to validation of siRNA as potential drug therapy against infectious 
diseases. In this study, the 3Dpol gene of EV71 was selected as the target site since it has 
been shown in Chapter 4 and two other studies that the siRNAs targeted at the 3Dpol gene 
exerted the most potent inhibitory effect on EV71 replication (Lu et al., 2004; Sim et al., 
2005).  The 3Dpol gene of EV71 encodes the viral RNA-dependent RNA polymerase and 
is highly conserved, thus is less likely to mutate to generate mutants. This is important 
when designing siRNAs to target viruses that mutate frequently such as poliovirus (Gitlin 
et al., 2005).  
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 When used either as a prophylactic or as a treatment drug, both the synthetic 19-
mer siRNAs and the psiStrike plasmids expressing shRNAs targeted at the 3Dpol region 
of EV71 were shown to be effective in inhibiting EV71 replication in a murine model. 
The growth of the treated suckling mice was essentially comparable to those uninfected 
mice, showing that both the synthetic 19-mer siRNAs and the psiStrike plasmids 
expressing shRNAs were able to protect the suckling mice from EV71 infections instead 
of simply delaying the infection. The inhibitory effects on EV71 replication exerted by 
both forms of siRNAs were dosage dependent as shown by real-time RT-PCR and 
Western blot analysis. Protection of the infected suckling mice by the siRNAs was also 
shown histologically by immunohistochemistry, as no EV71 or intestinal tissue damage 
was observed in the suckling mice treated with the chemically synthesized 19-mer 
siRNAs or the psiStrike plasmids expressing shRNAs. In addition, since the 3D region 
encodes the non-structural proteins, it is conserved among different EV71 strains. This 
was highlighted by the ability of both the chemically synthesized 19-mer siRNAs and the 
psiStrike plasmids expressing shRNAs to inhibit the replication of the heterologous EV71 
strains belonging to other genogroups such as B2, C2, C4 and B5.  
 
 In this study, the chemically synthesized 29-mer shRNAs (29mer-3D) failed to 
protect the suckling mice from EV71 infections despite demonstrating enhanced potency 
in inhibiting EV71 replication in the in vitro system. Since the flow cytometric analysis 
showed similar uptake efficiencies of chemically synthesized 19-mer siRNAs (19mer-
3D), 29-mer shRNAs (29mer-3D) and the psiStrike plasmids expressing shRNAs (psi-
3D) by the intestinal cells, the lack of the protective effects exerted by the 29-mer 
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shRNAs was not due to the poor uptake of the siRNAs by the mice tissues, and it is likely 
that the suckling mice lack certain mechanism or cellular proteins which facilitate the 
delivery of the 29-mer shRNAs to the Dicer to be processed into the functional 19-mer 
siRNAs.  
  
 Delivering siRNAs in vivo to animal tissues is complicated and has been one of 
the most challenging issues. This is due to the fact that the accessibility of siRNAs into 
different tissue types makes it almost impossible to have a universal in vivo delivery 
system (Aigner, 2005; Xie et al., 2006). For in vivo applications, a suitable delivery 
system which is capable of protecting siRNAs from RNase activity and allows effective 
cellular uptake is crucial (Xie et al., 2006). Here, two systemic methods of delivering 
siRNAs into the infected suckling mice were compared. Systemic administration 
approach was used in this study since EV71 infections can affect multiple organs, 
including the intestines and the brainstem (Chen et al., 2004). Both the chemically 
synthesized 19-mer siRNAs and the psiStrike plasmids expressing shRNAs were able to 
protect the infected suckling mice from EV71 infection when administered via the i.p. 
route. In contrast, delivery of siRNAs via the oral route failed to protect the suckling 
mice from EV71 infections. This could be due to the degradation of the siRNAs in the 
gastrointestinal tract, which resulted in their inability to exert their antiviral effects. It was 
also shown in this study that the suckling mice were protected from EV71 infections 
when administered with siRNAs without coupling to any transfection agent. This is 
noteworthy as although coupling the siRNA with cationic lipids can enhance siRNA 
delivery via systemic routes, it has been reported that this can trigger the cellular 
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interferon pathway (Sledz et al., 2003), resulting in the death of the animals. It is also 
worth noting that the flow cytometric analysis demonstrated very poor delivery of the 
siRNAs to the brainstem. This is due to the fact that the siRNAs were unable to penetrate 
the blood-brain barrier effectively (Beklke, 2006; Xie et al., 2006). To date, an effective 
mechanism to deliver siRNAs to the central nervous system remains to be elucidated. 
Thus early detection and treatment of the EV71 infections is essential so that the siRNAs 
can be delivered effectively to inhibit the viral replication before irreversible damage to 
the central nervous system occurs.  
 
 Although both chemically synthesized 19-mer siRNAs and the psiStrike 
recombinant plasmids expressing shRNAs were shown to be very effective in inhibiting 
EV71 replication in suckling mice, the lasting effects of the chemically synthesized      
19-mer siRNAs in the suckling mice were observed to be shorter than the psiStrike 
plasmids expressing shRNAs. This is because the chemically synthesized 19-mer siRNAs 
were delivered transiently, unlike the psiStrike plasmids expressing shRNA system which 
can express siRNAs endogenously.  
  
 It has been established that long dsRNAs (~30 nts) or/and high concentrations of 
siRNAs can elicit non-specific interferon response, especially the IFN-α pathway. IFNs 
drive a cascade of intracellular signaling, resulting in expression of a large number of 
interferon-stimulated genes (ISGs) that cause the pleiotropic effects of IFN, which 
include interference with viral replication and modulation of host immune response 
(Sledz et al., 2003). Thus it is important to use a suitable concentration of siRNAs which 
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can optimally inhibit EV71 replication, but do not elicit any immune responses. The data 
showed that there was no activation of IFN-α or IFN-β response, indicating that both 
chemically synthesized siRNAs and the psiStrike plasmids expressing shRNAs are 
specific in inhibiting EV71 replication and do not cause undesirable side effects. 
  
 In conclusion, this study showed that both the chemically synthesized 19-mer 
siRNAs and the psiStrike plasmids expressing shRNAs can be used to inhibit EV71 
replication in a murine model. Thus RNAi strategy may prove to be a potent therapeutic 
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CHAPTER 6 
Evolution frequency of EV71 
 
6.1 Introduction 
 Evolution is the result of changes in the genetic composition of an organism with 
time. It involves sequential steps of complex interplay between the intrinsic modifications 
in the genetic makeup of the organism and the environmental influences (Domingo et al., 
1994). The evolutionary rates for viruses vary greatly, encompassing periods of very high 
evolution during active viral replication under selective pressures and periods of very low 
evolution (stasis) due to limited replications or replications near population equilibrium 
(without modification to the consensus sequences) (Drake et al., 1991; Domingo et al., 
1994).  
 
In many positive-stranded RNA viruses, the frequency of RNA recombination is 
relatively high and has a significant influence on virus evolution (King et al., 1982; Nagy 
et al., 1997). Previous studies based on phylogenetic analyses have shown that RNA 
viruses evolve at the rate which ranges from 10-2 to 10-5 substitutions per nucleotide per 
year (Domingo et al., 1994; Drake et al., 1998). For example, in the pol gene of human 
immunodeficiency virus (HIV), the mutation frequency was found to be as high as 1.1 X 
10-2 substitutions per nucleotide (Najera et al., 1995). Generally high mutation rates have 
also been observed in DNA viruses such as hepadnaviruses and hepatitis B virus which 
use RNA copies as replication intermediates (Drake, 1991).  
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In picornaviruses, studies on the mutation frequencies have been reported based 
on two regions of the viral genome, namely the VP1 which encodes the structural capsid 
protein, and the RNA-dependent RNA polymerase (3Dpol) gene which is responsible for 
synthesis of new viral genomes. The VP1 region of the foot-and-mouth disease virus 
(FMV) was shown to have a mutation frequency ranging from 1.6 X 10-3 to 6.4 X 10-3 
substitutions per nucleotide per year (Villaverde et al., 1988). Relatively high 
evolutionary rates was also observed in the VP1 regions for poliovirus type 1 (3.36 X 10-2 
substitutions per nucleotide per year) and EV70 (2.2 X 10-2 substitutions per nucleotide 
per year) (Takeda et al., 1994; Kew et al., 1998). Analysis of the 3Dpol gene was reported 
in FMV and poliovirus, in which both studies showed a mutation rate of 7.0 X 10-4 and 
4.5 X 10-4 substitutions per nucleotide per year, respectively (Villaverde et al., 1988; 
Ward et al., 1988; Wells et al., 2001).  
 
Brown et al., (1999) analysed the VP1 region of 113 EV71 strains which were 
isolated in the United States and five other countries during the period from 1970 to 
1998. An evolutionary rate of 1.35 X 10-2 substitutions per nucleotide per year was 
shown, indicating that EV71 is a genetically diverse and rapidly evolving virus (Brown et 
al., 1999). However, little is known about the evolutionary rate of the 3Dpol gene of the 
EV71 genome. In this study, the complete VP1 (891bp) and 3Dpol (1386bp) sequences of 
EV71 strains isolated in the Asia Pacific region from 1995 to 2005 were obtained from 
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6.2 Results 
6.2.1 Estimation of genetic distance and evolutionary rate 
The genetic distances for both the 3Dpol and the VP1 regions were calculated 
using Kimura-Nei method, based on pairwise comparison between each individual strain 
and the prototype BrCr as the reference strain.  Based on the slope of the linear regression 
line generated from the genetic distance versus year of isolation, the evolutionary rate of 
both the 3Dpol and the VP1 regions were calculated. The slope of the regression line 
generated for the 3Dpol region was found to be linear (-0.0006), indicating very low 
evolutionary rate in the 3Dpol region (Figure 6.1). On the other hand, the VP1 region 
showed an evolutionary rate of 1.8 X 10-3 substitutions per nucleotide per year (Figure 
6.2). 
 
6.2.2 Synonymous/Nonsynonymous Test 
The one-tailed Z-test of selection based on the relative abundance of synonymous 
(dS) and nonsynonymous substitutions (dN) that occurred in the nucleotide sequences of 
both the 3Dpol and the VP1 regions were calculated by the MEGA4 software. A value of  
-6.228 and -38.662 was obtained for the 3Dpol and the VP1 region, respectively. Based 
the one-tailed Z-test, the null hypothesis in which dN = dS was rejected. Since negative 
values were obtained for the 3Dpol and VP1 region, the alternative hypothesis of purifying 
selection occurring in both genes was accepted, i.e. the number of synonymous 
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Figure 6.1: Evolutionary rate of the 3Dpol gene of EV71. The rate of mutation was 
calculated by the linear regression of the genetic distances of 25 EV71 strains from the 
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Figure 6.2: Evolutionary rate of the VP1 gene of EV71. The rate of mutation was 
calculated by the linear regression of the genetic distances of 398 EV71 strains from the 
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6.3 Discussion 
The rapid evolution of RNA viruses is a well accepted phenomenon (Holland et 
al., 1993; Domingo et al., 1996). Several factors that lead to the evolution of RNA 
viruses have been identified, including (i) genetic variation, notably high mutation and/or 
recombination rates during RNA genome replication, which resulted in a diversity of 
mutants which are also known as viral quasispecies (Eigen et al., 1988; Eigen, 1996); (ii) 
competition among the quasispecies replicating simultaneously in a defined environment; 
and (iii) positive selection on the heterologous viral populations, resulting in a genetic 
diversification of the viral populations over time (Domingo et al., 1994). 
 
Study of spontaneous mutations is critical to understand the genetic structure of 
viral populations over time and subsequently leading to the understanding the course of 
evolution (Drake et al., 1996). The estimation of the pattern of nucleotide substitution 
relates to the analysis of evolutionary distances. The pairwise evolutionary distance 
between the virus and its origin forms the basis of the study of molecular evolution. By 
computing the rate of evolution, the evolutionary relationships and the divergence over 
time among the viruses or genes can be determined (Saitou et al., 1987; Gu et al., 1997). 
Thus, it is essential to obtain reliable estimates of the evolutionary distances. If the 
evolutionary distances are not accurately estimated, all the distance matrix methods in the 
phylogenetic construction may be misleading (Felsenstein, 1988; Nei, 1996). For this 
reason, much effort has been made to develop general methods of nucleotide substitution. 
(Saitou et al., 1987).  
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In the study reported by Brown et al. (1999), the genetic distances were calculated 
using the Kimura 2-parameter model (Kimura et al., 1980). This model was used as it 
took into account for both the transitional and transversional substitution rates and 
assumed that the rates of substitution do not vary among sites. In this study, the Tamura-
Nei model was used for the pairwise genetic distance analysis between each EV71 strain 
and the prototype BrCr strain as the reference strain. Besides the factors described in the 
Kimura 2-parameter model, the Tamura-Nei model also accounts for the differences in 
the substitution rate between nucleotides which is absent in the Kimura 2-parameter 
model (Kimura and Nei, 1993). This allows a more realistic estimation of the genetic 
distance in viruses which evolve frequently. The results showed that the evolutionary rate 
in the VP1 region was higher than the 3Dpol region, indicating high conservation in the 
3Dpol region.  Despite the rapid and high evolutionary rate in RNA viruses, the high 
conservation of the 3Dpol region was shown in this study and was in strong contrast to the 
divergence of the VP1 region which encodes the structural protein. This finding 
supported the previous study by Villaverde et al. (1988), who also demonstrated a higher 
evolutionary rate in the VP1 region as compared to that of the 3Dpol region. The 3Dpol 
region encodes the RNA-dependent RNA polymerase and has been shown to be 
relatively conserved in some enteroviruses such as FMV (Martinez-Salas et al., 1985). It 
was suggested that the conservation in the 3Dpol region was not due to the low mutability 
of the 3D gene, but rather due to recurrence of the same or related consensus as a result 
of competitive growth of variants (Domingo et al., 1978, 1985; Holland et al., 1982; 
Dopazo et al., 1988; Steinhauer and Holland, 1988). This was shown previously in 
poliovirus (Sedivy et al., 1987) and Sindbis virus (Durbin and Stollar, 1986).  
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On the other hand, the high divergence of the VP1 region is due to the selective 
pressure on the structural capsid protein of EV71 so as to maintain functionally active 
viruses (Villaverde et al., 1988), and this was supported by the higher mutation rate in the 
VP1 region as compared to the 3Dpol region. However, the evolutionary rate of the VP1 
region in this study was lower than the evolutionary rate reported by Brown et al. (1999) 
(1.8 X 10-3 vs 1.35 X 10-2 substitutions per nucleotide), suggesting that the evolution rate 
of EV71 strains isolated from 1995 to 2005 was not as rapid as compared to the EV71 
strains isolated from 1970 to 1998 reported by Brown et al. (1999).  
 
However, due to the limited data sequences in the GenBank, the evolutionary rate 
in the 3Dpol gene could only be estimated based on 25 complete nucleotide sequences, 
whereas a larger number (398) of complete VP1 nucleotide sequences were available for 
analysis, and thus allowed a more accurate prediction of the evolutionary rate. 
 
6.3.1 Implications of the evolution on the efficacies of real-time RT-PCR and 
RNAi 
 
The real-time RT-PCR and RNAi developed previously were designed to target at 
the VP1 and the 3Dpol region, respectively. Despite showing a relatively high 
evolutionary rate, the VP1 region of the EV71 genome was selected for the designing of 
the real-time RT-PCR as it possesses a high degree of antigenic and genetic diversity to 
distinguish between enterovirus serotypes (Oberste et al., 1999; Brown et al., 2000). As 
such, conserved regions in the VP1 genome were selected for the designing of the 
primers and the probes for the real-time RT-PCR to ensure effective and specific 
detection of EV71. This provided a higher confidence in the efficacy of the developed 
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real-time RT-PCR to detect EV71 specifically. Furthermore, with the lowered 
evolutionary rate of the VP1 gene over the last few years shown in this study, there will 
be lesser chances of the real-time RT-PCR in failing to detect EV71 specifically which 
could occur as a result of mutations. 
 
In the RNAi study, the siRNAs were designed to target at the specific and 
conserved sequences within the 3Dpol region of the EV71 genome. The low evolutionary 
rate shown in this study indicated that the 3Dpol region was highly conserved. This is an 
important feature during designing of siRNAs and is more significant when targeting 
RNA viruses that mutate frequently, for example the poliovirus (Gitlin et al., 2005).  
 
In conclusion, estimating the mutation rates in RNA viruses is critical in tracing 
their rapidly evolving paths (Zhao et al., 2004). The availability of EV71 sequence data 
from different parts of the world enabled effective development of detection methods and 
potential antiviral strategies against the virus. The real-time RT-PCR and the RNAi 
developed have shown to be effective in rapid detection and effective inhibition of the 
virus, respectively. Nevertheless, increased surveillance is necessary to monitor potential 




   
CONCLUSIONS 
 
EV71 has been increasingly recognized as the main etiological agent of large 
scale outbreaks of Hand, Foot and Mouth Disease (HFMD) (Brown et al., 1999; Chang et 
al., 1999). Large scale outbreaks of HFMD caused by EV71 were reported in the Asia 
Pacific region over the last few years and have resulted in 41 deaths in Sarawak, 
Malaysia in 1997 (Lum et al., 1998), 78 deaths in Taiwan in 1998 (Ho et al., 1999), 4 
deaths in Singapore in 2000 (Ahmad, 2000), and 13 deaths in Sarawak, Malaysia in 2006 
(Ministry of Health, Malaysia).  Unlike CA16 which also causes HFMD, EV71 infections 
were often associated with severe neurological diseases, thus raising public concerns. 
 
In view of the laborious work and poor sensitivity in diagnosing EV71 by tissue 
culture followed by neutralization using polyclonal antisera, a much more rapid and 
specific method of detecting EV71 from clinical specimens is urgently required. 
Although conventional RT-PCR have been reported and were shown to be specific in 
detecting EV71 (Brown et al., 2000; Singh et al., 2002; Tsao et al., 2002; Nix et al., 
2006), the whole process was still not rapid enough in handling large outbreak situations. 
 
 The wider acceptance of real-time PCR has made it an attractive tool in 
diagnostic laboratories. Although there are studies which have reported the use of real-
time PCR for detection of enteroviruses (Read et al., 2001; Verstrepen et al. 2001; 
Nijhuis et al., 2002; Watkins-Riedel et al. 2002; Petitjean et al., 2006), the approaches 
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were targeted at the 5′UTR which is well conserved among enteroviruses but correlates 
poorly with serotype.  
 
In this study, single-tube real-time RT-PCR based on Hybridization probe and 
TaqMan probe chemistries were developed for direct and specific detection of EV71 
from clinical specimens within 1 to 2 hours. The primers and probes were designed to 
target the VP1 region that was conserved amongst EV71 isolates, but differs significantly 
from CA16. Equally high specificities and sensitivities were demonstrated by both the 
Hybridization probe and TaqMan probed-based chemistries in detecting EV71 directly 
from clinical specimens. In comparison between both chemistries, although the 
Hybridization probe-based chemistry provided an advantage of melting curve analysis, 
the assay was exclusive to LightCycler real-time PCR machine. In contrast, the TaqMan 
probe-based assay provided a higher versatility of being able to be applied across 
different real-time PCR platforms. The higher rate of detection, higher sensitivity and 
specificity by real-time RT-PCR clearly demonstrated the vast improvement to the 
diagnosing EV71 from clinical specimens as compared to the current diagnostic methods. 
 
To date, no effective antivirals have been developed against EV71 infections, and 
most deaths from HFMD caused by EV71 occurred within 24 hours when the children 
were admitted with complications associated with HFMD (Ho et al., 1999; Wang et al., 
2006). Another significant part of this study thus focused on development of potential 
antiviral agents against EV71. With the emergence of RNA interference (RNAi) as a 
potential therapeutic approach against infectious diseases, it was evaluated as a possible 
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strategy against EV71 infections in this research study. Two siRNA systems, the plasmid-
based shRNA expression system and synthetic 29-mer shRNAs were developed and 
showed high efficacies in inhibiting EV71 replication in the in vitro system, as shown by 
real-time RT-PCR, plaque assay and Western blot. In particular, the chemically 
synthesized 29-mer shRNAs were shown to be more potent than both plasmid-derived 
shRNAs and the chemically synthesized 19-mer siRNAs reported previously (Sim et al., 
2005). All the studies have shown that the siRNAs designed to target at the RNA 
dependent RNA polymerase, 3Dpol region of EV71 were shown to be the most effective 
in inhibiting EV71 replication as compared to the 2C and 3Cpro regions of EV71.  
 
The efficacies of the siRNAs in protecting the mice from EV71 infections were 
then evaluated in murine model. Suckling mice (1 day old) were selected as the model in 
this study, since HFMD caused by EV71 affects mainly young children. This provided a 
better “mimic” model when evaluating the efficacies of the siRNAs in inhibiting EV71 
infections. The results showed that both the chemically synthesized 19-mer siRNAs and 
the psiStrike plasmids expressing shRNAs were effective in protecting the suckling mice 
from EV71 infections. The treated mice did not exhibit hind limb paralysis and weight 
loss, as what was observed in untreated infected-mice. EV71 replication was significantly 
reduced as shown by real-time RT-PCR and Western blot. However, despite 
demonstrating a more enhanced potency in the in vitro system, the synthetic 29-mer 
shRNAs failed to protect the mice from EV71 infections. Nevertheless, the RNAi 




   
In many positive-stranded RNA viruses such as EV71, the frequency of RNA 
recombination is relatively high and has a significant impact on virus evolution (King et 
al., 1982; Nagy et al., 1997). This will in turn affect the efficacies of the developed real-
time RT-PCR and the RNAi, in which both are nucleotide sequence dependent. In the last 
part of the study, the complete sequences of both the VP1 (891bp) and 3Dpol (1386bp) 
sequences of the EV71 strains isolated in the Asia Pacific region from 1995 to 2005 were 
obtained from the GenBank and the evolutionary rates of both the VP1 and the 3Dpol 
regions were calculated. The results showed that the evolutionary rate in the VP1 region 
was higher than the 3Dpol region, indicating high conservation in the 3Dpol region.  
However, the evolutionary rate of the VP1 region in this study was lower than the 
evolutionary rate reported by Brown et al. (1999) (1.8 X 10-3 vs 1.35 X 10-2 substitutions 
per nucleotide), suggesting that the evolution rate of EV71 strains isolated from 1995 to 
2005 was not as rapid as compared to the EV71 strains isolated from 1970 to 1998 
reported by Brown et al. (1999). In assessing the implications of the evolutionary rate on 
the efficacy of the real-time RT-PCR, since a lower evolutionary rate of the VP1 gene 
over the last few years was shown in this study, there is a higher confidence in detecting 
EV71 by real-time RT-PCR, as there is lower chances for the real-time RT-PCR in 
failing to specifically detect EV71 which could occur as a result of mutations. On the 
other hand, the low evolutionary rate of the 3Dpol region allows RNAi approach to be 
applied effectively, as there is minimal chance of mutations which can potentially affect 




   
In view of the rising concerns over EV71 infections with resulting fatalities in the 
large scale outbreaks in the Asia Pacific region, the results obtained in this study 
demonstrated an improvement in rapid and differential diagnosis of EV71 directly from 
clinical specimens, as well as development of a potential antiviral therapeutic agent 
against EV71 infections. The surveillance of the evolutionary rate provided a greater 
confidence in evaluating the efficacies of the real-time RT-PCR and the RNAi, which 



















   
FUTURE DIRECTIONS 
  
Since RNAi has been shown to be effective against EV71 infections in the mice 
model, there is a possibility that RNAi strategy might prove to be an effective antiviral 
approach to treat patients with EV71 infections. However, in this study, the siRNAs were 
administered via intraperitoneal (i.p.) route which is not feasible in human context. Thus, 
alternatives such as intravenous (i.v.) or intramuscular (i.m.) routes might be more 
suitable and worth evaluating. In addition, considering the lacking of siRNAs stability in 
humans, modifying the chemical structures to improve their stability might prove to be 
more effective in protection against EV71 infections. This is especially true in human 
model which have much more complex immune systems. Since cynomolgus monkeys 
have been shown to be susceptible to EV71 infections and represent a good non-human 
primate model for EV71 study (Nagata et al., 2002), it is worth evaluating the RNAi 
efficacy in treating EV71-infected cynomolgus monkeys prior to application in human 
clinical trials.  
In this study, the chemically synthesized 29-mer shRNAs failed to protect the 
suckling mice from EV71 infections despite showing higher potency and efficacy in 
vitro. It was postulated that the suckling mice lack certain mechanism or cellular proteins 
which facilitate the delivery of the 29-mer shRNAs to the Dicer to be processed into the 
functional 19-mer siRNAs. Thus, biochemical analysis should be carried out to validate if 
the 29-mer shRNAs is processed into the functional 19-mer siRNAs by the Dicer. This 
could be carried out by mapping the Dicer cleavage using primer extension; the 29-mer 
shRNAs will first be delivered into the intestinal cells, followed by Myc-tagged human 
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Argonaute proteins (Ago 1 and Ago 2) after 24 hours. After 24 hours, the intestinal cell 
will be harvested, lysed and immunoprecipitated using specific antibody against the Myc. 
Primer extension analysis will then be carried out on the immunoprecipitates using 
specific primer targeted at the 5’end of the 29-mer shRNAs. The controls will include 
intestinal cells treated with 19-mer siRNAs together with Myc-tagged Ago1 and Ago2, as 
well as intestinal cells treated with Myc-tagged Ago1 and Ago2 but without 29-mer 
shRNAs. Prior to primer extension, all the immunoprecipitates will be incubated with 
Dicer. If the 29-mer shRNAs were not cleaved by the Dicer into the functional 19-mer 
siRNAs, the extension products of the 29-mer shRNAs will be larger as compared to the 
functional 19-mer siRNAs. The control in which the intestinal cells were treated with 
Myc-tagged Ago1 and Ago2 but without 29-mer shRNAs will not yield extension 
products. As a positive control, a cell line treated with the 29-mer shRNAs of the same 
sequence, Myc-tagged Ago 1 and Ago2 and treated with Dicer will be included. If the 
Dicer is able to cleave the 29-mer shRNAs into the functional 19-mer siRNAs in the cell 
line but not in the mouse model, this can effectively show a lack of certain mechanism or 
proteins in the intestinal cells of the suckling mice to deliver the 29-mer shRNAs to the 
Dicer to be processed into the effective 19-mer siRNAs (Siolas et al., 2005).  
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Tryptone  10.0 g 
NaCl   10.0 g 
Yeast extract  5.0 g 




Luria-Bertoni (LB) agar: 
 
Tryptone  10.0 g 
NaCl   10.0 g 
Yeast extract  5.0 g 
Agar   15.0 g 
The mixture was made up to 1 litre with water. After autoclaving, the molten media was 
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Materials required for tissue culture 
 
 
10X Minimum essential medium (MEM) powder (Gibco BRL)
 
The powdered medium is supplemented with Earle’s salt, L-glutamate, non-essential 
amino acids, without sodium bicarbonate. The MEM medium was prepared by dissolving 
the MEM powder in 1L of sterile water (20oC to 30oC) with gentle stirring, and the media 
was sterilized by membrane filtration.  
 
 
Maintanence media for RD cells: 
 
Fetal calf serum (FCS)  5.0 ml 
HEPES buffer (1M) 2.0 ml 
Sodium Bicarbonate (7%) 1.5 ml 
Pencillin/Streptomycin (1X) 1.0 ml 
MEM (1X) 90.5 ml 
Total 100.0 ml 
 
 
Media for cell freezing: 
 
Growth media with 5% FCS 9.0 ml 
Dimethyl sulphoxide (DMSO) 1.0 ml 
Total 10.0 ml 
 
The media for cell freezing was freshly prepared before carrying out the procedure for 
cell freezing. DMSO was protected from light and stored at room temperature.  
 
 
Media for cell thawing: 
 
Fetal calf serum (FCS)  10.0 ml 
HEPES buffer (1M) 2.0 ml 
Sodium Bicarbonate (7%) 1.5 ml 
Pencillin/Streptomycin (1X) 1.0 ml 
MEM (1X) 85.5 ml 





  APPENDICES 









Fetal calf serum (FCS)  5.0 ml 
HEPES buffer (1M) 2.0 ml 
Sodium Bicarbonate (7%) 1.5 ml 
Pencillin/Streptomycin (1X) 1.0 ml 
MEM (2X) 40.5 ml 
Total 50.0 ml 
 
A final concentration of 1% w/v carboxymethylcellulose (CMC) was prepared by 
dissolving 2.0g of carboxymethylcellulose (CMC) powder in 50ml of sterile water. 
Autoclaving was carried out to aid in complete dissolving of the CMC powder in water. 
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Materials required for SDS-PAGE and Western blot 
 
 
4X SDS loading buffer: 
 
0.5M Tris HCl, pH 6.8 5.0 ml 
Glycerol (100%)  4.0 ml 
β-Mercapthanol  0.8 ml 
Bromophenol blue  0.04 g 
10% SDS   0.8 g 




Resolution and stacking gels: 
 
    10% Resolution gel (10 ml) 5% Stacking  gel (5 ml)
 
Distilled water    4.0 ml    3.4 ml   
30% Acrylamide mix   3.3 ml    830 ul 
1.5M Tris (pH 8.8)   2.5 ml    - 
1.0M Tris (pH 8.8)   -    630 ul 
10% SDS    100 ul    50 ul 
10% Ammonium persulphate  100 ul    50 ul 




1X Transfer buffer for western blot: 
 
Tris-HCl   3.03 g 
Glycine   1.44 g 
Methanol   200 ml 
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No. of wells 
showing 





















10-3 4/4 9 0 9/9 100 
10-4 3/4 5 1 5/6 83 
10-5 2/4 2 3 2/5 40 
10-6 0/4 0 7 0/7 0 
 
TCID50 was calculated using the Reed and Muech formula (Hsiung, 1994): 
 
1. The cumulative number of infected wells was obtained by adding all the wells 
which showed CPE at every dilution (e.g. at dilution 10-5, 2 wells showed CPE. 
At dilution 10-4, 3 wells showed CPE. Thus, the total number of wells which were 
showed CPE up to dilution factor 10-4  was 2 + 3 = 5) 
 
2. The cumulative number of wells which were not infected with the virus was 
obtained by subtracting the number of wells which showed CPE from the number 
of wells inoculated (e.g. at dilution 10-4, 1 well did not show CPE. At dilution 10-
5, 2 wells did not show CPE. Thus, the total number of wells which did not show 
CPE up to the dilution factor 10-5  was 1 + 2 = 3). 
 
3. The percentage of infectivity was calculated by dividing the total sum of the wells 
which showed CPE and those did not show CPE by the cumulative number of 
wells which showed CPE (e.g. at dilution 10-4, 5/5+1 = 0.83 = 83%). 
 
4. The proportionate distance between the two dilutions, 10-4 and 10-5 , where 50% 
lies: 
 
 Infectivity above 50% - 50%   83 - 50 
      =   = 0.7 
 Infectivity above 50 % - Infectivity   83 - 40 
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5. TCID50 end point calculation: 
The negative logarithm of the dilution factor which was the closet to 50% was -4. 
Thus, the TCID50 end point = -4.0 + (0.7) = -4.7.  Therefore, the log of TCID50 
end point or titre = 10-4.7. 
 
6. Interpretation of TCID50 titre: A virus suspension with a TCID50 of 10-4.7 per 0.1 
ml represents one TCID50: at such dilution, 50% of the cultures inoculated with 
the virus will be infected. A dilution of 10-2.7 will contain 100 TCID50 in a volume 
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APPENDIX VI 
Genetic distances of the 3Dpol gene based on pairwise comparison of the 1386bp 
nucleotide sequences of each of the 25 EV71 strains and the prototype BrCr as the 
reference strain. The genetic distance was calculated using the Kimura-Nei method 















































































AY794027 2000 0.26 
 
    
    
    
    
  APPENDICES 
   
    
    
    
SB2864-SAR-00 
 



























































  APPENDICES 
   
APPENDIX VII 
Genetic distances of the VP1 gene based on pairwise comparison of the 891bp nucleotide 
sequences of each of the 398 EV71 strains and the prototype BrCr as the reference strain. 


















1095-SYD-95 AY940110 1995 0.217 
 
2644-AUS-95 AF135949 1995 0.186 
 
2642-AUS-95 AF135948 1995 0.186 
 
2641-AUS-95 AF135947 1995 0.186 
 
2640-AUS-95 AF135946 1995 0.21 
 
1232-SYD-96 AY940111 1996 0.207 
 
0036-MAA-97 AY207641 1997 0.182 
 
0091-MAA-97 AY207649 1997 0.19 
 
0128-MAA-97 AY207647 1997 0.204 
 
0175-MAA-97 AY207640 1997 0.206 
 
0245-MAA-97 AY207639 1997 0.209 
 
0283-MAA-97 AY207638 1997 0.202 
 
03300-MAA-97 AY207613 1997 0.204 
 
0343-MAA-97 AY207637 1997 0.211 
 
03750-MAA-97 AY207615 1997 0.207 
 
03784-MAA-97 AY207612 1997 0.214 
 
03907-MAA-97 AY207611 1997 0.206 
 
0414-MAA-97 AY207646 1997 0.202 
 
04716-MAA-97 AY207636 1997 0.208 
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0618-MAA-97 AF135909 1997 0.206 
 
0632-MAA-97 AF135910 1997 0.214 
 
0731-MAA-97 AF135911 1997 0.186 
 
0754-MAA-97 AF135912 1997 0.206 
 
0770-MAA-97 AF135913 1997 0.214 
 
0870-MAA-97 AY207614 1997 0.207 
 
0884-MAA-97 AY207645 1997 0.183 
 
0897-MAA-97 AY207644 1997 0.212 
 
0898-MAA-97 AY207643 1997 0.208 
 
0899-MAA-97 AY207642 1997 0.214 
 
0903-MAA-97 AY207648 1997 0.18 
 
1102-MAA-97 AF190559 1997 0.204 
 
1103-MAA-97 AF190560 1997 0.206 
 
1105-MAA-97 AF190561 1997 0.21 
 
1106-MAA-97 AF190562 1997 0.207 
 
1107-MAA-97 AF190563 1997 0.211 
 
1108-MAA-97 AF190564 1997 0.208 
 
1109-MAA-97 AF190565 1997 0.206 
 
1110-MAA-97 AF190566 1997 0.208 
 
1112-MAA-97 AF190567 1997 0.208 
 
1113-MAA-97 AF190568 1997 0.211 
 
1424-SIN-97 AF286490 1997 0.209 
 
2286-TX-97 AF135941 1997 0.204 
 
2289-MAA-97 AF135914 1997 0.211 
 
2294-MAA-97 AF190569 1997 0.213 
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2303-MAA-97 AF135917 1997 0.213 
 
2304-MAA-97 AF135918 1997 0.204 
 
2305-MAA-97 AF135919 1997 0.204 
 
2306-MAA-97 AF135920 1997 0.193 
 
2325-MAA-97 AF135922 1997 0.193 
 
2331-MAA-97 AF135923 1997 0.189 
 
2332-MAA-97 AF135924 1997 0.209 
 
2333-MAA-97 AF135925 1997 0.204 
 
2334-MAA-97 AF190570 1997 0.204 
 
2335-MAA-97 AF135926 1997 0.208 
 
2336-MAA-97 AF135927 1997 0.209 
 
2337-MAA-97 AF135928 1997 0.206 
 
2355-OK-97 AF135942 1997 0.208 
 
2381-MA-97 AF135943 1997 0.209 
 
7202-MAA-97 AF190571 1997 0.206 
 
7204-MAA-97 AF135929 1997 0.206 
 
7208-MAA-97 AF135930 1997 0.208 
 
97-56-CHN-97 AB115494 1997 0.209 
 
C7/Osaka/Japan-97 AB059818 1997 0.206 
 
MY104/9/SAR/97 AF376072 1997 0.209 
 
MY16/1/SAR/97 AF376073 1997 0.206 
 
MY21/2/SAR/97 AF376074 1997 0.211 
 
MY6/2/SAR/97 AF376075 1997 0.211 
 
MY755/3/SAR/97 AF376076 1997 0.206 
 
MY821/3/SAR/97 AF376077 1997 0.211 
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1095/Japan-97 AB059817 1997 0.213 
 
Tainan/6092/98 AF304459 1998 0.182 
 
Tainan/4643/98 AF304458 1998 0.184 
 
Tainan/5746/98 AF304457 1998 0.186 
 
AFP98111263-TW DQ841972 1998 0.214 
 
E981085-TW DQ841962 1998 0.182 
 
E98815-TW DQ841961 1998 0.182 
 
E98683-TW DQ841960 1998 0.187 
 
E98551-TW DQ841959 1998 0.181 
 
E98143-TW DQ841958 1998 0.182 
 
E98083-TW DQ841957 1998 0.181 
 
E98046-TW DQ841956 1998 0.182 
 
E98014-TW DQ841955 1998 0.187 
 
AFP98111207-TW DQ841954 1998 0.182 
 
AFP98111341-TW DQ841953 1998 0.204 
 
0964-SYD-98 AY940113 1998 0.193 
 
1181-SYD-98 AY940112 1998 0.193 
 
705-Yamagata-98 AB213615 1998 0.183 
 
671-Yamagata-98 AB213614 1998 0.183 
 
0557-MAA-98 AY207631 1998 0.211 
 
0808-MAA-98 AY207630 1998 0.209 
 
Germany/FS/98 AY079098 1998 0.204 
 
2731-TAI-98 AF286491 1998 0.204 
 
2732-TAI-98 AF286492 1998 0.184 
 
2733-TAI-98 AF286493 1998 0.184 
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2785-TAI-98 AF286496 1998 0.181 
 
2848-TAI-98 AF286497 1998 0.182 
 
2849-TAI-98 AF286498 1998 0.181 
 
2850-TAI-98 AF286499 1998 0.184 
 
2851-TAI-98 AF286500 1998 0.186 
 
2852-TAI-98 AF286501 1998 0.186 
 
2861-TAI-98 AF286502 1998 0.179 
 
2862-TAI-98 AF286503 1998 0.184 
 
2864-TAI-98 AF286504 1998 0.184 
 
2865-TAI-98 AF286505 1998 0.182 
 
2867-TAI-98 AF286506 1998 0.211 
 
2868-TAI-98 AF286507 1998 0.182 
 
2871-TAI-98 AF286508 1998 0.182 
 
2872-TAI-98 AF286509 1998 0.184 
 
2873-TAI-98 AF286510 1998 0.186 
 
2878-TAI-98 AF286511 1998 0.184 
 
2885-TAI-98 AF286512 1998 0.179 
 
2892-TAI-98 AF286513 1998 0.182 
 
2894-TAI-98 AF286514 1998 0.182 
 
2895-TAI-98 AF286515 1998 0.186 
 
2896-TAI-98 AF286516 1998 0.179 
 
2897-TAI-98 AF286517 1998 0.176 
 
2899-TAI-98 AF286518 1998 0.182 
 
2901-TAI-98 AF286519 1998 0.215 
 
2906-TAI-98 AF286520 1998 0.187 
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2913-TAI-98 AF286523 1998 0.215 
 
2914-TAI-98 AF286524 1998 0.184 
 
2915-TAI-98 AF286525 1998 0.186 
 
2916-TAI-98 AF286526 1998 0.186 
 
2917-TAI-98 AF286527 1998 0.184 
 
2943-TAI-98 AF286528 1998 0.186 
 
2945-TAI-98 AF286529 1998 0.182 
 
2949-TAI-98 AF286530 1998 0.186 
 
3254-TAI-98 AF286531 1998 0.187 
 
1423-SIN-98 AF286489 1998 0.206 
 
3526/SIN/98 AF376116 1998 0.204 
 
3799/SIN/98 AF376117 1998 0.207 
 
4284/SIN/98 AF376118 1998 0.206 
 
4350/SIN/98 AF376119 1998 0.222 
 
4575/SIN/98 AF376120 1998 0.206 
 
S10822/SAR/98 AF376079 1998 0.205 
 
S10862/SAR/98 AF376080 1998 0.207 
 
S11051/SAR/98 AF376081 1998 0.207 
 
1114-MAA-98 AF190572 1998 0.211 
 
1115-MAA-98 AF190573 1998 0.21 
 
1116-MAA-98 AF190574 1998 0.209 
 
1117-MAA-98 AF190575 1998 0.206 
 
1118-MAA-98 AF190576 1998 0.211 
 
2814-MO-98 AF135950 1998 0.191 
 
E99254-TW DQ841978 1999 0.223 
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E99216-TW DQ841975 1999 0.224 
 
E99214-TW DQ841974 1999 0.226 
 
E990005-TW DQ841963 1999 0.184 
 
1002-Yamagata-99 AB213619 1999 0.191 
 
983-Yamagata-99 AB213618 1999 0.199 
 
957-Yamagata-99 AB213617 1999 0.189 
 
932-Yamagata-99 AB213616 1999 0.187 
 
73442-PA-99 AY278249 1999 0.202 
 
0615-MAA-99 AY207652 1999 0.206 
 
0627-MAA-99 AY207651 1999 0.216 
 
0749-MAA-99 AY207653 1999 0.232 
 
0838-MAA-99 AY207629 1999 0.231 
 
0919-MAA-99 AY207650 1999 0.207 
 
9F/AUS/6/99 AF376110 1999 0.194 
 
8M/AUS/6/99 AF376109 1999 0.194 
 
7F/AUS/6/99 AY794030 1999 0.197 
 
6F/AUS/6/99 DQ281846 1999 0.194 
 
5M/AUS/5/99 AF376106 1999 0.196 
 
4F/AUS/4/99 AF376105 1999 0.212 
 
3F/AUS/3/99 AF376104 1999 0.214 
 
2M/AUS/3/99 AF376103 1999 0.194 
 
27M/AUS/2/99 AF376102 1999 0.189 
 
26M/AUS/2/99 AF376101 1999 0.207 
 
25M/AUS/2/99 AF376100 1999 0.203 
 
20F/AUS/6/99 AF376099 1999 0.207 
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18F/AUS/6/99 AF376095 1999 0.201 
 
17M/AUS/5/99 AF376094 1999 0.207 
 
16F/AUS/6/99 AF376093 1999 0.211 
 
15M/AUS/8/99 AF376092 1999 0.197 
 
14F/AUS/9/99 AF376091 1999 0.207 
 
12F/AUS/6/99 AF376090 1999 0.211 
 
11F/AUS/6/99 AF376089 1999 0.207 
 
10M/AUS/6/99 AF376088 1999 0.208 
 
31214-AZ-99 AF190577 1999 0.193 
 
5865/sin/000009 AF316321 2000 0.224 
 
5666/sin/002209  AF352027 2000 0.224 
 
E2000005-TW DQ841981 2000 0.227 
 
E2000260-TW DQ841980 2000 0.231 
 
E2000094-TW DQ841979 2000 0.224 
 
2266-SYD-00 AY722910 2000 0.225 
 
9918-SYD-00 AY940106 2000 0.225 
 
9924-SYD-00 AY940108 2000 0.223 
 
9929-SYD-00 AY940109 2000 0.226 
 
1084-Yamagata-00 AB213626 2000 0.223 
 
1067-Yamagata-00 AB213625 2000 0.218 
 
980-Yamagata-00 AB213624 2000 0.221 
 
962-Yamagata-00 AB213623 2000 0.218 
 
786-Yamagata-00 AB213622 2000 0.221 
 
739-Yamagata-00 AB213621 2000 0.223 
 
738-Yamagata-00 AB213620 2000 0.221 
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F2-CHN-00 AB115491 2000 0.201 
 
H25-CHN-00 AB115492 2000 0.206 
 
H26-CHN-00 AB115493 2000 0.206 
 
05716-MAA-00 AY207635 2000 0.22 
 
0774-MAA-00 AY207634 2000 0.222 
 
0815-MAA-00 AY207633 2000 0.211 
 
0832-MAA-00 AY207632 2000 0.218 
 
0467-MAA-00 AY207628 2000 0.224 
 
0431-MAA-00 AY207627 2000 0.231 
 
0389-MAA-00 AY207626 2000 0.217 
 
0113-MAA-00 AY207625 2000 0.217 
 
0066-MAA-00 AY207624 2000 0.226 
 
0042-MAA-00 AY207623 2000 0.227 
 
0948-MAA-00 AY207622 2000 0.212 
 
0937-MAA-00 AY207621 2000 0.212 
 
0915-MAA-00 AY207620 2000 0.21 
 
0836-MAA-00 AY207619 2000 0.212 
 
0807-MAA-00 AY207618 2000 0.217 
 
0778-MAA-00 AY207617 2000 0.229 
 
5511/SIN/00 AF376121 2000 0.224 
 
5536/SIN/00 AF376122 2000 0.224 
 
5546/SIN/00 AF376123 2000 0.222 
 
5556/SIN/00 AF376124 2000 0.224 
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5869/SIN/00 AF376127 2000 0.225 
 
5881/SIN/00 AF376128 2000 0.222 
 
5926/SIN/00 AF376129 2000 0.211 
 
1M/AUS/12/00 AF376098 2000 0.206 
 
S40221/SAR/00 AF376087 2000 0.209 
 
S40201/SAR/00 AF376086 2000 0.232 
 
S2861/SAR/00 AF376085 2000 0.227 
 
S21082/SAR/00 AF376084 2000 0.234 
 
S12502/SAR/00 AF376083 2000 0.226 
 
S12172/SAR/00 AF376082 2000 0.23 
 
CN9502/SAR/00 AF376071 2000 0.226 
 
CN0942/SAR/00 AF376070 2000 0.235 
 
SB0635/SAR/00 AF376069 2000 0.229 
 
CN062334/SAR/00 AF376068 2000 0.234 
 
CN04104/SAR/00 AF376067 2000 0.231 
 
SB2864/SAR/00 AF376066 2000 0.228 
 
SB1647/SAR/00 AF376065 2000 0.239 
 
SB1191/SAR/00 AF376064 2000 0.23 
 
AFP2001529-TW DQ841988 2001 0.22 
 
AFP2001009-TW DQ841987 2001 0.221 
 
AFP2001477-TW DQ841986 2001 0.221 
 
AFP2001474-TW DQ841985 2001 0.221 
 
AFP2001480-TW DQ841984 2001 0.219 
 
E20001220-TW DQ841983 2001 0.223 
 
2287-SYD-01 AY722915 2001 0.225 
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9901-SYD-01 AY940100 2001 0.224 
 
9902-SYD-01 AY940101 2001 0.224 
 
9906-SYD-01 AY940102 2001 0.225 
 
9911-SYD-01 AY940103 2001 0.222 
 
9912-SYD-01 AY940104 2001 0.225 
 
9917-SYD-01 AY940105 2001 0.225 
 
9923-SYD-01 AY940107 2001 0.227 
 
1585-Yamagata-01 AB177812 2001 0.201 
 
1695-Yamagata-01 AB213627 2001 0.202 
 
1814-Yamagata-01 AB213628 2001 0.201 
 
shzh01-4 AY895134 2001 0.22 
 
shzh01-3 AY895132 2001 0.209 
 
shzh01-8 AY895091 2001 0.2 
 
2027/SIN/01 AF376111 2001 0.226 
 
2120/SIN/01 AF376112 2001 0.227 
 
2123/SIN/01 AF376113 2001 0.227 
 
2267/SIN/01 AF376114 2001 0.22 
 
2386/SIN/01 AF376115 2001 0.225 
 
E2003033-TW DQ841991 2002 0.223 
 
E2002117-TW DQ841990 2002 0.224 
 
E2002042-TW DQ841989 2002 0.221 
 
2779-Yamagata-02 AB213629 2002 0.195 
 
shzh02-62 AY895136 2002 0.213 
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2786-SIN-02 AY258321 2002 0.222 
 
3742-SIN-02 AY258320 2002 0.227 
 
4381-SIN-02 AY258319 2002 0.218 
 
5026-SIN-02 AY258318 2002 0.215 
 
S18191/SAR/02 AY189154 2002 0.222 
 
KOR-EV71-01 AY125966 2002 0.226 
 
KOR-EV71-02 AY125967 2002 0.221 
 
KOR-EV71-03 AY125968 2002 0.223 
 
KOR-EV71-05 AY125969 2002 0.221 
 
KOR-EV71-06 AY125970 2002 0.223 
 
KOR-EV71-07 AY125971 2002 0.223 
 
KOR-EV71-08 AY125972 2002 0.225 
 
KOR-EV71-09 AY125973 2002 0.225 
 
KOR-EV71-10 AY125974 2002 0.223 
 
KOR-EV71-11 AY125975 2002 0.22 
 
KOR-EV71-13 AY125976 2002 0.225 
 
100-Yamagata-03 AB177814 2003 0.197 
 
1144-Yamagata-03 AB213635 2003 0.209 
 
1268-Yamagata-03 AB213636 2003 0.223 
 
1469-Yamagata-03 AB213637 2003 0.224 
 
1530-Yamagata-03 AB213638 2003 0.216 
 
1716-Yamagata-03 AB213639 2003 0.218 
 
1725-Yamagata-03 AB213640 2003 0.211 
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2321-Yamagata-03 AB213645 2003 0.221 
 
2399-Yamagata-03 AB213646 2003 0.221 
 
2419-Yamagata-03 AB213647 2003 0.221 
 
2542-Yamagata-03 AB177815 2003 0.2 
 
2716-Yamagata-03 AB177816 2003 0.194 
 
2933-Yamagata-03 AB213648 2003 0.194 
 
2934-Yamagata-03 AB213649 2003 0.198 
 
2972-Yamagata-03 AB213650 2003 0.196 
 
452-Yamagata-03 AB213630 2003 0.195 
 
638-Yamagata-03 AB213631 2003 0.193 
 
75-Yamagata-03 AB177813 2003 0.195 
 
804/NO/03 DQ452074 2003 0.198 
 
828-Yamagata-03 AB213632 2003 0.197 
 
944-Yamagata-03 AB213633 2003 0.196 
 
946-Yamagata-03 AB213634 2003 0.196 
 
AFP2003163-TW DQ841992 2003 0.198 
 
AFP2003194-TW DQ841993 2003 0.196 
 
CN30014-SAR-03 AY258317 2003 0.196 
 
CN30552-SAR-03 AY258316 2003 0.196 
 
CQ03-1 AY547501 2003 0.198 
 
S110031-SAR-03 AY258307 2003 0.225 
 
S110101-SAR-03 AY258306 2003 0.221 
 
S110121-SAR-03 AY258305 2003 0.197 
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S19691-SAR-03 AY258315 2003 0.209 
 
S19731-SAR-03 AY258314 2003 0.209 
 
S19741-SAR-03 AY258313 2003 0.193 
 
S19761-SAR-03 AY258312 2003 0.188 
 
S19791-SAR-03 AY258311 2003 0.193 
 
S19841-SAR-03 AY258310 2003 0.191 
 
S19871-SAR-03 AY258309 2003 0.188 
 
S23141-SAR-03 AY258308 2003 0.193 
 
SB10712-SAR-03 AY905550 2003 0.203 
 
SB11977-SAR-03 AY905549 2003 0.219 
 
SB12007-SAR-03 AY905548 2003 0.217 
 
SB12278-SAR-03 AY905547 2003 0.223 
 
SB12282-SAR-03 AY905546 2003 0.22 
 
SB12869-SAR-03 AY905545 2003 0.213 
 
SB9465-SAR-03 AY258302 2003 0.223 
 
SB9508-SAR-03 AY258301 2003 0.216 
 
SB9522-SAR-03 AY258300 2003 0.213 
 
SB9533-SAR-03 AY258299 2003 0.215 
 
SB9564-SAR-03 AY258298 2003 0.216 
 
SB9579-SAR-03 AY258297 2003 0.215 
 
SB9582-SAR-03 AY258296 2003 0.213 
 
SB9604-SAR-03 AY258295 2003 0.214 
 
SB9869-SAR-03 AY258294 2003 0.216 
 
SHZH03 AY465356 2003 0.213 
 
shzh03-105 AY895133 2003 0.217 
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ZJ-CHN-1-03 AY905614 2003 0.218 
 
ZJ-CHN-2-03 AY905615 2003 0.219 
 
ZJ-CHN-3-03 AY905616 2003 0.219 
 
ZJ-CHN-4-03 AY905617 2003 0.217 
 
ZJ-CHN-5-03 AY905618 2003 0.219 
 
ZJ-CHN-6-03 AY905619 2003 0.226 
 
E20041623-TW DQ841966 2004 0.196 
 
E2004912-TW DQ841965 2004 0.199 
 
E2004104-TW DQ841964 2004 0.199 
 
shzh04-38 AY895145 2004 0.204 
 
shzh04-12 AY895144 2004 0.198 
 
shzh04-20 AY895143 2004 0.209 
 
shzh04-3 AY895142 2004 0.209 
 
shzh04-23 AY895141 2004 0.212 
 
shzh04-J39 AY895140 2004 0.208 
 
shzh04-2 AY895139 2004 0.211 
 
shzh04-J40 AY895137 2004 0.208 
 
shzh04-J42 AY895131 2004 0.213 
 
shzh04-J38 AY895129 2004 0.208 
 
pinf7-54A DQ060149 2005 0.193 
 
E20051733-TW DQ841971 2005 0.196 
 
E200510989-TW DQ841970 2005 0.201 
 
E20051509-TW DQ841969 2005 0.2 
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Abstract
Enterovirus 71 (EV71) is one of the main causative agents of hand, foot and mouth disease (HFMD) in young children. Infections caused by
EV71 could lead to many complications, ranging from brainstem encephalitis to pulmonary oedema, resulting in high mortality. Thus, rapid
detection of the virus is required to enable measures to be implemented in preventing widespread transmission. Based on primers and probes
targeting at the VP1 region, a real-time reverse-transcriptase polymerase chain reaction (RT-PCR) hybridization probe assay was developed for
specific detection of EV71 from clinical specimens. Quantitative analysis showed that the assay was able to detect as low as 5 EV71 viral copies
and EV71 was detected from 46 of the 55 clinical specimens obtained from pediatric patients suffering from HFMD during the period from 2000
to 2003 in Singapore. This study showed that the single tube real-time RT-PCR assay developed in this study can be applied as a rapid and
sensitive method for specific detection of EV71 directly from clinical specimens.
q 2005 Elsevier Ltd. All rights reserved.
Keywords: Enterovirus 71 (EV71); Hand, foot and mouth disease (HFMD); Quantitative real-time hybridization probe assay; Rapid detection1. Introduction
Enteroviruses (EVs) constitute a genus within the Picorna-
viridae family. They are single (positive)-stranded RNA
viruses that comprise 68 serotypes, and can be subdivided
into echoviruses, polioviruses and non-assigned enterovirus 68
through 71 [1]. Among them, Enterovirus 71 (EV71) is the
main causative agent of hand, foot and mouth disease (HFMD)
in children and infants. It was first discovered and isolated from
the stool of an infant who was suffering from encephalitis in
California in 1969 [2]. Australia was the first country with an
epidemic of aseptic meningitis caused by EV71 between 1972
and 1973. Since then, small-scale epidemics were also reported
in Sweden [3] and Japan [4]. However, large outbreaks with
significant fatalities in Malaysia [5], Taiwan [6] and Singapore0890-8508/$ - see front matter q 2005 Elsevier Ltd. All rights reserved.
doi:10.1016/j.mcp.2005.11.003
* Corresponding author. Present address: School of Biomedical Sciences,
Curtin University of Technology, Bentley, WA 6845, Australia. Tel.: C65
6874 3674; fax: C65 6776 6872.
E-mail address: micpohcl@nus.edu.sg (C.L. Poh).[7] in recent years have raised public concerns about the
virulence of the virus.
Clinically, HFMD caused by EV71 is indistinguishable
from that caused by Coxsackievirus A16 (CA16), another main
causative agent. These two enterovirus serotypes are closely
related genetically, sharing 64% nucleotide and 72% amino
acid homologies [8]. However, infection by EV71 is more
often associated with severe neurological diseases like aseptic
meningitis, brainstem and cerebellar encephalitis which are not
observed in HFMD cases caused by CA16 [9]. Since the
clinical symptoms of EV71- and CA16- associated HFMD are
quite similar, diagnosis depends largely on virus isolation and
serotyping. The classical diagnostic method for enterovirus
identification, which is also known as the ‘gold standard’, is by
cell culture and followed by neutralization tests with serotype-
specific antisera. However, this requires 1–2 weeks of growth
and antigenic typing could be hindered by non-neutralizable
virus due to aggregation, antigenic drifts, or the presence of
multiple viruses in the specimen. Thus, this method has little
clinical significance. The development of molecular methods
such as conventional polymerase chain reaction (PCR)
techniques has contributed significantly to laboratory diagnosis
of virus infection in terms of sensitivity, specificity and rate ofMolecular and Cellular Probes 20 (2006) 135–140www.elsevier.com/locate/ymcpr
E.L. Tan et al. / Molecular and Cellular Probes 20 (2006) 135–140136detection in comparison to cell culture. Using reverse-
transcription PCR (RT-PCR) strategy, specific detection of
EV71 in clinical samples had been reported [10,11] and proved
to be more sensitive than the cell culture method [11].
However, the two-step RT-PCR process is time-consuming
and also increases the risk of cross-contamination. In addition,
the speed of detection which is based on conventional RT-PCR
during outbreak situations could be a limiting factor.
In recent years, real-time PCR has gained wider acceptance
for viral diagnosis due to the speed of detection, higher
sensitivity, reduced risk of carry-over contamination and real
time monitoring of the amplification process through changes
in fluorescence emission [12]. Previous studies have shown that
enteroviruses could be differentiated from viruses such as VZV,
poliovirus and HSV using real-time PCR SYBR Green I based
[13] and TaqMan probe-based assays [14]. However, with the
increased concerns on neurovirulence caused by EV71, there is
a need for a rapid and highly specific method to distinguish this
virus from other enteroviruses such as CA16, CA5, CA9 and
Echovirus 7 (Echo 7) which are also common causative agents
of HFMD. In this study, we developed a real-time PCR
hybridization probe-based assay for specific detection of EV71
using the LightCyclerw real-time PCR system (Roche
Molecular Biochemicals, Mannheim, Germany).2. Materials and methods
2.1. Virus strains
A neurovirulent EV71 strain, 7423/MS/87 and a CA16 strain
(CA16-G-10) were gifts from DrM.A. Pallansch, CDC, Atlanta,
USA. Two Singapore strains, the fatal 5865/SIN/00009 strain
(designated as Strain 41) and the non-fatal 5666/SIN/002209
strain (designated as Strain 10)were isolated frompatients during
the outbreak in October 2000 and cultivated in tissue cultures. A
total of 55 clinical specimens obtained from pediatric patients
suffering from HFMD during the period from 2000 to 2003 in
Singapore were also included in this study. Other enterovirus
isolates analyzed included CA24, Coxsackieviruses B1 (CB1),
CB2, CB3, CB4, CB5 and Echoviruses 4,6,7,18,19,24,30.2.2. Sample processing and storage
Out of the 55 clinical specimens used in this study, 48 were
obtained from National University Hospital, Singapore, fromTable 1
Primers and probe sequences for real-time PCR hybridization probe assay




EvVP1-LCc LC Red 640-GCTGGCAGGGCCTGGG
a Nucleotide positions based on the alignment of the three enterovirus strains:Str
b Primers used in real-time PCR hybridization assay.
c Probes used in real-time PCR hybridization probe assay. EvVP1-FL was labeled w
5 0 end and phosphorylated at the 30 end.August to December 2001. The remaining seven clinical
specimens were obtained from K K Women’s and Children’s
Hospital from May 2003 to February 2004. The clinical
specimens included CSF, stool, rectal swabs, blood, throat
swabs and urine specimens. The CSF and urine specimens were
processed immediately upon receiving them.
A 10% stool suspension was made by adding 0.5 g of stool
(0.5 ml for fluid stools) to 5 ml of phosphate buffered saline at
pH 7.4. The suspension was then centrifuged at 13,000!g for
10 min and filtered. The filtrate was then subsequently
processed.
Blood samples were allowed to stand in a vertical position
for about 15–20 min. After centrifuging for 10 min at 13,000!
g, the serum was then aspirated and transferred to a clean
1.5 ml sterile eppendorf tube.2.3. RNA extraction
Viral RNA extraction was carried out using QIAampw Viral
RNA Mini Kit (Qiagen, Valencia, USA) according to the
manufacturer’s instruction. This kit was used for RNA
extractions. In brief, the specimens were first lysed with a
buffer and the RNA released would be bound to the membrane.
The bound RNA was washed twice with wash buffers to
remove any contaminating proteins and lipids. The RNA was
then eluted with an elution buffer (Qiagen, Valencia, USA).2.4. Design of EV71 primers and probes
The VP1 nucleotide sequences of 6 EV71 strains and 2
CA16 strains from the GenBank were analyzed. Using BLAST
(http://www.ncbi.nlm.nih.gov/BLAST) together with DNAS-
TAR program, a highly conserved VP1 region of EV71 strains
that differed from CA16 was defined. For the real-time RT-
PCR hybridization probe analysis, two primers (designated as
EvVP1F and EvVP1R) and two hybridization probes (desig-
nated as EvVP1-FL and EvVP1-LC) were designed. The
sequences are shown in Table 1.2.5. Real-time RT-PCR hybridization probe assay
The specificity of the real-time RT-PCR assay was analyzed
using the LightCycler (Roche Molecular Biochemicals,
Germany). The LightCycler RNA amplification hybridization





ain 41, 10 and 7423/MS/87.
ith fluorescein at the 3 0 end and EvVP1-LC was labeled with LC Red 640 at the
E.L. Tan et al. / Molecular and Cellular Probes 20 (2006) 135–140 137RT-PCR in glass capillaries using the LightCycler instrument.
The enzyme mix contains a mixture of reverse transcriptase
and ‘Faststart’ Taq Polymerase that allows reverse transcrip-
tion of RNA template and subsequent cDNA amplification.
The reaction mix in the hybridization probe kit also contains
reaction buffer and dNTP mix (dUTP instead of dTTP). Each
reaction was performed in a reaction capillary by mixing the
reagents, followed by spinning down the mixture briefly with
the help of a special LightCycler Centrifuge Adapter. Each
10 ul reaction contained 1.0 ml of RNA, 5 mM MgCl2, 0.5 mM
of the forward primer, 0.3 mM of reverse primer, 0.2 mM of
each hybridization probe, 2.0 ml RNA hybridization probe
amplification reaction solution, 0.2 ml enzyme mix and water.
cDNA was first synthesized from the RNA by reverse
transcription for 20 min at 95 8C and subsequently amplified
for 40 cycles at 95 8C for 35 s, 55 8C for 15 s and 72 8C for 9 s.
Melting curve analysis was also carried out after the PCR
reaction. A rapid thermal ramp to 95 8C was achieved for
complete denaturation of the PCR amplicons, followed by
hybridization at 60 8C for 10 s. A slow steady transition from
60 to 95 8C was then performed. Subsequently, a graph was
plotted using dF/dT against temperature which would show a
peak corresponding to the Tm of the PCR amplicon.2.6. Conventional semi-nested RT-PCR amplification
of VP1 region
Aset of primers,VP1F4 (50-GATAGAGTGGCAGATGTG
AT-30) and VP1R1 (50-AAC TTT CCA AGG GTA GTA ATG-
30)was alsodesignedbased on the conservedVP1 regionofEV71
that differed fromCA16.Using the primers VP1F4 andVP1R1, a
first-round PCR was carried out using a one step RT-PCR kit
(Qiagen, Valencia, USA). Each 50 ml reaction mixture contained
5.0 ml of RNA, 1! one-step RT-PCR buffer, 0.4 mM of each
dNTP, 0.6 mM of each primer, 2.0 ml of enzyme mix and water.
ThePCRreactionwas carriedout in a thermal cycler (GeneAmpw
PCR system 2400PE, Applied Biosystems, CA, USA) with theFig. 1. Detection of EV71 based on amplification of the VP1 region by real-tim
7423/MS/87) were tested against other enterovirus serotypes. Numbers 1–3 repr
amplification was observed for other enterovirus serotypes (Number 4). The negatifollowing steps: reverse transcription at 50 8C for 30 min,
followed by 35 cycles of denaturation at 95 8C for 1 min,
annealing at 55 8C for 30 s, extension at 72 8C for 2 min and a
final extension step at 72 8C for 7 min.
A second-round PCR was performed using the primers
EvVP1F and VP1R1. The second amplification was carried out
under the same conditions as the first. Agarose gel electro-
phoresis of the 867 bp amplified product was carried out in a
1.2% agarose gel prepared in 1!TBE buffer, and the PCR
products were visualized by UV illumination.2.7. Nucleotide sequence analysis
The purified products (amplicons) were cycle sequenced
using the ABI PRISM Big Dye Terminator cycle sequencing
ready reaction kit. DNA sequencing was performed using the
ABI PRISM 377 DNA sequencer (Applied Biosystems).
Homology searches were carried out using the BLAST
algorithm (http://www.ncbi.nlm.nih.gov/BLAST).2.8. Quantification of EV71
A standard was first generated by conventional PCR
amplification of a 204 bp VP1 fragment using the primers—
EvVP1F and EvVP1R. The PCR product was then cloned into
the pGEM-T easy vector (Promega, USA), orientated behind
the T7 promoter. The plasmid was then linearized by digestion
with SalI and was purified by phenol–chloroform extraction
and ethanol precipitation before being used for in vitro
transcription. RNA standards were synthesized in vitro by
using the T7 RNA Polymerase in vitro transcription kit
(Promega, USA) according to the manufacturer’s protocol.
After purification by phenol–chloroform extraction and ethanol
precipitation, the concentration of the RNA was determined
spectrophotometrically at 260 nm. A series of 10-fold dilutions
which yield viral copies ranging from 5!100 copies to 5!109
copies were prepared and analyzed.e PCR hybridization probe assay. Different EV71 strains (Strain 41, 10 and
esent the amplifications of strains 41, 10 and 7423/MS/87, respectively. No
ve control includes all reagents but no template RNA (Number 4).
Fig. 2. Hybridization probe melting curve analysis of the amplicons generated from three different EV71 viral isolates. The melting curves of strains 41, 10 and
7423/MS/87 were represented by Numbers 1–3, respectively. The Tm value of strain 7423/MS/87 was established to be 72.0 8C, while the Tm values of both strains
41 and 10 were observed at 71.5 8C.
Table 2
Detection of EV71 in viral isolates and clinical specimens based on real-time
PCR hybridization probe assay
Sample type No. of specimens Real-time PCR hybridization
probe assay
Positive Negative
Strain 41a 1 1 0
Strain 10a 1 1 0
Strain 7423/MS/87a 1 1 0
Clinical specimensb 55 46 9
a Viral isolates.
b Clinical specimens isolated from pediatric patients included stools, CSF,
blood, urine, rectal and throat swabs.
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3.1. Specificity of real-time RT-PCR hybridization probe assay
The specificity of the real-time RT-PCR assay developed in
this study for EV71 detection was investigated by testing
different EV71 strains (strains 41, 10 and 7423/MS/87) against
other enteroviruses which are also known to cause HFMD.
Amplifications of EV71 strains 41, 10 and 7423/MS/87 in a
single tube real time RT-PCR assay were observed, whereas all
other enteroviruses such as CA16, CA24, CB1 – CB5,
Echoviruses 4, 6, 7, 18, 19, 24 and 30 were not amplified
(Fig. 1). The 204 bp amplicons from the three EV71 strains
generated by real-time RT-PCR assays were sequenced and
found to correlate with the VP1 region of EV71 (98–100%
homology). Thus, the assay was shown to be specific for EV71
detection as they were able to differentiate EV71 from other
enteroviruses. The amplicons generated from the real-time RT-
PCR assay were also analyzed by melting curve analysis. The
Tm (melting temperature) of strain 7423/MS/87 was observed
to be 72.0 8C and the Tm of the other two EV71 strains (strains
41 and 10) were 71.5 8C, indicating that there are slight
differences in the nucleotide sequence of strain 7423/MS/87
when compared with strains 41 and 10 (Fig. 2).
A total of 55 clinical specimens were analyzed for the
presence of EV71 and the results are presented in Table 2. The
real-time RT-PCR assay was able to detect the presence of
EV71 in 46 out of the 55 clinical specimens. In order to verify
that the positive clinical specimens did contain EV71, the cell
culture method and a conventional semi-nested RT-PCR
amplification of the VP1 region of EV71 were carried out
with 20 representative clinical specimens that were positive
based on the real-time RT-PCR assay. For the cell culture
method, none of the 20 clinical specimens tested positive for
EV71. However, amplification of the VP1 region was observed
for the same 20 clinical specimens by the semi-nested
conventional RT-PCR, and DNA sequencing results showedthat the 867 bp PCR amplicon correlated highly with the VP1
region of EV71 (98–100% sequence homology; data not
shown).
No EV71 RNA was detected in nine clinical specimens by
the real-time RT-PCR hybridization probe assay. To determine
whether these specimens contained EV71, conventional semi-
nested RT-PCR was conducted with these nine clinical
specimens and no amplification of the VP1 region was
observed.3.2. Quantification of real-time PCR hybridization assay for
EV71
The sensitivity and reproducibility of the real-time RT-PCR
assay were assessed by repeated testing of the serially diluted
EV71 RNA in two independent experiments. The standard
curve was calculated by regression analysis of the Ct values
versus log10 of the standard viral copy number (Fig. 3). The
real-time RT-PCR hybridization probe assay was able to detect
EV71 RNA over a linear range of 5–5!109 copies. Statistical
analysis of the standard curves showed that there was a good
correlation coefficient (R2Z1.000) between the Ct value and
copy number, and the linearity was consistent for both
experiments.
Fig. 3. Quantification of real-time PCR hybridization probe assay for the detection of EV71. The standard curve was obtained by plotting the Ct values against
starting copy number. The coefficients (R2) and linear equations are as shown.
E.L. Tan et al. / Molecular and Cellular Probes 20 (2006) 135–140 1394. Discussion and conclusion
In this study, we have developed a new real-time RT-PCR
assay which allows rapid and specific detection of EV71
directly from clinical specimens. A previous study showed that
enteroviruses could be differentiated from other viruses based
on real-time PCR SYBR Green I melting curve analysis [13],
but detection based on SYBR Green I can be rather non-
specific as fluorescence is emitted from the fluorophore when it
is in association with any double-stranded DNA, including
primer–dimers or non-specific amplicons. In addition, the
approach employed a conventional nested PCR which was
coupled with a real-time PCR. By using a nested multiplex
PCR reaction using tissue culture isolates of different
enterovirus serotypes, Read et al. (2001) found that different
serotypes could be differentiated, as a specific Tm value was
observed for each serotype. However, the RT-PCR assay
developed was not evaluated for the ability to differentiate
various EV71 strains. Besides, this approach was not only time
consuming, requiring at least 8–9 h but also increased the likely
chance of false positives as a result of cross-contamination
between specimens due to an additional processing step. In a
separate study, a TaqMan probe real-time PCR was developed
using the ABI Prism 7700 Sequence Detection System
(Applied Biosystems, California, USA) to differentiate
enteroviruses from other genera under the Picornaviridae
family [14]. In both studies, the primers and the probe were
designed based on the 5 0-untranslated region (5 0UTR) of the
enterovirus genome which is highly conserved among
enteroviruses. However, molecular epidemiological studies
have shown that the diversity in this region did not correlate
well with enterovirus serotypes [15]. Thus, in both studies,
EV71 could not be differentiated effectively from other
enterovirus serotypes without DNA sequencing.
EV71 was the predominant serotype involved in the HFMD
outbreak in Singapore in October, 2000 which resulted inseveral fatalities [7]. A rapid and specific diagnosis of EV71
infection is thus important so as to prevent widespread
transmission and unnecessary antibiotic usage in outbreak
situations. In this study, since there was no amplification being
observed for the other enterovirus serotypes, the assay was
shown to be highly specific for EV71 detection from clinical
specimens. Besides, the whole procedure for detection of EV71
based on the real-timeRT-PCRassay could be completedwithin
2 h upon receiving the clinical specimens. This is in contrast to
the conventional semi-nested RT-PCR strategy developed by
Singh et al. (2002) [11],whereby the procedure for identification
of EV71 required at least 1–2 days and is not rapid enough for
investigations during outbreaks. Besides the specificity and
rapidity in detection, the real-time PCR assay was also shown to
be more sensitive than the cell culture method, as the assay was
able to detect EV71 at far lower concentrations. In the present
study, a detection rate of 100% was achieved based on the RT-
PCR hybridization probe assay in contrast to the cell culture
assay which failed to detect presence of EV71 in any of the 20
clinical specimens tested. This also supports the previous
findings of Singh et al. [11], in which the cell culture method
detected EV71 in only 20% of the tested clinical specimens. The
primers and probes were designed based on the VP1 region of
the EV71 genome as it is known to possess a high degree of
antigenic and genetic diversity that may be useful in
distinguishing between enterovirus serotypes [15].
In the melting curve analysis, since the two hybridization
probes are not hydrolyzed during amplification, the Light-
Cycler is able to monitor the fluorescence changes during the
denaturation of the probes from their templates. This allows
fluorescence melting curves to be generated and provide
significant information about the sequence that the probes bind
to. In this study, strain 7423/MS/87 demonstrated a slightly
higher Tm at 72.0 8C than the Tms of EV71 strains 41 and 10
(TmZ71.5 8C). The slight differences in their Tm values when
compared with strain 7423/MS/87 were likely due to mutations
E.L. Tan et al. / Molecular and Cellular Probes 20 (2006) 135–140140in their nucleotide sequences, since any mutation(s) in the viral
templates would have resulted in a decrease in Tm due to the
destabilization of the probe/target duplex [12]. The results from
this study showed that the real-time RT-PCR hybridization
probe-based approach can be used diagnostically to discrimi-
nate single nucleotide polymorphisms in the DNA templates.
Determination of the Tms from melting curve analysis of EV71
viral amplicons will be helpful in elucidating phylogenetic
relationships of the strains isolated in an outbreak or from
different outbreaks.
4.1. Semi-nested PCR for validation of EV71 RNA
from clinical specimens
The clinical specimenswhich tested positive based on the real-
timeRT-PCRhybridization probe assay could be regarded as true
positives forEV71, since the sequence analysis of the 867 bpVP1
PCR amplicons generated from a representative group of 20
clinical specimens correlated very well with the EV71 VP1
region. Similarly, the results showed that thePCRmethod ismore
sensitive than the traditional cell culturemethod, inwhich noneof
the same 20 clinical specimens tested positive. On the other hand,
no EV71 was detected in nine clinical specimens based on the
real-time PCR assay. The possible reasons could be either be due
to the low initial viral titre in the clinical specimens or they
contained other enteroviruses. Since none of them was amplified
by the conventional semi-nested PCR, it is highly likely that these
nine clinical specimens were true negatives, and contained other
enterovirus serotypes. The conventional semi-nested PCR
method was also shown to be a highly sensitive method for
detection of EV71 in this study, and the high sensitivity could be
attributed to further amplifications of the first round PCRproduct.
In conclusion, real-time PCR assay provides a rapid, highly
sensitive and specific detection of EV71 directly from clinical
specimens. The detection of EV71 can be obtained within
1–2 h upon receiving the clinical samples and thus allow better
management of patients with suspected HFMD infections.
Although EV71 and CA16 are closely related, the hybridiz-
ation probe assay developed in this study was able to
differentiate EV71 from CA16. This will be useful, especially
in HFMD outbreaks where rapid and specific diagnosis of
enterovirus serotypes is necessary.
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bstract
Enterovirus 71 (EV71) is the main causative agent of hand, foot, and mouth disease (HFMD) in young children. It has been associated with severe
eurological complications and has caused significant mortalities in large-scale outbreaks in Asia. In this study, we demonstrated an enhanced
ilencing of EV71 through the use of chemically synthesized 29-mer shRNAs. The 29-mer shRNAs were designed to target three highly conserved
egions of EV71 genome. Transfection of rhabdomyosarcoma (RD) cells with the 29-mer shRNAs significantly inhibited EV71 replication in a
ose-dependent manner as demonstrated by reduction of viral RNA, VP1 protein and plaque forming units. The inhibitory effects were more potent
nd were achieved at 10-fold lower concentrations when compared to 19-mer siRNAs reported previously [Sim, A.C.N., Luhur, A., Tan, T.M.C.,
how, V.T.K., Poh, C.L., 2005. RNA interference against Enterovirus 71 infection. Virology 341, 72–79]. The viral inhibitory effects lasted 72 h
ost-infection and there was no adverse off-target silencing effect. Gene silencing by 29-mer shRNAs targeted at the 3Dpol region (sh-3D) was
he most effective, achieving 91% viral inhibition. Further evaluation found that no enhanced inhibitory effects were observed when sh-3D was
otransfected with each of the other two candidates. This study showed an improvement in triggering RNAi using the more potent 29-mer shRNAs,
ndicating its therapeutic potential against EV71.
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. Introduction
Enterovirus 71 (EV71) belongs to the human Enterovirus
species of the Picornaviridae family. It is a positive single-
tranded RNA virus with a non-enveloped capsid and a genome
ize of 7411 bases. It was first discovered and isolated from the
tool of an infant who was suffering from encephalitis in Cali-
ornia in 1969 (Schmidt et al., 1974). EV71 infections manifest
ost frequently as hand, foot, and mouth disease (HFMD), a
ild childhood exanthem which mainly affects young children
<6 years of age), and is characterized by 3–4 days of fever,
evelopment of vesicular exanthema on the buccal mucosa,
ongue and gums. The clinical symptoms caused by EV71 are
ndistinguishable from Coxsackievirus A16 (CA16), another
ommon causative agent of HFMD. However, EV71 is more
ften associated with severe neurological diseases such as acute
∗ Corresponding author. Tel.: +65 6516 3674; fax: +65 6776 6872.
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accid paralysis, cerebellar encephalitis, aseptic meningitis and
ven death (Lum et al., 1998; McMinn et al., 2001). Significant
ortalities in recent HFMD outbreaks in the Asia Pacific region
ave raised public concerns about the virulence of EV71 (Ho
t al., 1999). The current use of antivirals such as pleconaril
as been shown to be effective for most enteroviruses but not
or EV71 (Robart et al., 1998; McMinn, 2002). Thus, there is a
eed to develop a specific antiviral therapy against EV71.
Over the last few years, RNA interference (RNAi) has
merged as a promising approach to develop potential thera-
eutic agents based on specific gene silencing. The siRNA is
rocessed by the RNase III-like enzyme known as the Dicer
nto smaller interfering RNAs (siRNAs) of 21–23 nucleotides.
he antisense strand of the siRNA will serve as the template and
nduce the formation of the RNA-induced silencing complexes
RISCs) which subsequently recognize and degrade comple-
entary target mRNAs (Fire et al., 1998). Majority of the studies
hich use RNAi strategies involve the use of 21 nucleotides
hich contain the 19-mer core sequences and 2d-TT at the 3′
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shRNAs) have enhanced potency and are more efficient than
9-mer siRNAs in silencing genes without inducing any inter-
eron response (Siolas et al., 2005). Therefore, the use of 29-mer
hRNAs may prove to be even more efficient as potential ther-
peutic agents against EV71 in comparison to the two different
orms of 19-mer siRNAs reported previously (Lu et al., 2004;
im et al., 2005). Lu et al. (2004) reported a plasmid-derived
hRNA system producing siRNAs which targeted the VP1 and
Dpol regions of the EV71 genome that were able to inhibit EV71
eplication in both HeLa and Vero cell lines. In a separate study,
hemically synthesized 19-mer siRNAs targeted at the 2C, 3C,
Dpol and 3′UTR regions of the EV71 genome have also shown
ignificant inhibition of EV71 replication in the RD cell line.
oth studies showed that siRNAs targeting the RNA-dependent
NA polymerase, 3Dpol were the most effective in inhibiting
V71 replication (Sim et al., 2005).
In this study, we demonstrated that the chemically synthe-
ized 29-mer shRNAs targeted at the 2C, 3Cpro, and 3Dpol
egions of the EV71 genome were more potent than the chem-
cally synthesized 19-mer siRNAs and the plasmid-derived
hRNAs in inhibiting EV71 replication in RD cells.
. Methods and materials
.1. Cell culture and virus strain
The EV71 strain isolated from a fatal case during the outbreak
n Singapore in October 2000, designated as 5865/SIN/00009
Genbank accession no. AF316321) was used in this study.
habdomyosarcoma (RD) cells were routinely grown in
inimum essential medium (Gibco, Boston, MA, USA) supple-
ented with 5% fetal calf serum, HEPES, 1% sodium pyruvate,
nd 1.5% sodium bicarbonate.
.2. Design and synthesis of double stranded 29-mer
hRNAs
The 29-nt double-stranded shRNAs were designed to tar-








Molecular weight: 20,519.3 g/mol
h-3C 5′-AGCUACUUUGCGAGUAUGCAAGGUGAGAU U
3′-UUUCGAUGAAACGCUCAUACGUUCCACUCUA
Molecular weight: 20,474.3 g/mol
h-3D 5′-AGAAAUUGGCUCGAAUUGUUUUAAUAUUA U
3′-UUUCUUUAACCGAGCUUAACAAAAUUAUAA
Molecular weight: 20,384.2 g/mol
cr 5′-AAAGAACCUUAAGACCUCGGUUAAUAUUA U
3′-UUUUUCUUGGAAUUCUGGAGCCAAUUAUAA
Molecular weight: 20,414.2 g/mol
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V71 and designated as sh-2C, sh-3C and sh-3D, respectively.
he design of the shRNAs was based on the general guide-
ines as described (Elbashir et al., 2001a,b). The sequences
ere subjected to BLAST search of the National Center for
iotechnology Information database to ensure that they target
he desired viral genes specifically. The shRNA oligonucleotides
ere synthesized with 3′-dUU extensions. A scrambled
equence (scr) with the same base composition as the sh-3D
as also used as a negative control. The sequences of the chemi-
ally synthesized siRNAs were listed in Table 1. For comparative
urpose, the chemically synthesized 19-mer siRNAs targeted at
Dpol region (designated as 19mer-3D) of EV71 reported previ-
usly (Sim et al., 2005) was included in this study. All the siRNA
ligonucleotides were synthesized by Dharmacon, USA.
.3. Transfection and infection
Transfection was carried out under optimal conditions.
riefly, RD cells (5 × 104) were seeded into each well of a 24-
ell plate and grown at 37 ◦C overnight. The growth medium in
ach well was then replaced with 500l of pre-warmed reduced-
erum medium, OPTI-MEM I (Gibco, Boston, MA, USA) for
nother 24 h. Upon reaching 80% confluency, the cells were
ransfected with complexes containing shRNAs and Lipofec-
amine 2000CD (Invitrogen Life Technologies, Carlsbad, CA).
fter 48 h, each well was infected with EV71 at an MOI of 10
or 1 h. The cells were then overlaid with the growth medium
nd incubated at 37 ◦C in 5% CO2. At different time points post-
nfection, cell lysates and cell supernatants were collected and
tored at −80 ◦C for further studies. To evaluate the therapeutic
otentials of the 29-mer shRNAs, the RD cells were infected
ith EV71 (MOI of 10) and at each hourly interval (up to 5 h)
fter infection, the RD cells were then transfected with 29-mer
hRNAs..4. SDS-PAGE and Western blot
RD cells were grown in wells of a six-well plate and trans-
ection was performed according to the experimental set up
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s described. At 24 h post-infection, the cells were harvested
or determination of total proteins. The cells were first lysed
sing 200l of CelLytic M Cell Lysis Reagent (Sigma, USA).
n aliquot of 20l of each lysate was electrophoresed in a
enaturing 10% polyacrylamide gel. Western blotting was then
erformed following standard procedures. The detection pro-
edure was based on the chromogenic method as described
reviously using EV71 VP1 monoclonal antibody (Chemicon
nternational, USA), the anti-PKR antibody (Sigma, USA), the
nti-phospho PKR antibody (Sigma, USA) and the -actin anti-
ody (Sigma, USA) (Sim et al., 2005).
.5. Viral plaque assay
To determine the viral infectivity of EV71 after siRNA treat-
ent, plaque assays were carried out after the transfection
rotocol. After 24 h of transfection, 1% (w/v) carboxymethyl-
ellulose (CMC) in 2× growth medium was layered onto the
nfected cell monolayer. The plates were then incubated at 37 ◦C
or 48 h. Plaques of EV71 were observed by fixing with 20% for-
alin in PBS and staining with 1% crystal violet for 30 min at
oom temperature.
.6. Real-time reverse transcription (RT) PCR
At 48 h post-infection, total RNA was extracted from each
ell using TRIzol LS reagent (Invitrogen Life Technologies,
arlsbad, CA), according to the manufacturer’s instructions. The
fficiency of the various shRNAs in inhibiting EV71 replica-
ion were then analysed using real-time RT-PCR Hybridization
robe-based assay for the detection of EV71 RNA as described
reviously (Tan et al., 2006). Briefly, the real-time RT-PCR
ybridization probe assay was carried out using the LightCy-
ler real-time machine and the LightCycler RNA Amplification
ybridization Probe kit (Roche Molecular Biochemicals, Ger-
any). Each reaction was performed in a reaction capillary tube
y mixing the reagents, followed by spinning down the mixture
riefly with the help of a special LightCycler centrifuge adapter.
ach 10l reaction contained 1.0l of RNA, 5 mM MgCl2,
.5M of the forward primer, 0.3M of the reverse primer,
.2M of each hybridization probe, 2.0l hybridization probe
eaction mix, 0.2l enzyme mix and water.
The cDNA was first synthesized from the RNA template by
everse transcription for 20 min at 95 ◦C and subsequently ampli-
ed for 40 cycles at 95 ◦C for 35 s, 55 ◦C for 15 s and 72 ◦C for
s. Melting curve analysis was carried out after the PCR reac-
ion. A rapid thermal ramp to 95 ◦C was achieved for complete
enaturation of the PCR amplicons, followed by hybridization
t 60 ◦C for 10 s. A slow steady transition from 60 to 95 ◦C was
hen performed. Subsequently a graph was plotted using dF/dT
gainst temperature which would show a peak corresponding to
he Tm of the PCR amplicon..7. Cell viability assay
To assay for cell viability due to the toxicity of the 29-mer
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ection of cells were performed as described above. At 1 and
days post-transfection, cells were trypsinized, and 100l of
he resuspended cells were transferred to the wells of a 96-well
late in triplicates. A total of 20l of the MTS/PMS reagent
Promega, USA) were then added into each well. After incuba-
ion at 37 ◦C for 1 h, the absorbance at 490 nm was measured.
ll assays were performed in triplicates and carried out as two
ndependent experiments.
. Results
.1. Protection of RD cells from EV71-induced CPE by
9-mer shRNAs
Three 29-mer shRNAs were designed to target specific
equences in the non-structural genes such as the 2C, 3Cpro
nd 3Dpol of EV71. A BLAST search showed that the 29-mer
hRNAs designed were specific for the three targets and there
as no homology with human genes.
The efficacy of the 29-mer shRNAs in inhibiting EV71 repli-
ation were first evaluated by transfecting the RD cells with
h-3D at a final concentration of 1 and 10 nM. At 48 h post-
ransfection, the RD cells were infected with EV71 at a MOI of
0. Significant inhibition of EV71-induced CPE was observed
ith as low as 1 nM of the sh-3D. This is in sharp contrast to
he RD cells treated with the scrambled shRNAs which showed
00% CPE. No CPE was observed in RD cells transfected with
0 nM of sh-3D. The inhibition of EV71-induced CPE was
bserved to last by up to 72 h post-infection (hpi). The result
howed that the 29-mer shRNAs targeted the 3Dpol region of
V71 genome was able to inhibit EV71-induced CPE in RD
ells (Fig. 1).
To ascertain that there is no cytotoxicity induced by the chem-
cally synthesized shRNAs, the MTS assay which measured the
iability of cells was carried out. The assay was performed at
8 h post-transfection and it was observed that the three 29-mer
hRNAs did not cause any cytotoxic effects on the growth and
iability of the RD cells (Fig. 2).
.2. Inhibition of EV71 replication by 29-mer shRNAs
After demonstrating the inhibition of EV71-induced CPE in
D cells by the 29-mer shRNAs, we next determined the potency
f the 29-mer shRNAs by studying the inhibitory effects of dif-
erent concentrations of shRNAs on EV71 replication. The RD
ells were transfected with graded concentrations of each of the
hree 29-mer shRNAs (1, 5 and 10 nM), followed by infections
ith EV71 at a MOI of 10. The inhibitory effects of each of the
hree 29-mer shRNAs on EV71 replication were analyzed by
estern blots, plaque assays and real-time RT-PCR Hybridiza-
ion probe assay, respectively. Our results showed that when the
oncentration of each of the 29-mer shRNAs was increased from
to 10 nM, VP1 viral protein levels were observed to decreaseorrespondingly. Similar observations were obtained when the
D cells were treated with 1, 5 and 10 nM of 19-mer siRNAs.
owever, the decrease in the VP1 protein levels were not as sig-
ificant as what was observed in the RD cells transfected with
12 E.L. Tan et al. / Antiviral Research 74 (2007) 9–15


























Che morphological changes of the RD cells were observed at 72 hpi under the
ells transfected with 10 nM sh-3D; (c) infected RD cells in the absence of sh-
ells treated with 10 nM of sh-3D; (f) RD cells treated with 10 nM scrambled 2
he 29-mer shRNAs. As expected, there was no decrease in the
P1 protein levels in the RD cells treated with the scrambled
9-mer shRNAs (Fig. 3a). To corroborate with the significant
ecrease in VP1 viral proteins expression, the infectious titre
f EV71 in the RD cells transfected with 29-mer shRNAs was
etermined by plaque assay. Transfection of RD cells with sh-2C
esulted in inhibition of EV71 by 52%, 73% and 87% when the
oncentrations of sh-2C were increased from 1 to 10 nM. Simi-
ar dosage dependency effects were observed when the RD cells
ere treated with 1, 5 and 10 nM of sh-3C (60%, 77% and 89%)
nd sh-3D (64%, 81% and 91%). In contrast, when the RD cells
ig. 2. Viability of RD cells was determined by MTS assay after transfection
ith 10 nM of 29-mer shRNAs targeted at the 2C (sh-2C), 3Cpro (sh-3C) and
Dpol (sh-3D) genes of the EV71 genome for 48 h. Absorbance values were
btained by measuring at 490 nM. The data shown represent the mean ± S.D.
rom two independent experiments. Ten nanomolars of scrambled shRNAs (scr)




















imicroscope at 40× magnification. (a) Uninfected RD cells; (b) uninfected RD
) EV71-infected RD cells treated with 1 nM of sh-3D; (e) EV71-infected RD
shRNA. The tests were carried out in two independent experiments.
ere treated with the 1 nM, 5 nM and 10 nM of 19-mer siRNA
argeted at the 3Dpol region, the efficiency of EV71 inhibition
as found to be only 60%, 66% and 71%, respectively (Fig. 3b).
The amount of EV71 viral transcripts in the RD cells treated
ith different concentrations of sh-2C, sh-3C and sh-3D was
etermined by real-time RT-PCR Hybridization probe assay.
ompared to untreated RD cells which were infected with EV71,
2.5 log unit reduction in viral RNA transcripts was observed
hen the RD cells were treated with 10 nM of sh-3D. The RD
ells treated with 10 nM of sh-2C and sh-3C showed a 1.5 log
nit decrease in viral RNA transcripts. In the case of the 19-mer
iRNAs targeting at the 3Dpol region, a 0.8 log unit decrease
n the EV71 viral transcripts was observed (data not shown).
ased on the results, we demonstrated that the 29-mer shRNAs
argeted at the specific sequences of the 2C, 3Cpro and 3Dpol of
V71 were effective in inhibiting EV71 replication in RD cells
n a dosage dependent manner. The 29-mer shRNAs targeting
t the 3Dpol region (sh-3D) of EV71 was found to exhibit the
ost potent anti-EV71 effects in RD cells. It is also established
n this study that a much lower concentration of the 29-mer
hRNAs was able to inhibit EV71 replication more effectively
s compared to the chemically synthesized 19-mer siRNAs.
The efficacy of 29-mer shRNAs in inhibiting an on-going
V71 infection was tested by infecting the RD cells at a MOI
f 10 over a period of 5 h. At every hour interval, the RD cells
ere transfected with 10 nM of the sh-2C, sh-3C or sh-3D and
ere observed for CPE at 48 hpi. Significant CPE was observed
n the untreated EV71-infected cells. In contrast, survival of the
E.L. Tan et al. / Antiviral Research 74 (2007) 9–15 13
Fig. 3. Dose-dependent inhibition of EV71 replication with 29-mer shRNAs targeted at the 2C (sh-2C), 3Cpro (sh-3C) and 3Dpol (sh-3D) genes of the EV71 genome.
The RD cells were transfected with 1, 5 and 10 nM of sh-2C, sh-3C or sh-3D, followed by infections with EV71 at a MOI of 10. The RD cells treated with 1, 5 and
10 nM of 19-mer siRNAs (19mer-3D), 10 nM of scrambled shRNAs (scr) and untransfected (−) RD cells were used as controls. The cell lysates and cell supernatants
were harvested to determine viral titres and VP1 protein levels. (a) Western blot analysis was performed using monoclonal antibodies against the VP1 structural
proteins of EV71. -Actin was used as an internal control, using anti--actin monoclonal antibodies. The tests were carried out in two independent experiments.





























nfectious EV71 titre was observed. The ANOVA analysis for comparison betw
NOVA analysis for comparison between the untransfected RD cells and the tre
nd the 19mer-3D was P < 0.01.
D cells treated with 10 nM of each of the 29-mer shRNAs was
till observed 3 h post-infection. Thus, administration of 29-mer
hRNAs to RD cells after EV71 infection can still effectively
nhibit viral replication.
.3. No enhanced inhibitory effects on EV71 replication by
ombinations of two 29-mer shRNAs
It has been reported that an enhanced antiviral effects of
ombinations of siRNAs was observed in HIV infection (Ji
t al., 2003). To test whether cotransfection with two specific
iRNAs targeted at different regions of the EV71 genome will
mprove the antiviral effect in this study, two 29-mer shRNAs
ere cotransfected into the RD cells, followed by infection with
V71 as described in part 2.3. A combination of sh-3D and each
w
t
ig. 4. PKR and phosphor-PKR protein levels in the RD cells were shown by Western
h-3C and sh-3D for 48 h, followed by EV71 infections at a MOI of 10. The RD cells
scr) and untransfected (−) RD cells were used as controls. Western blot analysis w
-Actin was used as an internal control, using anti--actin monoclonal antibodies. Thifferent concentrations of each 29-mer shRNA was found to be P < 0.05. The
D cells was P < 0.01. The ANOVA analysis for comparison between the sh-3D
f the remaining two 29-mer shRNAs (sh-2C and sh-3C) were
valuated at a combined final concentration of 10 nM. The effi-
acy in inhibiting EV71 replication was measured by real-time
T-PCR Hybridization probe assay. Results by the real-time RT-
CR showed that similar inhibitory efficacy on EV71 replication
as observed as compared to the 29-mer shRNAs when used
ndividually (data not shown). This suggests that there is no
nhanced antiviral effect when a combination of 29-mer shRNAs
as used.
.4. No activation of interferon pathway when RD cells
ere treated with 29-mer shRNAs
There is a possibility that inhibition of viral replication is due
o activation of PKR and induction of the interferon response.
blotting. The RD cells were transfected with various concentrations of sh-2C,
treated with alpha interferon, 19-mer siRNAs (19mer-3D), scrambled shRNAs
as performed using monoclonal antibodies against the PKR or phospho-PKR.
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o rule out such possibility, we carried out Western blot using
pecific monoclonal antibodies against endogenous PKR. As a
ositive control for the induction of PKR, the RD cells were
reated with human alpha interferon (Sigma, USA) as described
reviously (Kanda et al., 2004). Our results showed that there
as no increase in PKR expressions in the RD cells after they
ere transfected with each of the three 29-mer shRNAs for
8 h. However, IFN specifically stimulated the PKR expression
Fig. 4). It is well-established that activation of the interferon
esponse is characterized by the transient autophosphorylation
f PKR in the early stages of the initiation process (Khabar et al.,
003). We thus analysed the expression of phopho-PKR in the
ransfected RD cells by Western blot using specific monoclonal
ntibodies against phospho-PKR (Sigma, USA). Other than the
ositive control, we did not observe any phospho-PKR expres-
ion in the RD cells treated with each of the 29-mer shRNAs
Fig. 4). These observations indicated that each of the three 29-
er shRNAs did not elicit interferon response and we conclude
hat viral inhibition was mediated through RNAi.
. Discussion
RNAi technique has been extensively exploited as poten-
ial therapeutic approaches to treat infectious diseases such as
olioviruses (Gitlin et al., 2002), HIV (Capodici et al., 2002),
epatitis C virus (Yokota et al., 2003) and Hepatitis B virus (Li
t al., 2004). Currently, antivirals have been developed against
ome members of the enteroviruses, but none of them was found
o be effective against EV71. The ‘WIN’ group of compounds
as found to be the most promising among these antiviral agents.
ne of the “WIN” compounds, pleconaril, was found to be
ffective in treating aseptic meningitis and encephalitis caused
y some enteroviruses but showed limited therapeutic benefit
gainst EV71 (McMinn, 2002). Thus, it is of great interest to
evelop therapeutic strategies against EV71 infections.
In this study, specific sequences within the 2C, 3Cpro and
Dpol regions of EV71 were chosen as the target sites as they
re highly conserved and are less likely to mutate to generate
utants. This is an important feature for the design of siRNAs
nd is more significant when targeting viruses that mutate fre-
uently such as poliovirus (Gitlin et al., 2005). We observed
90% inhibitory effects on EV71 replication when 10 nM of
9-mer shRNAs targeted at each of the three specific sites were
sed. The inhibitory effects exhibited by the each of the three
9-mer shRNAs on EV71 replication were more potent than
he siRNAs expressed from the plasmid-derived shRNA vector
ystem (Lu et al., 2004) and the chemically synthesized 19-mer
iRNAs (Sim et al., 2005). In both studies, at least 10 fold higher
oncentrations of siRNAs were needed to exert significant inhi-
ition of EV71 replication. In assessing the protection of the
ransfected RD cells against CPE caused by EV71, we observed
hat all three 29-mer shRNAs at 10 nM were able to protect
he RD cells from EV71-induced CPE by up to 72 h. This is
n contrast to only 48 h of protection of RD cells conferred by
he siRNAs reported by Lu et al., 2004 and Sim et al., 2005. In
his study, we demonstrated that the 29-mer shRNAs were more
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otency of the 29-mer shRNAs could be due to higher affinity of
he 29-mer shRNAs for the Dicer enzyme (Rusk, 2005; Siolas
t al., 2005). An alternative explanation is that the hairpin RNAs
ay interact with specific cellular proteins which facilitate the
elivery of these 29-mer shRNA substrates to the Dicer (Siolas
t al., 2005). The loss of the protective effects conferred by the
9-mer shRNAs after 72 h post-infection is likely due to the
ecrease in the 29-mer shRNA concentration as the RD cells
ivide.
All the three chemically synthesized 29-mer shRNAs exam-
ned in this study showed a dosage dependent inhibition of EV71
eplication. Among the three 29-mer shRNAs, sh-3D was shown
o be the most potent in inhibiting EV71 replication, followed by
h-3C and sh-2C. This supported the findings by Lu et al., 2004
nd Sim et al., 2005 which also showed that targeting at the viral
NA-dependent RNA polymerase, 3Dpol, is the most effective
n inhibiting EV71 replication. The specific function of 2C has
et to be identified. The 3C region encodes a protease which per-
orms majority of the secondary processing of the polyprotein.
he 3D region encodes the viral RNA-dependent RNA poly-
erase which oligomerizes into a complex and subsequently
inds to the viral RNA. Since the 3Dpol gene and the other cel-
ular factors form an important component in facilitating viral
eplication, its down-regulation could produce the most potent
nhibitory effect on EV71 replication.
It has been shown that cotransfection of cells with two or
ore siRNAs targeted at different sites resulted in enhanced
ene silencing when compared to single siRNA is used (Ji et al.,
003). The underlying mechanism of enhanced gene silencing
ith multiple siRNAs has yet to be elucidated. It was postulated
hat the binding of one siRNA may change the secondary struc-
ure of the target RNA, thus result in more accessible sites for
nother siRNA (Ji et al., 2003). However, in this study, we did not
bserve any enhancement effects when we cotransfected the RD
ells with different combinations of the three 29-mer shRNAs.
he possible reason for the discrepancy may be because the
9-mer shRNAs developed in this study did not affect the sec-
ndary structure of the EV71 mRNA, and thus do not increase
ccessibility to other 29-mer shRNAs. Nevertheless, although
he mechanism of the enhanced gene silencing with multiple
iRNAs is unknown, it may be a good approach for treatment of
iral infections, especially for viruses which mutate and escape
rom RNA interference.
Longer dsRNAs (∼30 nts) can elicit non-specific interferon
esponse, leading to subsequent inactivation of the cellular tran-
criptional machinery and resulting in death of the mammalian
ells (Persengiev et al., 2004; Sledz et al., 2004). The inter-
eron response is also responsible for protection against viral
nfections (Khabar et al., 2003). The main mechanism in the
nterferon pathway is the induction of dsRNA-dependent pro-
ein kinase R (PKR). PKR is a serine–threonine kinase which
s normally inactive. Upon activation by interferon or dsRNA,
KR are phosphorylated and the levels are upregulated. The acti-
ated PKR will then phosphorylate the cellular proteins, notably
IF2, which are downstream of the interferon pathway, and
ubsequently leading to translational arrest (Khabar et al., 2003;
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esign of RNAi strategy, the siRNAs must be long enough for
ffective gene silencing, but short enough to prevent the induc-
ion of the interferon response. Our study used a much lower
oncentration of siRNAs and showed a higher efficacy in silenc-
ng EV71. This minimized the chances of “off target effects”
ue to the interferon response. Since no increase in the endoge-
ous PKR and phospho-PKR levels was detected, our data
ndicated no engagement of the interferon pathway in the RD
ells when they were transfected with each of the three 29-mer
hRNAs.
In conclusion, our study showed an improvement in trigger-
ng RNAi in mammalian cells using the more potent 29-mer
hRNAs. We have shown that increased RNAi potency was
bserved for all the three-targeted sites (2C, 3Cpro and 3Dpol)
hen compared to the inhibitory effects shown by the 19-mer
iRNAs. The improved efficacy of the 29-mer shRNA at 3Dpol
ndicated its high potential to be developed as an antiviral ther-
peutic agent against EV71.
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Inhibition of Enterovirus 71 in Virus-infected Mice 
by RNA Interference
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Enterovirus 71 (EV71) is the main causative agent of 
hand, foot, and mouth disease (HFMD) in young chil-
dren. It is often associated with neurological compli-
cations and has caused high mortality levels in recent 
outbreaks in the Asia Pacific region. Currently, there 
is no effective antiviral therapy against EV71 infec-
tions. In this study, we have evaluated and compared 
the efficacies of three different forms of small inter-
fering RNAs (siRNAs) in inhibiting EV71 replication in 
a murine model. We have shown that both synthetic 
19-mer siRNAs and plasmid-borne short hairpin RNAs 
(shRNAs) targeted at the conserved 3Dpol region were 
able to inhibit EV71 infections in suckling mice when 
delivered with or without lipid carrier via the systemic 
route. The treated mice did not exhibit hind limb paral-
ysis and weight loss, as was observed in untreated mice. 
EV71 replication was significantly reduced as revealed 
by real-time reverse transcription polymerase chain 
reaction (RT-PCR) and Western blot. In addition, no evi-
dence of interferon (IFN) induction was detected in the 
 intestinal tissues harvested from the mice as a result of 
siRNA administration. However, the chemically synthe-
sized 29-mer shRNA did not protect the suckling mice 
from EV71 infections despite being more potent in the 
in vitro system. Our results indicate that RNA interfer-
ence (RNAi) may be a promising therapeutic approach 
for fighting EV71 infections.
Received 18 April 2007; accepted 16 July 2007; published online  
21 August 2007. doi:10.1038/sj.mt.6300287
INTRODUCTION
Enterovirus 71 (EV71) is a positive single-stranded RNA virus 
with a non-enveloped capsid and a genome size of ~7.5 kilobase. 
It is one of the main etiological agents of hand, foot, and mouth 
disease (HFMD), a mild childhood disease that mainly affects 
young children (<6 years of age). HFMD is characterized by 
3–4 days of fever, development of rashes, and vesicles on the 
limbs as well as multiple ulcers in the mouth. Although other 
enteroviruses such as CA16, CA5, CA9, and Echo 7 are also able 
to cause HFMD, serious neurological manifestations such as 
 brainstem and/or cerebellar encephalitis, acute flaccid paraly-
sis, and aseptic meningitis were observed in many children with 
acute EV71 infections during the large scale HFMD outbreaks in 
the Asia Pacific region.1 These neurological manifestations were 
frequently accompanied by complications such as pulmonary 
edema and myocarditis and sometimes lead to death.2,3 At pres-
ent, there is no effective antiviral therapy or vaccine available to 
treat the disease. It is important to note that most deaths from 
HFMD caused by EV71 occur within 24 hours, due to children 
developing complications associated with HFMD.1,3 With rising 
concern about the virulence of EV71, there is a need to develop 
a specific antiviral therapy against EV71.
RNA interference (RNAi) is a defense strategy that was 
first described in Caenorhabditis elegans.4 Since then, RNAi 
has been widely applied as cellular defense against viruses, 
and has shown promise as a potential therapeutic strategy to 
fight against infectious diseases. It is a multi-step process of 
sequence-specific, post-transcriptional gene silencing initi-
ated by double-stranded RNA molecules.4 The double-stranded 
RNAs are processed by the RNase III-like enzyme, Dicer, into 
small interfering RNAs (siRNAs) of 21–23 nucleotides. The 
siRNA will induce the formation of the RNA-induced silencing 
complexes that subsequently recognize and degrade homolo-
gous target messenger RNAs.
By targeting viral transcripts and/or host genes which pro-
duce co-factors critical for viral replication, the RNAi approach 
has been shown to be effective against a wide range of viruses 
such as the human immunodeficiency virus,5–7 hepatitis C 
virus,8–10 and the influenza virus A11 in the in vitro systems. 
This approach has also been used successfully against viruses 
of the Picornaviridae family, including the poliovirus,12 rhino-
virus13 as well as the Coxsackievirus B3.14,15 Several studies have 
shown that siRNAs were effective in inhibiting replication of 
viruses such as hepatitis B,16 influenza virus A,17 and the respi-
ratory syncytial virus18 in murine model. Thus, the RNAi strat-
egy possesses great potential for being developed as antiviral 
therapy to fight against EV71.
Previous investigations have shown that both chemically syn-
thesized 19-mer siRNAs and DNA vector-based short hairpin 
RNA (shRNA) producing systems targeted at specific regions 
of EV71 were able to significantly inhibit replication of EV71 
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in the in vitro systems without inducing the interferon (IFN) 
response.19,20 In this study, we have evaluated and compared the 
efficacies of chemically synthesized 19-mer siRNAs, psiStrike 
plasmids expressing shRNAs, and the chemically synthesized 29-
mer shRNAs in inhibiting EV71 infections in a murine model. 
The siRNAs were designed to target the RNA-dependent RNA 
polymerase, 3Dpol region of the EV71 genome, and we have shown 
that both chemically synthesized siRNAs and shRNAs produced 
from psiStrike plasmids were equally effective in inhibiting EV71 
infections in mice. However, despite showing enhanced potency 
in inhibiting EV71 infections in the in vitro system, the chemically 
synthesized 29-mer shRNAs failed to protect the mice from EV71 
infections.
RESULTS
Designing siRNAs against EV71 infection
We have shown previously that the chemically synthesized 19-
mer siRNAs (19mer-3D) and the 29-mer shRNAs (29mer-3D) 
designed to target the 3Dpol region of the EV71 genome were 
highly effective in inhibiting EV71 replication in rhabdomyosar-
coma cell line.20,21 In this study, the oligonucleotide bearing the 
same sequence as the chemically synthesized 19-mer siRNAs 
(19mer-3D) was cloned into the psiStrike shRNA expression vec-
tor and a recombinant plasmid expressing 19mer-shRNAs (psi-
3D) was constructed. Our results showed that the 19-mer shRNAs 
expressed from the recombinant psiStrike plasmids (psi-3D) 
were highly effective in inhibiting EV71 replication in the in vitro 
system (data not shown).
siRNA-mediated inhibition of EV71 in vivo
To test the prophylactic activity of the various siRNAs, the suckling 
mice were first injected with 10 nmol of chemically synthesized 
19-mer siRNAs (19mer-3D), 10 nmol of 29-mer shRNAs (29mer- 
3D) or 50 µg of psiStrike plasmid expressing 19mer-shRNAs 
(psi-3D) coupled with Oligofectamine via the intraperitoneal 
(IP) route. After 24 hours, the suckling mice were infected with 
104 of a 50% tissue culture infective dose (TCID50) of EV71. The 
suckling mice that served as controls were either not treated with 
any siRNAs or treated with siRNAs with scrambled sequences 
(19mer-scr, psi-scr or 29mer-scr) prior to infection. Results 
showed that the suckling mice treated with 10 nmol of 19mer-
3D or 50 µg of psi-3D showed significant protection against EV71 
infection since the treated suckling mice showed no signs of sig-
nificant weight loss (Figure 1a and b) or acute flaccid paralysis 
of the hind limbs (Figure 1d) after 14 days of EV71 infection. 
In contrast, the suckling mice that received no siRNA treat-
ment or treated with the scrambled siRNAs showed significant 
weight loss and hind limb paralysis on day 6 post infection, and 
all the infected mice died between day 12 and 14 post infection 
(Figure 1e). Surprisingly, the suckling mice that were treated with 
29mer-3D did not recover from the EV71 infection (Figure 1c 
and d). Thus, the administration of both synthetic 19-mer siR-
NAs and the psiStrike plasmids expressing shRNAs were able to 
inhibit EV71 replication in a murine model.
To examine the therapeutic potential of 19mer-3D, psi-3D, 
or 29mer-3D, the mice were first infected with 104 of a TCID50 
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Figure 1 Prophylactic effect of different forms of small interfering RNAs (siRNAs) in protecting mice (n = 5) from Enterovirus 71 (EV71)-
infection as shown by changes in weight and hind limb paralysis. (a) EV71 infected suckling mice treated with 10 nmol of chemically synthesized 
19-mer siRNAs (19mer-3D). (b) EV71 infected suckling mice treated with 50 µg of psiStrike plasmids expressing short hairpin RNAs (shRNAs) (psi-3D). 
(c) EV71 infected mice treated with chemically synthesized 29-mer shRNAs (29mer-3D). The untreated mice and mice treated with scrambled siRNAs 
(19mer-scr, psi-scr or 29mer-scr) were used as controls. All the data represent the mean weights ± SD of four independent experiments. The analysis of 
variance (ANOVA) for comparison of the weight changes between untreated infected mice and mice treated with 10 nmol of 19mer-3D was P < 0.01. 
The ANOVA for comparison of weight changes between untreated infected mice and mice treated with 50 µg of psi-3D was P < 0.01. The ANOVA for 
comparison of weight changes between untreated infected mice and mice treated with 10 nmol of 29mer-3D was P < 0.05. (d) A representative picture 
of a suckling mouse treated with 10 nmol 19mer-3D or 50 µg psi-3D compared to a suckling mouse treated with scrambled siRNAs (on the left-hand 
side). (e) A representative picture of an untreated mouse showing hind limb paralysis (indicated by the arrow) and significant weight loss caused by 
EV71 infection on day 6 post infection. (f) A representative picture of an age-matched healthy uninfected suckling mouse. All the observations repre-
sent the results from four independent experiments.
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 administered with 10 nmol of 19mer-3D, 10 nmol of 29mer-3D 
or 50 µg of psi-3D coupled with Oligofectamine via the oral or 
the IP route. It was observed that the infected mice that received 
no siRNA treatment or treated with the scrambled siRNAs 
showed significant weight loss on day 6 post infection (Figure 2) 
and all died between day 12 and 14 post infection. When the 
infected suckling mice were administered with 10 nmol of 
19mer-3D or 50 µg of psi-3D via the IP route, significant protec-
tion against EV71 infection was observed as these treated suck-
ling mice showed no signs of weight loss or hind limb paralysis 
after 14 days of EV71 infection (Figure 2a and b). In contrast, 
the infected suckling mice did not recover from the EV71 infec-
tion when they were treated with 29mer-3D (Figure 2c). All the 
treated suckling mice were further monitored for another 2 weeks 
for any delayed EV71 infection. Since none of them showed any 
signs of hind limb paralysis or weight loss, this is indicative of 
full recovery from the EV71 infection. Notably, similar protective 
effects from EV71 infections were observed in the suckling mice 
when 19mer-3D and psi-3D were administered without using 
Oligofectamine as the lipid carrier (Figure  3). This indicated 
that the siRNAs were capable of providing significant protec-
tion against EV71 infections even when they were administered 
without being coupled with a lipid carrier. However, the suckling 
mice failed to be protected from EV71 infections when they were 
treated with either 19mer-3D or psi-3D via the oral route (data 
not shown).
Efficiency of siRNA delivery to mice tissues
We next determined the uptake efficiencies of the three different 
forms of siRNAs by the intestinal cells by injecting the suck-
ling mice with 10 nmol of 19mer-3D, 10 nmol of 29mer-3D or 
50 µg of psi-3D coupled with Oligofectamine as the lipid car-
rier. Flow cytometry analysis was carried out on the intestinal 
cells which were harvested 24 hours after siRNAs injection and 
the uptake efficiencies were determined based on the fluores-
cein isothiocyanate emission which were tagged to the 3′-end 
of the chemically synthesized 19mer-3D and 29mer-3D. In the 
case of psi-3D, the uptake efficiency was evaluated based on the 
green fluorescent protein expression from the recombinant plas-
mids. Our results based on flow cytometry showed equally high 
uptake efficiencies of 19mer-3D, 29mer-3D, or 50 µg of psi-3D 

































0 2 4 6
Days post infection











0 2 4 6
Days post infection















Figure 2 Changes in weight in Enterovirus 71 (EV71)-infected 
mice (n = 5) treated with different forms of small interfering RNAs 
(siRNAs) coupled with Oligofectamine. (a) EV71 infected suckling 
mice treated with 10 nmol of 19mer-3D. (b) EV71 infected suckling mice 
treated with 50 µg of psi-3D. (c) EV71 infected mice treated with 29mer-
3D. Untreated mice and mice treated with scrambled siRNAs (19mer-scr, 
psi-scr or sh-scr) were used as negative controls. All the data represent 
the mean weights ± SD of four independent experiments. The analysis of 
variance (ANOVA) for comparison of weight changes between untreated 
infected mice and mice treated with 10 nmol of 19mer-3D was P < 0.01. 
The ANOVA for comparison of weight changes between untreated 
infected mice and mice treated with 50 µg of psi-3D was P < 0.01. The 
ANOVA for comparison of weight changes between untreated infected 
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Figure 3 Changes in weight in Enterovirus 71 (EV71)-infected 
mice (n = 5) treated with different forms of small interfering RNAs 
(siRNAs) not coupled with Oligofectamine. (a) EV71 infected suckling 
mice treated with 10 nmol of 19mer-3D. (b) EV71 infected suckling mice 
treated with 50 µg of psi-3D. (c) EV71 infected mice treated with 29mer-
3D. Untreated mice and mice treated with scrambled siRNAs (19mer-scr, 
psi-scr or sh-scr) were used as negative controls. All the data represent 
the mean weights ± SD of four independent experiments. The analysis of 
variance (ANOVA) for comparison of weight changes between untreated 
infected mice and mice treated with 10 nmol of 19mer-3D was P < 0.01. 
The ANOVA for comparison of weight changes between untreated 
infected mice and mice treated with 50 µg of psi-3D was P < 0.01. The 
ANOVA for comparison of weight changes between untreated infected 
mice and mice treated with 10 nmol of 29mer-3D was P < 0.05.
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obtained even when the siRNAs were administered without 
Oligofectamine (data not shown).
Dosage dependency of siRNAs in inhibition of EV71 
replication
To determine the dose–response kinetics and the optimal concen-
trations of 19mer-3D, 29mer-3D, and psi-3D in inhibiting EV71 
replication, we injected the suckling mice with different con-
centrations of 19mer-3D, 29mer-3D, or psi-3D. On day 14 post 
infection, the intestinal cells were harvested from the suckling 
mice and the inhibitory effects of each of the three different forms 
of siRNAs on EV71 replication were analyzed by using the real-
time hybridization probe, reverse transcription polymerase chain 
reaction (RT-PCR) and Western blot methods. It was observed 
that treatment with 1 nmol of 19mer-3D led to ~40% decrease 
in viral transcripts while treatment with 10 mol of 19mer-3D led 
to 100% reduction in the intestines (Figure 5a). Similar dosage 
dependency effects were observed when the concentration of psi-
3D was increased from 10 to 50 µg (Figure 5a). However, there 
was no significant decrease in the EV71 viral RNA transcripts 
in the suckling mice when they were treated with 29mer-3D 
(Figure 5a). To corroborate the results obtained from the real-
time RT-PCR, the Western blot method was carried out to ana-
lyze the EV71 viral proteins in the intestinal cells harvested from 
the suckling mice that had earlier been treated with 19mer-3D, 
psi-3D, or 29mer-3D. Our results showed that when the con-
centration of 19mer-3D was increased from 1 to 10 nmol, the 
VP1 viral protein levels decreased correspondingly (Figure 5b). 
Similar dosage dependency effects were observed when the mice 
were treated with 10, 25, or 50 µg of psi-3D (Figure 5b). There 
was, however, no significant decrease in the VP1 protein levels 
observed in the intestinal cells harvested from the suckling mice 
treated with 29mer-3D (Figure 5b). No significant decrease in 
the VP1 protein levels or EV71 RNA transcripts was observed 
either, when the suckling mice were treated with 10 nmol of 
the chemically synthesized scrambled siRNAs (19mer-scr and 
29mer-scr) or 50 µg of psiStrike plasmids expressing scrambled 
shRNAs (psi-scr).
These results put together helped us conclude that both the 
chemically synthesized 19-mer siRNAs (19mer-3D) and the 
psiStrike plasmid expressing shRNAs (psi-3D) were effective in 
inhibiting EV71 replication in suckling mice in a dosage depen-
dent manner, and the most effective inhibitory concentrations 
of 19mer-3D and psi-3D were 10 nmol and 50 µg, respectively. 
On the other hand, the chemically synthesized 29-mer shRNAs 
(29mer-3D) failed to protect the suckling mice from EV71 infec-
tions despite showing enhanced potency in inhibiting EV71 
 replication in the in vitro system.
We next conducted a kinetic study to determine the inhibitory 
effects of 19mer-3D and psi-3D (that lead to protecting the suck-
ling mice from EV71 infection) by treating the infected suckling 






Figure 4 Delivery efficiencies of the various forms of small interfering 
RNAs (siRNAs) by the intestinal cells. The uptake efficiencies (%) of 
(a) 19mer-3D, (b) psi-3D, and (c) 29mer-3D by the intestinal cells were 
compared to untreated intestinal cells. The delivery efficiencies of the scram-
bled siRNAs, namely (d) 19mer-scr, (e) psi-scr and (f) 29mer-scr were also 
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Figure 5 Dose dependent inhibition of small interfering RNAs on 
enterovirus 71 (EV71) replication. The infected suckling mice (n = 5) 
were treated with graded concentrations of 19mer-3D, 29mer-3D, and 
psi-3D. Untreated infected suckling mice and infected suckling mice 
treated with 10 nmol of 19mer-scr, 10 nmol of 29mer-scr or 50 µg of psi-
scr were used as controls. Cell lysates and cell supernatants were harvested 
from the intestines to determine the EV71 RNA transcripts and VP1 protein 
levels. (a) Real-time reverse transcription polymerase chain reaction was 
performed to determine the levels of the EV71 RNA transcripts. The results 
represent the mean percentage of EV71 RNA transcripts ± SD of two inde-
pendent experiments. The analysis of variance (ANOVA) for comparison 
of the decrease in EV71 RNA transcripts between untreated infected mice 
and mice treated with 10 nmol of 19mer-3D was P < 0.01. The ANOVA for 
comparison of the decrease in EV71 RNA transcripts between untreated 
infected mice and mice treated with 50 µg of psi-3D was P < 0.01. The 
ANOVA for comparison of the decrease in EV71 RNA transcripts between 
untreated infected mice and mice treated with 10 nmol of 29mer-3D was 
P > 0.05. (b) Western blot analysis was performed using specific mono-
clonal antibodies against the VP1 structural proteins of EV71. β-actin was 
used as an internal control with anti β-actin monoclonal antibodies. The 
tests were carried out in two independent experiments.
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first contracted the EV71 infection. Our observations revealed 
that the protective effects of 19mer-3D and psi-3D were the 
strongest when they were administered on day 1 post infection, 
as the suckling mice showed no evidence of either acute flaccid 
paralysis or significant weight loss. These inhibitory effects were 
observed to diminish thereafter, so much so that 19mer-3D failed 
to protect the suckling mice from EV71 infection when they were 
administered after 3 days of having contracted the infection. In 
the case of psi-3D, protection of the suckling mice was still evi-
dent when they were administered after 4 days of EV71 infection 
(data not shown).
Immunohistochemistry staining for presence of EV71 
in the organs of the treated suckling mice
The effects of 19mer-3D, 29mer-3D, and psi-3D on EV71 rep-
lication were determined histologically by immunohistochemi-
cal staining of the intestines harvested from the mice on day 7 
and 14 post EV71 infection. On day 7 post infection, presence of 
EV71 was observed in the intestines harvested from untreated 
suckling mice (Figure  6a), and there was extensive damage 
done to the intestinal epithelia and intestinal cells after 14 days 
of infection with EV71 (Figure  6b). Similar extensive intesti-
nal damage was observed in the intestines harvested from the 
suckling mice treated with 29mer-3D (Figure 6c). In contrast, 
no presence of EV71 was observed in the intestines when the 
suckling mice were treated with either 10 nmol 19mer-3D or 50 
µg of psi-3D (Figure 6d). These results highlighted the signifi-
cance of both 19mer-3D and psi-3D for their ability to inhibit 
EV71 replication in vivo.
siRNAs do not activate IFNs
To provide further evidence that EV71 inhibition was due to the 
specific antiviral effects exerted by both 19mer-3D and psi-3D 
and not due to activation of IFNs, we measured the levels of IFN-
α and IFN-β in the homogenates of the intestines harvested from 
the treated suckling mice. The results showed no activation of 
IFN-α or IFN-β and we therefore concluded that the EV71 inhibi-
tion in the suckling mice was mediated specifically through RNAi 
(Figure 7).
DISCUSSION
Currently, most cases of HFMD are managed with symptomatic 
treatment.22 There are a number of other antiviral agents that 
may be effectively used against enteroviruses; however, these are 
still under study. One of the “WIN” compounds—­pleconaril—­is 
found to have significant therapeutic effects in aseptic meningitis, 
acute flaccid paralysis, and encephalitis resulting from enteroviral 
infections.22,23 However, pleconaril was found to have only limited 
effectiveness against EV71,23 especially EV71-associated neuro-
logical complications. Thus, it is of great interest to develop thera-
peutic strategies against EV71 infections.
The success of RNAi has been widely reported in in vitro 




Figure 6 Histological changes in Enterovirus 71 (EV71)-infected suck-
ling mice (n = 5) under ×40 magnification. Immunohistochemical stain-
ing was carried out with specific anti-EV71 antibody. (a) Presence of EV71 
was detected (indicated by arrow) at the epithelia of the intestines on 
day 7 post infection. (b) Extensive damage to the epithelia and the intes-
tinal cells caused by EV71 on day 14 post infection. (c) Presence of EV71 
and extensive damage in the intestines harvested from mice treated with 
chemically synthesized 29-mer short hairpin RNAs (29mer-3D). (d) No 
presence of EV71 was detected when the suckling mice were treated with 
either 19mer-3D or psi-3D. (e) Normal morphology of the intestines in 
healthy suckling mice that served as negative controls. The results repre-
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b
Figure 7 Absence of interferon (IFN) induction following small inter-
fering RNA treatment. The levels of (a) IFN-α and (b) IFN-β were deter-
mined by measuring the absorbance values at 490 nm. The data shown 
represent the mean ± SD from two independent experiments.
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 applications and could eventually lead to its validation as 
 potential drug therapy for use against infectious diseases. In this 
study, the 3Dpol region of EV71 was selected as the target site 
since it has been previously shown that siRNA targeted at the 
3D region exerted the most potent inhibitory effect on EV71 
replication.19–21 The 3Dpol region of EV71 encodes the viral RNA-
dependent RNA polymerase and being highly conserved, is less 
likely to mutate and generate mutants. This is important when 
designing siRNAs to target viruses that mutate frequently such 
as poliovirus.24
When used either as a prophylactic or as a treatment drug, we 
demonstrated that both synthetic 19-mer siRNAs and psiStrike 
plasmids expressing shRNAs were effective in inhibiting EV71 
replication in a murine model. The growth of the treated suckling 
mice was essentially comparable to that of the uninfected mice, 
showing that both the synthetic 19-mer siRNAs and psiStrike 
plasmids expressing shRNAs were actually able to protect the 
suckling mice from developing EV71 infections instead of just 
delaying the onset of infection. The inhibitory effects on EV71 
replication exerted by both forms of siRNAs were dosage depen-
dent as shown by Western blot and real-time RT-PCR analysis. 
The shorter lasting time of the effects of the chemically synthe-
sized 19-mer siRNAs in the suckling mice (3 days) as compared 
to plasmid-borne shRNAs (4 days) may be due to the transient 
delivery nature of the chemically synthesized 19-mer siRNAs, 
unlike the recombinant DNA-vector system which can express 
shRNAs endogenously.
In this study, the chemically synthesized 29-mer shRNAs 
(29mer-3D) failed to protect the suckling mice from EV71 
infection despite demonstrating enhanced potency in inhibit-
ing EV71 replication in the rhabdomyosarcoma cell line.21 Since 
the flow cytometric analysis showed similar uptake efficiencies 
of chemically synthesized 19-mer siRNAs (19mer-3D), 29-mer 
shRNAs (29mer-3D) and the psiStrike plasmids expressing 
 shRNAs (psi-3D) by the intestinal cells, the lack of protective 
effect exerted by the 29-mer shRNAs cannot be attributed to 
poor siRNA uptake by the mice tissues; we suggest, therefore, 
that the suckling mice might lack certain mechanisms or cellular 
proteins which facilitate the delivery of the 29-mer shRNAs 
to the Dicer so as to be processed into the functional 19-mer 
siRNAs.
Delivering siRNAs to animal tissues is a complicated pro-
cess and has been a challenging one. This is due to the fact that 
the accessibility of the siRNAs to different tissue types makes it 
almost impossible to have a universal in vivo delivery system.25 In 
this study, we have compared two systemic methods of delivering 
siRNAs into the infected suckling mice. The systemic administra-
tion approach was used in this study since EV71 infections can 
affect multiple organs, including the intestines and the brain-
stem.26 Our results showed that both forms of siRNAs were able 
to protect the infected suckling mice from EV71 infection when 
administered via the IP route. In contrast, delivery of the siRNAs 
via the oral route failed to protect the suckling mice from EV71 
infections. This could be due to the degradation of the siRNAs in 
the gastrointestinal tract; this might have resulted in their inability 
to exert their antiviral effects. We have also shown in this study 
that the suckling mice were protected from EV71 infections when 
the siRNAs were administered even without coupling with any 
transfection agent. This is a noteworthy result. Even though cou-
pling the siRNAs with cationic lipids has been shown to enhance 
the siRNA delivery via systemic routes, it has been reported that 
this can also trigger the cellular IFN pathway.27 To date, an effec-
tive mechanism to deliver siRNAs to the central nervous system 
remains to be elucidated. Thus, early detection and treatment of 
the EV71 infections is essential so that the siRNAs can be deliv-
ered effectively to inhibit the viral replication before irreversible 
damage to the central nervous system occurs.
It has been established that long double-stranded RNAs (~30 
nucleotides) and/or high concentrations of siRNAs can elicit a 
non-specific IFN response, resulting in the expression of a large 
number of IFN-stimulated genes that cause the pleiotropic effects 
of IFN; these include interference with viral replication and mod-
ulation of host immune response.27 Thus, it is important to use 
a judicious concentration of siRNAs which can optimally inhibit 
EV71 replication, while at the same time not eliciting any immune 
responses. Our data showed no activation of IFN responses, 
Table 1 Nucleotide sequences of the chemically synthesized 19-mer siRNA (19mer-3D), 29-mer shRNA (29mer-3D), and the psiStrike plasmid 
expressing shRNA (psi-3D) and their corresponding nucleotide positions in the EV71 genome
siRNA Nucleotide sequence Nucleotide location
psi-3D 5′-ACCGa GAAATTGGCTCGAATTGTT CTTCCTGTCAb  
AACAATTCGAGCCAATTTC TTTTTCc-3′
7304–7322















Abbreviations: siRNA, small interfering RNA; shRNA, short hairpin RNA.
aOverhang sequences to allow cloning into the psiStrike expression vector. bStem loop sequence. cU6 termination sequence. dStem loop sequence.
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 indicating that both chemically synthesized siRNAs and psiStrike 
plasmid expressing shRNAs were specific in inhibiting EV71 
 replication and do not cause undesirable side effects. In conclu-
sion, since this study has shown that RNAi can be used to inhibit 
EV71 replication in a murine model, it may prove to be a potential 
therapeutic strategy for use against EV71 infections in children.
MATERIALS AND METHODS
Cell culture and virus strain. The EV71 strain, designated as 5865/
SIN/00009 (GenBank accession no. AF316321), isolated from a fatal case 
during the outbreak in Singapore in October 2000, was used in this study. 
The virus was cultured in rhabdomyosarcoma cell lines and purified by 
sucrose gradient centrifugation.
psiStrike plasmid expressing shRNAs and synthetic siRNAs. The chemi-
cally synthesized 19-mer siRNAs and the 29-mer shRNAs were designed to 
target the 3Dpol region of the EV71 genome and were designated as 19mer-
3D and 29mer-3D, respectively, as described previously.20,21 The same 
oligonucleotide sequence of the 19mer-3D was also cloned into psiStrike 
U6 shRNA expression vector according to the manufacturer’s instruc-
tions (Promega, Madison, WI). A recombinant plasmid was constructed 
and designated as psi-3D. The vector contained the human U6 promoter 
that allowed endogenous transcription of the 19-mer shRNAs. These were 
subsequently processed into 19-mer siRNAs by the Dicer inside the cells. 
The delivery efficiency of the psiStrike plasmid vector could also be deter-
mined by the presence of a green fluorescent protein, which was driven by 
the cytomegalovirus promoter. A scrambled sequence with the same base 
composition as the 19mer-3D and 29mer-3D (designated as 19mer-scr and 
29mer-scr, respectively) was used as a negative control. The same oligonu-
cleotide sequence of 19mer-scr was also cloned into the psiStrike plasmid 
vector and the recombinant plasmid expressing scrambled sequences (psi-
scr) was used as negative control. The sequences of 19mer-3D, 29mer-3D, 
psi-3D, and the scrambled siRNAs are shown in Table 1. Integrated DNA 
Technologies synthesized all the siRNA oligonucleotides.
siRNA treatment in vivo. For all the in vivo experiments, 1-day-old Balb/c 
suckling mice were used. The suckling mice (n = 5) were first infected with 
104 of a TCID50 of EV71 via the IP route. The first group of infected suckling 
mice was used as positive control. 24 hours post infection, six other groups 
of infected suckling mice were treated with 1, 5, or 10 nmol of 19mer-3D, 1, 
5, or 10 nmol of 29mer-3D, 10, 25, or 50 µg of psi-3D, 10 nmol of 19mer-scr, 
10 nmol of 29mer-scr or 50 µg of psi-scr via the oral or IP route. All the siR-
NAs were complexed with Oligofectamine (Invitrogen, Carlsbad, CA) and 
made up to 100 µl with Opti-MEM (Gibco Life Technologies, Invitrogen, 
Carlsbad, CA) prior to administration. One group of suckling mice (n = 5) 
was not infected by EV71 and was used as negative control. When the 
siRNA was used without Oligofectamine, the Opti-MEM was substituted 
with 1× phosphate-buffered saline. During the course of the experiment, 
the weights of all the suckling mice were monitored every alternate day. 
On day 14 post infection, the intestines were harvested from the suck-
ling mice, and the mouse intestinal cells were extracted according to the 
method described by Zhang et al. (2003).28 The extracted intestinal cells 
were stored under –20 °C until further testing. All the mice experiments 
were carried out according to the guidelines of the Institutional Animal 
Care and Use Committee of the National University of Singapore, and were 
repeated four times independently to ensure good reproducibility.
RT-PCR assay. Total RNA was extracted from the supernatants using the 
RNeasy extraction kit (Qiagen, Valencia, CA), according to the manufac-
turer’s instructions. The total RNA extracted were then analyzed for pres-
ence of EV71 using the real-time hybridization probe RT-PCR for detection 
of EV71 RNA transcripts, as described previously.29 Briefly, the real-time 
 hybridization probe RT-PCR, was carried out using the LightCycler 
real-time PCR system and the LightCycler RNA Amplification Hybridization 
Probe kit (Roche Molecular Biochemicals, Mannheim, Germany). Each 
10 µl reaction contained 300 ng of RNA, 5 mmol/l MgCl2, 0.5 µmol/l of the 
forward primer, 0.3 µmol/l of the reverse primer, 0.2 µmol/l of each hybrid-
ization probe, 2.0 µl hybridization probe reaction mix, 0.2 µl enzyme mix 
and water. The complementary DNA was first synthesized from the RNA 
template by reverse transcription for 20 minutes at 95 °C and subsequently 
amplified for 40 cycles at 95 °C for 35 seconds, 55 °C for 15 seconds and 
72 °C for 9 seconds.
Immunoblot. The extracted intestinal cells were then lysed using 200 µl of 
CelLytic M Cell Lysis Reagent (Sigma, California). An aliquot of 20 µl of 
each lysate was electrophoresed in a denaturing 10% polyacrylamide gel. 
Western blotting was then performed following standard procedures. The 
detection procedure was based on the chromogenic method described pre-
viously using EV71 VP1 monoclonal antibody (Chemicon International, 
Madison, WI) and the β-actin antibody (Sigma, California)20,21
Immunohistochemical analysis. On day 7 and 14 post infection, the intes-
tines of the infected and treated suckling mice were harvested and stored 
immediately at –80 °C. Cryosections of 4 µm from the frozen tissues were 
made and fixed on poly-l-lysine glass slides. Permeabilization of the fixed 
tissues was carried out by incubation with 0.2% Triton for 10 minutes. 
EV71 was detected using the mouse monoclonal antibody against EV71 
(Chemicon International, Madison, WI). After washing with 1× phos-
phate-buffered saline, the tissues were incubated with biotinylated anti-
mouse secondary antibodies (Zymed Laboratories, San Fransisco, CA). A 
red colored peroxidase stain was developed using aminoethyl carbazole 
substrate and counterstained with hematoxylin (Zymed Laboratories, San 
Fransisco, CA).
IFN-α and IFN-β assay. The suckling mice were first injected with 10 nmol 
19mer-3D or 50 µg psi-3D via the IP route. After 24 hours, homogenates of 
the intestines were prepared. The levels of IFN-α and IFN-β in the homog-
enates were then measured by the enzyme-linked immunosorbent assay 
(PBL Biomedical Laboratories, Piscataway, NJ) according to the manufac-
turer’s instructions.
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bstract
ackground: Enterovirus 71 (EV71) is the main etiological agent of Hand, Foot and Mouth Disease (HFMD) and has been associated with
eurological complications which resulted in fatalities during recent outbreaks in Asia Pacific region.
bjective: Develop a real-time TaqMan RT-PCR for rapid detection of EV71.
tudy design: Specific primers and probe were designed based on highly conserved VP1 region of EV71. The sensitivity of the real-time
T-PCR was evaluated with 67 clinical specimens collected from pediatric patients with suspected HFMD.
esults: Our real-time TaqMan RT-PCR showed 100% specificity in detecting EV71 and showed an analytical sensitivity of 5 viral copies.
igh sensitivity was also achieved in detecting EV71 directly from clinical specimens.
onclusions: Real-time TaqMan RT-PCR offers a rapid and sensitive method to detect EV71 from clinical specimens, and will allow quarantine
easures to be taken more effectively during outbreaks.









Reywords: Hand, Foot and Mouth Disease (HFMD); Enterovirus 71; Real-
. Introduction
EV71 is the main etiological agent of HFMD, a childhood
isease characterized by fever, multiple ulcers in the mouth
nd vesicles on the limbs and buttocks. It is associated with
eurological complications such as aseptic meningitis, brain-
tem encephalitis and poliomyelitis-like paralysis which have
ed to fatalities in recent outbreaks in the Asia Pacific regionPlease cite this article in press as: Tan EL, et al., Rapid detection of En
doi:10.1016/j.jcv.2008.01.001
Lum et al., 1998; Ho et al., 1999; Ahmad, 2000).
The classical “gold standard” diagnosis for EV71 is by cell
ulture followed by neutralization tests with serotype-specific
Abbreviations: RT-PCR, Reverse transcription polymerase chain reac-
ion; EV71, Enterovirus 71; HFMD, Hand, Foot and Mouth Disease.
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ntisera (Lim and Benyesh-Melnick, 1960). However, this
equires weeks of growth and diagnosis could be hindered by
ow viral titre or antigenic drifts in the specimens (Melnick,
996). Molecular methods such as PCR have been developed
o detect EV71 specifically and proved to be more sensitive
han the cell culture method (Brown et al., 2000; Singh et al.,
002; Nix et al., 2006). However the two-step semi-nested
T-PCR is also time-consuming and increases the risk of
ross-contamination. A real-time Hybridization probe-based
ssay for specific detection for EV71 was developed previ-
usly (Tan et al., 2006), but could only be applied on the
ightCycler platform.terovirus 71 by real-time TaqMan RT-PCR, J Clin Virol (2008),
With the increased concerns of the fatal HFMD caused by
V71, there is a need for a rapid and specific method to dis-
inguish this virus from other HFMD-causing enteroviruses
uch as Coxsackievirus A16 (CA16), Echovirus 4, 6 and 7.
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Fig. 1. Detection of EV71 by real-time TaqMan RT-PCR. Different EV71
strains (Strain 41, 10 and 7423/MS/87) and other enteroviruses, including
CA16, CA24, CB1 to CB5, Echoviruses 4, 6 and 7 were tested. The negative
control represents PCR reaction without any RNA template.
Fig. 2. Detection of EV71 strains belonging to other genogroups. The
real-time TaqMan RT-PCR was tested against EV71 strains from other







time TaqMan RT-PCR assays were able to detect EV71 in 49
clinical specimens. However, the tissue culture method failed
to detect EV71 in all the clinical specimens.ARTICLE
E.L. Tan et al. / Journal of C
ere, we developed a real-time TaqMan RT-PCR to detect
V71 specifically from clinical specimens.
. Methods
The EV71 viral isolates used in this study included a
eurovirulent strain (7423/MS/87), three Japanese strains
1585-Yamagata-01, 962-Yamagata-00 and 2933-Yamagata-
3), and two Singapore strains (5865/SIN/00009 strain –
esignated as Strain 41 and 5666/SIN/002209 strain – des-
gnated as Strain 10). Other enterovirus isolates analyzed in
his study included CA16, CA24, CB1 to CB5 and Echo 4, 6
nd 7.
A total of 67 clinical specimens were obtained from pedi-
tric patients admitted to the hospital with suspected HFMD.
he clinical specimens included stools, rectal swabs, serum,
hroat swabs and urine specimens. They were processed and
he viral RNA was extracted as described previously (Tan et
l., 2006).
The specificity of the real-time RT-PCR was evalu-
ted with the one-step LightCycler RNA Amplification
ybridization probe kit (Roche, Germany). The primers
EvVP1F and EvVP1R) designed for the real-time Hybridiza-
ion probe assay described previously was used in this study
Tan et al., 2006). A TaqMan probe was also designed and was
abeled with a 6-FAM reporter (at the 5′ end) and a TAMRA
uencher (at the 3′ end) (Table 1). Each reaction contained
.0l of RNA, 5 mM MgCl2, 0.4M each of EvVP1F and
vVP1R, 0.4M of TaqMan probe, 2.0l master reaction
ix, 0.2l enzyme mix and made up to 10l with water.
DNA was first synthesized from the RNA by reverse tran-
cription for 10 min at 55 ◦C and subsequently amplified for
0 cycles at 95 ◦C for 5 s, 55 ◦C for 15 s and 72 ◦C for 9 s.
he quantitative analysis of the developed real-time TaqMan
T-PCR was carried out as previously described (Tan et al.,
006). The tissue culture method was performed as described
reviously (Singh et al., 2002).
. Results
The real-time TaqMan RT-PCR was able to detect
V71 strains 41 (genogroup B4), 10 (genogroup B4) and
423/MS/87 (genogroup B2) (Fig. 1), as well as EV71
trains from other genogroups—strains 1585-Yamagata-01
genogroup C2), 962-Yamagata-00 (genogroup B4) and
933-Yamagata-03 (genogroup B5) (Fig. 2). No other
nterovirus serotypes were detected.
The analytical sensitivity of the real-time TaqMan RT-
CR developed was assessed using the serially diluted EV71Please cite this article in press as: Tan EL, et al., Rapid detection of En
doi:10.1016/j.jcv.2008.01.001
NA and the detection limit was established to be 5 viral
opies. The standard curve showed good correlation coeffi-
ient (R2 = 1.000) between the Ct (threshold) values and log10





(0 (genogroup B4) and 2933-Yamagata-03 (genogroup B5). Strain 41 was
sed as a positive control. The negative control represents PCR reaction
ithout any RNA template.
The sensitivity of the real-time TaqMan RT-PCR in detect-
ng EV71 from the clinical specimens was compared to the
issue culture method. A total of 67 clinical specimens were
nalyzed and the results are presented in Table 2. The real-terovirus 71 by real-time TaqMan RT-PCR, J Clin Virol (2008),
ig. 3. Quantitative analysis of real-time TaqMan RT-PCR for the detec-
ion of EV71. The standard curve was obtained by plotting the Ct values
gainst the starting copy number. The coefficient (R2) and linear equation
re as shown. The linearity was consistent in two independent experiments
P < 0.001).
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Table 1
Nucleotide sequences of the specific primers, hybridization probes and TaqMan probe designed for the specific amplification of EV71
Primer/Probes Nucleotide sequence (5′–3′) Position
EvVP1Fa GAG AGT TCT ATA GGG GAC AGT 2466–2489
EvVP1Ra AGC TGT GCT ATG TGA ATT A
EV TaqMan (6-FAM)-ACT TAC CCA GGC CC
a Primers described by Tan et al., 2006.
Table 2
Comparison of detection of EV71 directly from clinical specimensa by real-
time TaqMan RT-PCR with tissue culture method
Method Presence of EV71
Positive Negative
Real-time TaqMan RT-PCRb 49 18c
Tissue culture method 0 67
a Clinical specimens isolated from pediatric patients included stools, rectal
swabs, serum, throat swabs, saliva and urine specimens.
b Real-time TaqMan RT-PCR with primers and probe targeting at the VP1
region of EV71.






























































A1 clinical specimens contained CA16, 4 specimens contained Echo 7 and
specimens contained CB2. No enterovirus was found in one clinical spec-
men.
To verify that the positive clinical specimens are true posi-
ives, conventional semi-nested RT-PCR amplification of the
P1 region was carried out as described previously (Tan et
l., 2006). Amplification was observed for the tested clinical
pecimens, and sequence analysis of the 867 bp PCR ampli-
ons showed high correlations with the VP1 region of EV71
98% sequence homology; data not shown), indicating true
ositives for EV71.
Another conventional RT-PCR was also carried out on
ll the 67 clinical specimens using specific primers target-
ng at the 5′UTR region as described previously (Nijhuis et
l., 2002). Sequence analysis showed that all the 49 EV71-
ositive clinical specimens were truly EV71. Among the
emaining 18 EV71-negative specimens, 11 specimens were
ound to be CA16, 4 specimens contained Echo 7 and 2
ontained Echo 7. No enterovirus was found in one clinical
pecimen.
. Discussion
Real-time PCR has gained wider acceptance for viral diag-
osis due to higher sensitivity, more rapid and real-time
mplification monitoring (Mackay et al., 2002). There are
everal studies which differentiate enteroviruses from other
iruses using real time PCR (Read et al., 2001; Nijhuis et
l., 2002; Kares et al., 2003; Petitjean et al., 2006). However,
hese studies were based on the 5’UTR region which corre-
ates poorly with enterovirus serotypes and was not specificPlease cite this article in press as: Tan EL, et al., Rapid detection of En
doi:10.1016/j.jcv.2008.01.001
or EV71 detection (Oberste et al., 1999).
Here, we developed a one step real-time TaqMan RT-PCR
o detect EV71 specifically from clinical specimens. The VP1
egion of the EV71 genome was selected as it possesses
B
HGG AA 2669–2647
T GCC AGC TCC (TAMRA) 2497–2521
igh degree of antigenic and genetic diversity to distinguish
etween enterovirus serotypes (Oberste et al., 1999; Brown et
l., 2000). Since 6-FAM is a widely used reporter for TaqMan
robe chemistry, our real-time TaqMan RT-PCR is versatile
nd can be applied across other real-time PCR systems. The
ntire procedure for EV71 detection required only 2 h which
s more rapid than the tissue culture method, and no post PCR
andling was required. The high sensitivity of the real-time
aqMan RT-PCR in detecting EV71 in clinical specimens
as also shown in this study (49 out of 67) as compared to
he tissue culture method (0 out of 67).
No EV71 was detected in 18 clinical specimens by real-
ime TaqMan RT-PCR. Sequence analysis of the 5′UTR
howed that these clinical specimens contained CA16, CB2
nd Echo 7 which are also common causative agents
or HFMD. Since no amplification of 5′UTR region was
bserved for one specimen, the patient might be infected with
ther pathogens which resulted in HFMD-like symptoms.
In conclusion, this study demonstrated that real-time RT-
CR is rapid and sensitive to detect EV71 directly from
linical specimens. This allows clinicians to detect and
mplement measures to prevent further transmissions during
utbreak situations.
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